Disulfide oligosaccharide compounds and complexes

Cationic and ionizable oligosaccharide conjugates address the challenges of nucleic acid delivery by enhancing stability and safety, leading to improved cellular uptake and expression.

JP2024540977APending Publication Date: 2024-11-06BIONTECH SE +1
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2024523856
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2022-09-29
Filing Date
2022-10-21
Publication Date
2024-11-06

AI Technical Summary

Technical Problem

Existing nucleic acid delivery systems face challenges due to instability, poor membrane penetration, manufacturing difficulties, and insufficient safety and efficacy, particularly in lipid- or polymer-based compositions.

Method used

Development of cationic and/or ionizable oligosaccharide conjugates, including compounds of Formula I, for targeted delivery of biological agents such as nucleic acids, which enhance stability and safety.

Benefits of technology

The oligosaccharide conjugates improve nucleic acid delivery efficacy by reducing cytotoxicity and enhancing expression in target cells, as demonstrated by improved RNA expression and reduced cytotoxicity compared to conventional systems.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024540977000001_ABST
    Figure 2024540977000001_ABST
Patent Text Reader

Abstract

The present disclosure provides compounds, compositions, and complexes that are useful for the delivery of certain agents, including, for example, nucleic acids.
Need to check novelty before this filing date? Find Prior Art

Description

[Background technology]

[0001] explanation Targeted delivery and expression of therapeutic and / or prophylactic agents such as nucleic acids presents certain challenges due to the instability of nucleic acids and their inability to penetrate cell membranes.Certain approaches, including the use of lipid or polymer-based systems, are promising but suffer from drawbacks related to manufacturing difficulties, poor structure definition, and high polydispersity.Moreover, many such compositions lack sufficient safety and efficacy to be used in the delivery of therapeutic agents. Summary of the Invention

[0002] The present disclosure provides, inter alia, cationic and / or ionizable oligosaccharide conjugates that overcome certain deficiencies associated with previous compositions and are useful for targeted delivery of biological agents, including small molecules and nucleic acids.

[0003] In some embodiments, the present disclosure provides an oligosaccharide that is a compound of formula I: [ka] or a pharma- ceutically acceptable salt thereof, wherein: A is A 1 , A 2 , or A 3 and [ka] Each R 1 and R 2 But independently, in each case, H, R a , and -C(O)-R a Selected from R 1 or R 2 At least one instance of is not H, Each R a But independently, C1-C 20 Aliphatic, C3-C 20cycloaliphatic, C5-C6 aryl, 3- to 12-membered heterocyclyl containing 1 to 3 heteroatoms selected from N, O, and S; a But there is one or more R b optionally replaced by Each R b are independently halogen, -N3, -R c , -OR c , -SR c , -NHR c , -C(O)-R c , -OC(O)R c , -NHC(O)R c , -C(O)NHR c , and -NHC(O)NHR c is selected from Each R c are independently optionally substituted C-C 20 Aliphatic, optionally substituted C3-C 20 selected from cyclic aliphatic, optionally substituted C5-C6 aryl, optionally substituted 3-12 membered heterocyclyl containing 1-3 heteroatoms selected from N, O, and S, and optionally substituted 4-12 membered heteroaryl containing 1-3 heteroatoms selected from N, O, and S; Y 1 and Y 2 each independently represents an optionally substituted C 1-30 an aliphatic group in which one or more carbons are optionally and independently replaced with -Cy-, -NH-, -NHC(O)-, -C(O)NH-, -NHC(O)O-, -OC(O)NH-, -NHC(O)NH-, -NHC(S)NH-, -C(S)NH-, -C(O)NHSO2-, -SONHC(O)-, -OC(O)O-, -O-, -C(O)-, -OC(O)-, -C(O)O-, -SO-, or -SO2-; each Cy independently represents an optionally substituted C-C 14 a cyclic aliphatic ring, a 5- to 14-membered heterocyclyl ring having 1 to 3 heteroatoms selected from N, O, and S, or a 5- to 14-membered heteroaryl ring having 1 to 3 heteroatoms selected from N, O, and S; Z 1 and Z 2each independently represents an optionally substituted 5- to 14-membered heterocyclyl ring having 1 to 3 heteroatoms selected from N, O, and S; an optionally substituted 5- to 14-membered heteroaryl ring having 1 to 3 heteroatoms selected from N, O, and S; -N + (M)3, [ka] is a cationic or ionizable group selected from Each M is independently -C0-C6 aliphatic -R z , or -C0-C6 aliphatic -N + (R z )3, Each R z are independently H, optionally substituted C1-C6 aliphatic, optionally substituted C3-C 20 selected from cyclic aliphatic, optionally substituted C5-C6 aryl, optionally substituted 3-12 membered heterocyclyl containing 1-3 heteroatoms selected from N, O, and S, and optionally substituted 4-12 membered heteroaryl containing 1-3 heteroatoms selected from N, O, and S; or 2 or more R's z can be taken together with the atom to which they are attached to form an optionally substituted 3- to 12-membered heterocyclyl containing 1-3 heteroatoms selected from N, O, and S, or an optionally substituted 4- to 12-membered heteroaryl containing 1-3 heteroatoms selected from N, O, and S; p is an integer selected from 1, 2, 3, 4, or 5.

[0004] In some embodiments, the present disclosure provides a complex comprising an oligosaccharide described herein and a nucleic acid.

[0005] In some embodiments, the disclosure provides a method of delivering a composition to a target in a subject, the method comprising administering to the subject a conjugate described herein.

[0006] In some embodiments, the present disclosure provides a method of providing treatment and / or prevention of a disease, disorder, or condition in a subject, comprising administering to the subject a conjugate described herein.

[0007] In some embodiments, the present disclosure provides an oligosaccharide of formula Ia: [ka] or a pharma- ceutically acceptable salt thereof, comprising reacting a compound of formula II [ka] with a first acid to obtain a compound of formula Ia; Y 1 and Y 2 are each -CH-CH-NHC(S)NH-CH-CH-, Z 1 and Z 2 are each -NH3Cl, R 1 and R 2 are respectively -C(O)-R a and R a is optionally substituted C1-C 20 It is aliphatic, PG 1 is a nitrogen protecting group. [Brief description of the drawings]

[0008] [Figure 1A] FIG. 11 is a plot showing the percentage of free RNA quantified by gel electrophoresis of saRNA formulated at different N / P ratios from 0 to 3 for either JRL13 or ssJRL13. [Figure 1B] A plot showing the hydrodynamic diameter of saRNA formulated at different N / P ratios using either JRL13 or ssJRL13. [Figure 1C]Plot showing expression of luciferase-encoding saRNA 24 h after transfection of C2C12 cells with 12.5 ng–400 ng of RNA / well of saRNA formulated in N / P12 with either JRL13 or ssJRL13. Data here represent three independent experiments (n=3) that were technically repeated twice. [Figure 1D] Plot showing expression of luciferase-encoding saRNA 24 h after transfection of HepG2 cells with 12.5 ng–400 ng of RNA / well of saRNA formulated in N / P12 with either JRL13 or ssJRL13. Data here represent three independent experiments (n=3) that were technically repeated twice. [Figure 1E] A plot showing cell expression viability 24 hours after transfection of C2C12 cells with saRNA formulated in N / P12 with either JRL13 or ssJRL13 at 12.5 ng to 400 ng of RNA / well. [Figure 1F] A plot showing cell expression viability 24 hours after transfection of HepG2 cells with saRNA formulated in N / P12 with either JRL13 or ssJRL13 at 12.5 ng to 400 ng of RNA / well. [Figure 2A] FIG. 1 is a bar graph showing the hydrodynamic diameter of saRNA formulated with either JRL13 or ssJRL13. [Figure 2B] 1 is a plot showing serological levels of specific IgG to HA over the course of the experiment at a serum dilution of 1:300. [Figure 3A] FIG. 1 is a bar graph showing the hydrodynamic diameter of saRNA formulated with either JRL13 or ssJRL13. [Figure 3B] 1 is a plot showing serological levels of specific IgG to HA over the course of the experiment at a serum dilution of 1:300. [Figure 3C] 1 is a plot showing endpoint titration of serological levels of specific IgG to HA. [Figure 3D] 1 is a bar graph showing CD8 / CD4 responses to HA peptide pools. [Figure 4A] 1 is a bar graph of hydrodynamic diameter of saRNA formulated with either ssJRL13, ssJRL13, or ssJLF94. [Figure 4B] 1 is a plot showing serological levels of specific IgG to HA over the course of the experiment at a serum dilution of 1:300. [Figure 4C] 1 is a plot showing endpoint titration of serological levels of specific IgG to HA. [Figure 4D] 1 is a bar graph showing CD8 / CD4 responses to HA peptide pools. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0009] The compounds of the present disclosure include those generally described above, and are further exemplified by the classes, subclasses, and species disclosed herein.As used herein, the following definitions shall apply unless otherwise stated.For the purposes of this disclosure, chemical elements are identified according to the Periodic Table of the Elements, CAS version, Handbook of Chemistry and Physics, 75th edition.In addition, the general principles of organic chemistry are described in "Organic Chemistry", Thomas Sorrell, University Science Books, Sausalito: 1999, and "March's Advanced Organic Chemistry", 5th edition: Smith, MB and March, J., John Wiley&Sons, New York: 2001, the contents of which are incorporated herein by reference in their entirety.

[0010] Unless otherwise indicated, the structures depicted herein are intended to include all stereoisomeric (e.g., enantiomeric or diastereomeric) forms of the structure, as well as all geometric or conformational isomeric forms of the structure. For example, the R and S configurations of each stereocenter are contemplated as part of the present disclosure. Thus, single stereochemical isomers, as well as enantiomeric, diastereomeric, and geometric (or conformational) mixtures of the provided compounds are within the scope of the present disclosure. For example, in some cases, Table 1 depicts one or more stereoisomers of a compound, and each stereoisomer is represented alone and / or as a mixture unless otherwise indicated. Unless otherwise indicated, all tautomeric forms of the provided compounds are within the scope of the present disclosure.

[0011] Unless otherwise stated, structures depicted herein are meant to include compounds which differ only in the presence of one or more isotopically enriched atoms, for example, the replacement of hydrogen by deuterium or tritium, or 13 C or 14 Compounds having this structure including the replacement of a carbon with a C-rich carbon are within the scope of this disclosure.

[0012] definition About or Approximately: As used herein, the term "about" or "approximately" refers to a value similar to a stated reference value when applied to one or more values ​​of interest. In general, a person skilled in the art familiar with the context will fully understand the relevant degree of difference encompassed by "about" or "approximately" in that context. For example, in some embodiments, the term "about" or "approximately" may encompass a range of values ​​within (i.e., ±) 25%, 20%, 19%, 18%, 17%, 16%, 15%, 14%, 13%, 12%, 11%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, or less of the reference value.

[0013] Administration: As used herein, the term "administering" or "administration" typically refers to administration of a composition to a subject to achieve delivery of the composition or agent contained therein to a target site or site to be treated. A person skilled in the art will recognize various routes available for administration to a subject, e.g., a human, under appropriate circumstances. For example, in some embodiments, administration may be ocular, oral, parenteral, topical, etc. In some specific embodiments, administration may be bronchial (e.g., by bronchial instillation), buccal, transdermal (e.g., may be or include one or more of topical skin, intradermal, interdermal, transdermal, etc.), enteral, intraarterial, intradermal, intragastric, intramedullary, intramuscular, intranasal, intraperitoneal, intrathecal, intravenous, intraventricular, intraspecific organ (e.g., intrahepatic), mucosal, nasal, oral, rectal, subcutaneous, sublingual, topical, tracheal (e.g., by intratracheal instillation), vaginal, vitreous, etc. In some embodiments, administration may be parenteral. In some embodiments, administration may be oral. In some particular embodiments, administration may be intravenous. In some particular embodiments, administration may be subcutaneous. In some embodiments, administration may involve only a single dose. In some embodiments, administration may involve application of a fixed number of doses. In some embodiments, administration may involve administration that is intermittent (e.g., multiple doses separated in time) and / or periodic (e.g., individual doses separated by a common period of time) administration. In some embodiments, administration may involve continuous administration (e.g., perfusion) for at least a selected period of time. In some embodiments, administration may involve a prime and boost protocol. A prime and boost protocol may include administration of a first dose of a pharmaceutical composition (e.g., an immunogenic composition, e.g., a vaccine), followed after a fixed interval of time by administration of a second or subsequent dose of a pharmaceutical composition (e.g., an immunogenic composition, e.g., a vaccine). In the case of an immunogenic composition, a prime and boost protocol may result in an increased immune response in a patient.

[0014] Aliphatic: The term "aliphatic" refers to a linear (i.e., unbranched) or branched, substituted or unsubstituted hydrocarbon chain that is fully saturated or contains one or more unsaturated units, or a monocyclic or bicyclic hydrocarbon that is fully saturated or contains one or more unsaturated units, but is not aromatic (also referred to herein as "cycloaliphatic"), and has a single or multiple points of attachment to the remainder of the molecule. Unless otherwise specified, an aliphatic group contains 1-12 aliphatic carbon atoms. As used herein, it is understood that an aliphatic group can also be divalent (e.g., encompasses divalent hydrocarbon chains that are saturated or contain one or more unsaturated units, e.g., -CH2-, -CH2-CH2-, -CH2-CH2-CH2-, etc.). In some embodiments, an aliphatic group contains 1-6 aliphatic carbon atoms (e.g., C 1-6 In some embodiments, the aliphatic group contains 1-5 aliphatic carbon atoms (e.g., C 1-5 In some embodiments, the aliphatic group contains 1-4 aliphatic carbon atoms (e.g., C 1-4 In yet other embodiments, the aliphatic group contains 1-3 aliphatic carbon atoms (e.g., C 1-3 ), and in yet other embodiments, aliphatic groups contain 1-2 aliphatic carbon atoms (e.g., C 1-2 In some embodiments, "cycloaliphatic" refers to a monocyclic C ring that is fully saturated or contains one or more units of unsaturation, but is not aromatic and has a single or multiple points of attachment to the remainder of the molecule. 3-8 Hydrocarbon or bicyclic C 7-10 Refers to a hydrocarbon. Suitable aliphatic groups include, but are not limited to, linear or branched, substituted or unsubstituted alkyl, alkenyl, or alkynyl groups, and hybrids thereof. Preferred aliphatic groups are 1-6 It is an alkyl.

[0015] Alkyl: The term “alkyl” used alone or as part of a larger moiety means an alkyl group having 1 to 12, 1 to 10, 1 to 8, 1 to 6, 1 to 4, 1 to 3, or 1 to 2 carbon atoms (unless otherwise specified) (e.g., C1-12 , C 1-10 , C 1-8 , C 1-6 , C 1-4 , C 1-3 , or C 1-2 ), a saturated, optionally substituted, straight or branched chain hydrocarbon group. Exemplary alkyl groups include methyl, ethyl, propyl, butyl, pentyl, hexyl, and heptyl.

[0016] Alkenyl: The term “alkenyl” used alone or as part of a larger moiety refers to an alkyl group having at least one double bond and having 2 to 12, 2 to 10, 2 to 8, 2 to 6, 2 to 4, or 2 to 3 carbon atoms (unless otherwise specified) (e.g., C 2-12 , C 2-10 , C 2-8 , C 2-6、 C 2-4 , or C 2-3 ), an optionally substituted straight or branched chain or cyclic hydrocarbon group. Exemplary alkenyl groups include ethenyl, propenyl, butenyl, pentenyl, hexenyl, and heptenyl. The term "cycloalkenyl" refers to an optionally substituted non-aromatic monocyclic or multicyclic ring system containing at least one carbon-carbon double bond and having from about 3 to about 10 carbon atoms. Exemplary monocyclic cycloalkenyl rings include cyclopentenyl, cyclohexenyl, and cycloheptenyl.

[0017] Alkynyl: The term “alkynyl” used alone or as part of a larger moiety refers to an alkynyl group having at least one triple bond and having 2 to 12, 2 to 10, 2 to 8, 2 to 6, 2 to 4, or 2 to 3 carbon atoms (unless otherwise specified) (e.g., C 2-12 , C 2-10 , C 2-8 , C 2-6 , C 2-4 , or C 2-3), which means an optionally substituted straight or branched chain hydrocarbon group. Exemplary alkynyl groups include ethynyl, propynyl, butynyl, pentynyl, hexynyl, and heptynyl.

[0018] Analog: As used herein, the term "analog" refers to a substance that shares one or more specific structural features, elements, components, or moieties with a reference substance. Typically, an "analog" exhibits significant structural similarity with the reference substance, e.g., sharing a core or consensus structure, but also differs in certain distinct ways. In some embodiments, an analog is a substance that can be generated from a reference substance, e.g., by chemical manipulation of the reference substance. In some embodiments, an analog is a substance that can be generated through the execution of a synthetic process that is substantially similar (e.g., shares multiple steps) with the synthetic process that generates the reference substance. In some embodiments, an analog is generated or can be generated by the execution of a synthetic process that is different from the synthetic process used to generate the reference substance.

[0019] Aryl: The term "aryl" refers to an aryl group having a total of 5 to 14 ring members (e.g., C5-C 14 ) monocyclic and bicyclic ring systems, where at least one ring in the system is aromatic and each ring in the system contains 3 to 7 ring members. In some embodiments, "aryl" groups refer to ring systems containing a total of 6 to 12 ring members (e.g., C6-C 12 ). The term "aryl" may be used interchangeably with the term "aryl ring". In certain embodiments of the present invention, "aryl" refers to an aromatic ring system, including phenyl, biphenyl, naphthyl, anthracyl, and the like, which may bear one or more substituents. Unless otherwise specified, an "aryl" group is a hydrocarbon. In some embodiments, an "aryl" ring system is an aromatic ring (e.g., phenyl) fused to a non-aromatic ring (e.g., cycloalkyl). Examples of fused aryl rings include: [ka] Examples include:

[0020] Associated: Two events or entities are "associated" with each other, as this term is used herein, when the presence, level, and / or form of one correlates with that of the other. For example, a particular entity (e.g., a polypeptide, a gene signature, a metabolite, a microorganism, etc.) is considered to be associated with a particular disease, disorder, or condition if its presence, level, and / or state correlates with the occurrence and / or susceptibility of the disease, disorder, or condition (e.g., across a relevant population). In some embodiments, two or more entities are physically "associated" with each other when they interact directly or indirectly to be in physical proximity and / or remain in close proximity with each other. In some embodiments, two or more entities that are physically associated with each other are covalently linked to each other. In some embodiments, two or more entities that are physically associated with each other are not covalently linked to each other, but are non-covalently associated, for example, by hydrogen bonds, van der Waals interactions, hydrophobic interactions, magnetism, and combinations thereof.

[0021] Biological sample: As used herein, the term "biological sample" typically refers to a sample obtained or derived from a biological source of interest (e.g., a tissue or organism or cell culture) as described herein. In some embodiments, the source of interest includes an organism, such as an animal or human. In some embodiments, the biological sample is or includes a biological tissue or fluid. In some embodiments, the biological sample may be or include bone marrow, blood, blood cells, ascites, tissue or fine needle biopsy samples, cell-containing bodily fluids, suspended nucleic acids, sputum, saliva, urine, cerebrospinal fluid, peritoneal fluid, pleural fluid, feces, lymph, gynecological fluids, skin swabs, vaginal swabs, oral swabs, nasal swabs, washings or lavages such as ductal lavage or bronchoalveolar lavage, aspirates, scrapings, bone marrow specimens, tissue biopsy specimens, surgical specimens, feces, other bodily fluids (e.g., sperm, sweat, tears), secretions, and / or excretions, and / or cells therefrom, and the like. In some embodiments, the biological sample is or includes cells obtained from an individual. In some embodiments, the obtained cells are or include cells from the individual from whom the sample is obtained. In some embodiments, the sample is a "primary sample" obtained directly from the source of interest by any suitable means. For example, in some embodiments, the primary biological sample is obtained by a method selected from the group consisting of biopsy (e.g., fine needle aspiration or tissue biopsy), surgery, collection of bodily fluids (e.g., blood, lymph, feces, etc.), and the like. In some embodiments, as will be clear from the context, the term "sample" refers to a preparation obtained by processing (e.g., by removing one or more components and / or adding one or more agents) of the primary sample, for example, filtration using a semi-permeable membrane. Such a "processed sample" may include, for example, nucleic acids or proteins extracted from the sample or obtained by subjecting the primary sample to techniques such as amplification or reverse transcription of mRNA, isolation and / or purification of certain components, and the like.

[0022] Carrier: As used herein, the term "carrier" refers to a diluent, adjuvant, excipient, or vehicle used in administering a composition. In some exemplary embodiments, the carrier may comprise sterile liquids, such as, for example, water and oils, including those of petroleum, animal, vegetable, or synthetic origin, such as, for example, peanut oil, soybean oil, mineral oil, sesame oil, etc. In some embodiments, the carrier is or comprises one or more solid ingredients.

[0023] Combination therapy: As used herein, the term "combination therapy" refers to a situation in which a subject is exposed to two or more therapeutic regimens (e.g., two or more therapeutic agents or modalities) simultaneously. In some embodiments, the two or more regimens may be administered simultaneously. In some embodiments, the regimens may be administered sequentially (e.g., all "doses" of a first regimen are administered before any dose of a second regimen is administered). In some embodiments, the agents are administered in overlapping dosing regimens. In some embodiments, "administration" of a combination therapy may include administering one or more agent(s) or modality(s) in combination to a subject receiving the other agent(s) or modality(s). For clarity, combination therapy does not require that the individual agents be administered together in a single composition (or even necessarily at the same time), although in some embodiments, two or more agents or their active portions may be administered together in a combined composition or even a combined compound (e.g., as part of a single chemical complex or covalent conjugate).

[0024] Comparable: As used herein, the term "comparable" refers to two or more agents, substances, situations, sets of conditions, etc. that may not be identical to each other, but are sufficiently similar to allow a comparison between them that a person skilled in the art would understand that a conclusion can be reasonably drawn based on the observed differences or similarities. In some embodiments, a comparable set of conditions, situations, individuals, or populations is characterized by a number of substantially identical characteristics and one or a few different characteristics. A person skilled in the art will understand what degree of identity is required for two or more such agents, substances, situations, sets of conditions, etc. to be considered comparable in any given situation in the context. For example, a person skilled in the art will understand that a set of situations, individuals, or populations is comparable to each other when it is characterized by a sufficient number and type of substantially identical characteristics to ensure a reasonable conclusion that differences in results obtained or phenomena observed under or with the different sets of situations, individuals, or populations are due to or indicative of differences in these different characteristics.

[0025] Composition: Those skilled in the art will understand that the term "composition" may be used to refer to a separate physical entity that includes one or more defined components. In general, unless otherwise specified, a composition may be in any form, e.g., gas, gel, liquid, solid, etc.

[0026] Cycloaliphatic: As used herein, "cycloaliphatic" refers to a monocyclic C ring that is fully saturated or contains one or more units of unsaturation, but is not aromatic and has single or multiple points of attachment to the remainder of the molecule. 3-8 Hydrocarbon or bicyclic C 7-10 Refers to hydrocarbons.

[0027] Cycloalkyl: As used herein, the term "cycloalkyl" refers to an optionally substituted saturated monocyclic or polycyclic ring system of about 3 to about 10 ring carbon atoms. Exemplary monocyclic cycloalkyl rings include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and cycloheptyl.

[0028] Dosage form or unit dosage form: Those skilled in the art will understand that the term "dosage form" can be used to refer to a physically discrete unit of an active agent (e.g., a therapeutic or diagnostic agent) for administration to a subject. Typically, each such unit contains a predetermined amount of the active agent. In some embodiments, such amount is a unit dosage (or all of it) appropriate for administration according to a dosing regimen (i.e., a therapeutic dosing regimen) that has been determined to correlate with a desired or beneficial outcome when administered to a relevant population. Those skilled in the art will understand that the total amount of a therapeutic composition or agent to be administered to a particular subject is determined by one or more attending physicians and may include administration of multiple dosage forms.

[0029] Dosing regimen or treatment regimen: Those skilled in the art will understand that the terms "dosing regimen" and "treatment regimen" can be used to refer to a set of unit doses (typically more than one) typically administered to a subject separately over a period of time. In some embodiments, a given therapeutic agent has a recommended dosing regimen that can include one or more doses. In some embodiments, the dosing regimen includes multiple doses, each of which is spaced in time from the other doses. In some embodiments, the individual doses are separated from each other by an equally spaced period of time. In some embodiments, the dosing regimen includes multiple doses, and the individual doses are separated by two different periods of time. In some embodiments, all doses within the dosing regimen are of the same unit dose. In some embodiments, the different doses within the dosing regimen are of different amounts. In some embodiments, the dosing regimen includes a first dosing at a first dosage, followed by one or more additional doses at a second dosage that is different from the first dosage. In some embodiments, the dosing regimen comprises a first dosing at a first dosage amount, followed by one or more additional dosings at a second dosage amount that is the same as the first dosage amount, in some embodiments, the dosing regimen correlates with a desired or beneficial outcome when administered within a relevant population (i.e., is a therapeutic dosing regimen).

[0030] Excipient: As used herein, the term "excipient" refers to a non-therapeutic agent that may be included in a pharmaceutical composition, for example, to provide or contribute to a desired consistency or stabilizing effect. Suitable pharmaceutical excipients include, for example, starch, glucose, lactose, sucrose, gelatin, malt, rice, flour, chalk, silica gel, sodium stearate, glycerol monostearate, talc, sodium chloride, dried skim milk, glycerol, propylene, glycol, water, ethanol, and the like.

[0031] Heteroaliphatic: As used herein, the term "heteroaliphatic" or "heteroaliphatic group" refers to an optionally substituted hydrocarbon moiety having, in addition to carbon atoms, 1 to 5 heteroatoms, which may be linear (i.e., unbranched), branched, or cyclic ("heterocyclic"), and may be fully saturated or may contain one or more units of unsaturation, but is not aromatic. The term "heteroatom" means nitrogen, oxygen, or sulfur, and includes any oxidized form of nitrogen or sulfur, and any quaternized form of basic nitrogen. The term "nitrogen" also includes substituted nitrogen. Unless otherwise specified, heteroaliphatic groups contain 1 to 10 carbon atoms, with 1 to 3 carbon atoms being optionally and independently replaced with heteroatoms selected from oxygen, nitrogen, and sulfur. In some embodiments, heteroaliphatic groups contain 1 to 4 carbon atoms, with 1 to 2 carbon atoms being optionally and independently replaced with heteroatoms selected from oxygen, nitrogen, and sulfur. In yet other embodiments, heteroaliphatic groups contain 1-3 carbon atoms, with one carbon atom being optionally and independently replaced with a heteroatom selected from oxygen, nitrogen, and sulfur. Suitable heteroaliphatic groups include, but are not limited to, linear or branched chain heteroalkyl, heteroalkenyl, and heteroalkynyl groups. For example, heteroaliphatic groups of 1-10 atoms include exemplary groups such as -O-CH3, -CH2-O-CH3, -O-CH2-CH2-O-CH2-CH2-O-CH3.

[0032] Heteroaryl: The terms "heteroaryl" and "heteroaral-" are used alone or as part of a larger moiety, for example, "heteroaralkyl" or "heteroaralkoxy" refers to a monocyclic or bicyclic ring group having 5-12 ring atoms, 6, 10, or 14 pi electrons shared in the cyclic arrangement, and having 1-5 heteroatoms in addition to the carbon atoms (e.g., a 5-6 membered monocyclic heteroaryl or a 9-12 membered bicyclic heteroaryl). The term "heteroatom" means nitrogen, oxygen, or sulfur, and includes any oxidized form of nitrogen or sulfur, and any quaternized form of a basic nitrogen. Heteroaryl groups include, but are not limited to, thienyl, furanyl, pyrrolyl, imidazolyl, pyrazolyl, triazolyl, tetrazolyl, oxazolyl, isoxazolyl, oxadiazolyl, thiazolyl, isothiazolyl, thiadiazolyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, indolizinyl, purinyl, naphthyridinyl, pteridinyl, imidazo[1,2-a]pyrimidinyl, imidazo[1,2-a]pyridyl, imidazo[4,5-b]pyridyl, imidazo[4,5-c]pyridyl, pyrrolopyridyl, pyrrolopyrazinyl, thienopyrimidinyl, triazolopyridyl, and benzisoxazolyl. As used herein, the terms "heteroaryl" and "heteroara-" also include groups in which a heteroaromatic ring is fused to one or more aryl, cycloaliphatic, or heterocyclyl rings, and the radical or point of attachment is on the heteroaromatic ring (i.e., a bicyclic heteroaryl ring having 1-3 heteroatoms). Non-limiting examples include indolyl, isoindolyl, benzothienyl, benzofuranyl, dibenzofuranyl, indazolyl, benzimidazolyl, benzotriazolyl, benzothiazolyl, benzothiadiazolyl, benzoxazolyl, quinolyl, isoquinolyl, cinnolinyl, phthalazinyl, quinazolinyl, quinoxalinyl, 4H-quinolizinyl, carbazolyl, acridinyl, phenazinyl, phenothiazinyl, phenoxazinyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl, pyrido[2,3-b]-1,4-oxazin-3(4H)-one, 4H-thieno[3,2-b]pyrrole, and benzisoxazolyl.Heteroaryl groups may be monocyclic or bicyclic. The term "heteroaryl" may be used interchangeably with the terms "heteroaryl ring", "heteroaryl group", or "heteroaromatic", any of which terms include rings that are optionally substituted. The term "heteroaralkyl" refers to an alkyl group substituted by a heteroaryl, where the alkyl and heteroaryl portions independently are optionally substituted.

[0033] Heteroatom: As used herein, the term "heteroatom" means nitrogen, oxygen, or sulfur, and includes any oxidized form of nitrogen or sulfur, and any quaternized form of a basic nitrogen.

[0034] Heterocycle: As used herein, the terms "heterocycle", "heterocyclyl", "heterocyclic radical", and "heterocyclic ring" are used interchangeably and refer to a stable 3- to 8-membered monocyclic, 7- to 12-membered bicyclic, or 10- to 16-membered polycyclic heterocyclic moiety that is either saturated or partially unsaturated and has, in addition to carbon atoms, one or more, preferably one to four, heteroatoms as defined above. When used in reference to a ring atom of a heterocycle, the term "nitrogen" includes substituted nitrogen. As an example, in a saturated or partially unsaturated ring having 0-3 heteroatoms selected from oxygen, sulfur, or nitrogen, the nitrogen can be N (as in 3,4-dihydro-2H-pyrrolyl), NH (as in pyrrolidinyl), or NR +(such as N-substituted pyrrolidinyl). A heterocyclic ring may be attached to its pendant group at any heteroatom or carbon atom to provide a stable structure, and any of the ring atoms may be optionally substituted. Examples of such saturated or partially unsaturated heterocyclic radicals include, but are not limited to, azetidinyl, oxetanyl, tetrahydrofuranyl, tetrahydrothienyl, pyrrolidinyl, piperidinyl, decahydroquinolinyl, oxazolidinyl, piperazinyl, dioxanyl, dioxolanyl, diazepinyl, oxazepinyl, thiazepinyl, morpholinyl, and thiamorpholinyl. A heterocyclyl group may be monocyclic, bicyclic, tricyclic, or polycyclic, preferably monocyclic, bicyclic, or tricyclic, more preferably monocyclic or bicyclic. The term "heterocyclylalkyl" refers to an alkyl group substituted by a heterocyclyl, where the alkyl and heterocyclyl moieties are independently optionally substituted. Bicyclic heterocyclic rings also include groups in which a heterocyclic ring is fused to one or more aryl rings. Exemplary bicyclic heterocyclic groups include indolinyl, isoindolinyl, benzodioxolyl, 1,3-dihydroisobenzofuranyl, 2,3-dihydrobenzofuranyl, tetrahydroquinolinyl, [ka] The bicyclic heterocyclic ring may be a spirocyclic ring system (e.g., a 7- to 11-membered spirocyclic fused heterocyclic ring having, in addition to carbon atoms, one or more heteroatoms as defined above (e.g., 1, 2, 3, or 4 heteroatoms). The bicyclic heterocyclic ring may also be a bridged ring system (e.g., a 7- to 11-membered bridged heterocyclic ring having 1, 2, or 3 bridging atoms).

[0035] Nucleic acid / polynucleotide: As used herein, the term "nucleic acid" refers to a polymer of at least 10 or more nucleotides. In some embodiments, the nucleic acid is or comprises DNA. In some embodiments, the nucleic acid is or comprises RNA. In some embodiments, the nucleic acid is or comprises peptide nucleic acid (PNA). In some embodiments, the nucleic acid is or comprises single-stranded nucleic acid. In some embodiments, the nucleic acid is or comprises double-stranded nucleic acid. In some embodiments, the nucleic acid comprises both single-stranded and double-stranded portions. In some embodiments, the nucleic acid comprises a backbone comprising one or more phosphodiester bonds. In some embodiments, the nucleic acid comprises a backbone comprising both phosphodiester and non-phosphodiester bonds. For example, in some embodiments, the nucleic acid may comprise a backbone comprising one or more phosphorothioate or 5'-N-phosphoramidite bonds and / or one or more peptide bonds, e.g., "peptide nucleic acid". In some embodiments, a nucleic acid includes one or more, or all, naturally occurring residues (e.g., adenine, cytosine, deoxyadenosine, deoxycytidine, deoxyguanosine, deoxythymidine, guanine, thymine, uracil). In some embodiments, a nucleic acid includes one or more, or all, non-naturally occurring residues. In some embodiments, the non-natural residue comprises a nucleoside analog (e.g., 2-aminoadenosine, 2-thiothymidine, inosine, pyrrolo-pyrimidine, 3-methyladenosine, 5-methylcytidine, C-5 propynyl-cytidine, C-5 propynyl-uridine, 2-aminoadenosine, C5-bromouridine, C5-fluorouridine, C5-iodouridine, C5-propynyl-uridine, C5-propynyl-cytidine, C5-methylcytidine, 2-aminoadenosine, 7-deazaadenosine, 7-deazaguanosine, 8-oxoadenosine, 8-oxoguanosine, 6-O-methylguanine, 2-thiocytidine, methylated bases, intercalating bases, and combinations thereof).In some embodiments, the non-natural residue comprises one or more modified sugars (e.g., 2'-fluororibose, ribose, 2'-deoxyribose, arabinose, and hexose) compared to that of the natural residue. In some embodiments, the nucleic acid has a nucleotide sequence that encodes a functional gene product, such as an RNA or a polypeptide. In some embodiments, the nucleic acid has a nucleotide sequence that includes one or more introns. In some embodiments, the nucleic acid may be prepared by isolation from a natural source, enzymatic synthesis (e.g., polymerization based on a complementary template in vivo or in vitro, replication in a recombinant cell or system, or chemical synthesis. In some embodiments, the nucleic acid may be at least 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 20, 225, 250, 275, 300, 325, 350, 375, 400, 425, 450, 475, 500, 600, 700, 800, 900, 1000, 1500, 2000, 2500, 3000, 3500, 4000, 4500, 5000, 5500, 6000, 6500, 7000, 7500, 8000, 8500, 9000, 9500, 10,000, 10,500, 11,000, 11,500, 12,000, 12 ,500, 13,000, 13,500, 14,000, 14,500, 15,000, 15,500, 16,000, 16,500, 17,000, 17,500, 18,000, 18,500, 19,000, 19,500, or 20,000 or more residues or nucleotides in length.

[0036] Nucleic acid particles: "Nucleic acid particles" can be used to deliver nucleic acids to a desired target site (e.g., cells, tissues, organs, etc.). Nucleic acid particles can be formed from at least one cationic lipid or cationically ionizable lipid or lipid-like material, at least one cationic polymer such as protamine, or a mixture thereof, and nucleic acid. Nucleic acid particles include lipid nanoparticle (LNP)-based and lipoplex (LPX)-based formulations.

[0037] Nucleotide: As used herein, the term "nucleotide" refers to its art-recognized meaning. When a number of nucleotides is used, for example, as an indicator of the size of a polynucleotide, a certain number of nucleotides refers to the number of nucleotides on a single strand, for example, a polynucleotide.

[0038] Oral: As used herein, the phrases "oral administration" and "orally administered" have their art-understood meaning and refer to administration of a compound or composition by mouth.

[0039] Parenteral: As used herein, the terms "parenteral administration" and "administered parenterally" have their art-understood meanings and refer to modes of administration other than enteral and topical administration, usually by injection, and include, but are not limited to, intravenous, intramuscular, intraarterial, intrathecal, intracapsular, intraorbital, intracardiac, intradermal, intraperitoneal, transtracheal, subcutaneous, subcuticular, intraarticular, subcapsular, subarachnoid, intraspinal, and intrasternal injection and infusion.

[0040] Partially unsaturated: As used herein, the term "partially unsaturated" refers to a ring moiety that includes at least one double or triple bond between ring atoms. The term "partially unsaturated" is intended to encompass rings having multiple sites of unsaturation, but is not intended to include aromatic (e.g., aryl or heteroaryl) moieties as defined herein.

[0041] Patient or subject: As used herein, the term "patient" or "subject" refers to any organism to which a provided composition is or can be administered, e.g., for experimental, diagnostic, prophylactic, cosmetic, and / or therapeutic purposes. Exemplary patients or subjects include animals (e.g., mammals such as mice, rats, rabbits, non-human primates, and / or humans). In some embodiments, the patient is a human. In some embodiments, the patient or subject suffers from or is susceptible to one or more disorders or conditions. In some embodiments, the patient or subject exhibits one or more symptoms of a disorder or condition. In some embodiments, the patient or subject has been diagnosed with one or more disorders or conditions. In some embodiments, the patient or subject is undergoing or has undergone a particular therapy to diagnose and / or treat a disease, disorder, or condition.

[0042] Pharmaceutical composition: As used herein, the term "pharmaceutical composition" refers to an active agent formulated with one or more pharma- ceutically acceptable carriers. In some embodiments, the active agent is present in a unit dose suitable for administration in a treatment or dosing regimen that exhibits a statistically significant probability of achieving a predefined therapeutic effect when administered to a relevant population. In some embodiments, the pharmaceutical composition may be specially formulated for administration in solid or liquid form, including oral administration, e.g., drenches (aqueous or non-aqueous solutions or suspensions), tablets, e.g., buccal, sublingual, and those targeted for systemic absorption, boluses, powders, granules, pastes for application to the tongue; parenteral administration, e.g., by subcutaneous, intramuscular, intravenous, or epidural injection, e.g., as a sterile solution or suspension, or sustained release formulation; topical application, e.g., as a cream, ointment, or controlled release patch or spray, applied to the skin, lung, or oral cavity; vaginally or rectally, e.g., as a pessary, cream, or foam; sublingually; ophthalmically; transdermally; or compatible with nasal, pulmonary, and other mucosal surfaces.

[0043] Pharmaceutically acceptable: As used herein, the phrase "pharmacologically acceptable" means compounds, materials, compositions, and / or dosage forms that are, within the scope of good medical judgment, suitable for use in contact with the tissues of human beings and animals without undue toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit / risk ratio.

[0044] Pharmaceutically acceptable carrier: As used herein, the term "pharmacologically acceptable carrier" refers to a pharma- ceutically acceptable material, composition, or vehicle, such as a liquid or organ filler, diluent, excipient, or solvent encapsulating material, involved in the conveyance or transport of a compound of interest from one organ or body part to another. Each carrier must be "acceptable" in the sense of being compatible with the other ingredients of the formulation and not injurious to the patient. Some examples of materials which may function as pharma- ceutically acceptable carriers include sugars such as lactose, glucose, and sucrose; starches such as corn starch and potato starch; cellulose and its derivatives, for example, sodium carboxymethylcellulose, ethylcellulose, and cellulose acetate; powdered tragacanth; malt; gelatin; talc; excipients such as cocoa butter and suppository wax; oils such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil, and soybean oil; glycols such as propylene glycol; polyols such as glycerin, sorbitol, mannitol, and polyethylene glycol; esters such as ethyl oleate and ethyl laurate; agar; buffers such as magnesium hydroxide and aluminum hydroxide; alginic acid; pyrogen-free water; isotonic saline; Ringer's solution; ethyl alcohol; pH buffer solutions; polyesters, polycarbonates, and / or polyanhydrides; and other non-toxic, compatible substances used in pharmaceutical formulations.

[0045] Pharmaceutically acceptable salts: As used herein, the term "pharmaceutical acceptable salts" refers to salts of compounds that are suitable for use in pharmaceutical situations, i.e., salts that are suitable for use in contact with the tissues of humans and lower animals without undue toxicity, irritation, allergic response, etc., within the scope of good medical judgment, and commensurate with a reasonable benefit / risk ratio. Pharmaceutically acceptable salts are well known in the art. For example, SM Berge et al. describe pharmaceutical acceptable salts in detail in J. Pharmaceutical Sciences, 66:1-19 (1977). In some embodiments, pharmaceutical acceptable salts include, but are not limited to, non-toxic acid addition salts, which are salts of amino groups formed with inorganic acids such as hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid, and perchloric acid, or organic acids such as acetic acid, maleic acid, tartaric acid, citric acid, succinic acid, or malonic acid, or by using other methods used in the art, such as ion exchange. In some embodiments, pharma- ceutically acceptable salts include, but are not limited to, adipate, alginate, ascorbate, aspartate, benzenesulfonate, benzoate, bisulfate, borate, butyrate, camphorate, camphorsulfonate, citrate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, formate, fumarate, glucoheptonate, glycerophosphate, gluconate, hemisulfate, heptanoate, hexanoate, hydroiodide, 2-hydroxybutanol ... Examples of suitable salts include s-ethanesulfonate, lactobionate, lactate, laurate, lauryl sulfate, malate, maleate, malonate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, nitrate, oleate, oxalate, palmitate, pamoate, pectinate, persulfate, 3-phenylpropionate, phosphate, picrate, pivalate, propionate, stearate, succinate, sulfate, tartrate, thiocyanate, p-toluenesulfonate, undecanoate, valerate, etc. Representative alkali metal or alkaline earth metal salts include sodium, lithium, potassium, calcium, magnesium salts, etc.In some embodiments, pharma- ceutically acceptable salts include non-toxic ammonium, quaternary ammonium, and amine cations formed, where appropriate, using counterions such as halides, hydroxides, carboxylates, sulfates, phosphates, nitrates, alkyls having 1 to 6 carbon atoms, sulfonates, and arylsulfonates.

[0046] Polycyclic: As used herein, the term "polycyclic" refers to a saturated or unsaturated ring system having two or more rings (e.g., heterocyclyl, heteroaryl, cycloalkyl, or aryl rings) having 7-20 atoms, with one or more carbon atoms being common to two adjacent rings. For example, in some embodiments, a polycyclic ring system refers to a saturated or unsaturated ring system having three or more rings (e.g., heterocyclyl, heteroaryl, cycloalkyl, or aryl rings) having 14-20 atoms, with one or more carbon atoms being common to two adjacent rings. The rings in a polycyclic ring system may be fused (i.e., bicyclic or tricyclic), spirocyclic, or combinations thereof. Exemplary polycyclic rings are steroids.

[0047] Polypeptide: As used herein, the term "polypeptide" typically has its art-recognized meaning of a polymer of at least three or more amino acids. Those skilled in the art will appreciate that the term "polypeptide" is intended to be general enough to encompass not only polypeptides having the complete sequences described herein, but also polypeptides that represent functional, biologically active, or characteristic fragments, portions, or domains of such complete polypeptides (e.g., fragments, portions, or domains that retain at least one activity). In some embodiments, a polypeptide may include L-amino acids, D-amino acids, or both, and / or any of a variety of amino acid modifications or analogs known in the art. Useful modifications include, for example, terminal acetylation, amidation, methylation, and the like. In some embodiments, a polypeptide may include (e.g., may be or may include) natural amino acids, unnatural amino acids, synthetic amino acids, and combinations thereof.

[0048] Prevention or prophylaxis: As used herein, the terms "prevention" or "prophylaxis," when used in relation to the onset of a disease, disorder, and / or condition, refer to a reduction in the risk of the disease, disorder, and / or condition occurring and / or a delay in the onset of one or more characteristics or symptoms of the disease, disorder, or condition. Prevention may be considered complete when the onset of the disease, disorder, or condition has been delayed for a predetermined period of time.

[0049] Reference: as used herein describes a standard or control against which a comparison is made. For example, in some embodiments, an agent, animal, individual, population, sample, sequence, or value of interest is compared to a reference or control agent, animal, individual, population, sample, sequence, or value. In some embodiments, the reference or control is tested and / or determined substantially simultaneously with the test or determination of interest. In some embodiments, the reference or control is a historical reference or control, optionally embodied in a tangible medium. Typically, as will be understood by those of skill in the art, the reference or control is determined or analyzed under conditions or circumstances comparable to those to be evaluated. Those of skill in the art will understand when there is sufficient similarity to justify reliance on and / or comparison to a particular reference or control considered.

[0050] Ribonucleotide: As used herein, the term "ribonucleotide" encompasses unmodified and modified ribonucleotides. For example, unmodified ribonucleotides include the purine bases adenine (A) and guanine (G), and the pyrimidine bases cytosine (C) and uracil (U). Modified ribonucleotides may include one or more modifications, including, but not limited to, (a) terminal modifications, such as 5'-terminal modifications (e.g., phosphorylation, dephosphorylation, conjugation, inverted linkage, etc.), 3'-terminal modifications (e.g., conjugation, inverted linkage, etc.), (b) base modifications, such as substitutions with modified bases, stabilized bases, destabilized bases, or bases that have an expanded repertoire of partners or conjugate bases, (c) sugar modifications (e.g., at the 2' or 4' position) or sugar substitutions, and (d) internucleoside bond modifications, including modifications or substitutions of phosphodiester bonds. The term "ribonucleotide" also encompasses ribonucleotide triphosphates, including modified and unmodified ribonucleotide triphosphates.

[0051] Ribonucleic acid (RNA): As used herein, the term "RNA" refers to a polymer of ribonucleotides. In some embodiments, the RNA is single stranded. In some embodiments, the RNA is double stranded. In some embodiments, the RNA includes both single stranded and double stranded portions. In some embodiments, the RNA can include a backbone structure as described in the definition of "nucleic acid / polynucleotide" above. The RNA can be a regulatory RNA (e.g., siRNA, microRNA, etc.) or a messenger RNA (mRNA). In some embodiments, the RNA is an mRNA. In some embodiments, the RNA is an mRNA, and the RNA typically includes a poly(A) region at its 3' end. In some embodiments, the RNA is an mRNA, and the RNA typically includes an art-recognized cap structure at its 5' end, for example, for recognition and binding of the mRNA to ribosomes to initiate translation. In some embodiments, the RNA is a synthetic RNA. Synthetic RNA includes RNA that is synthesized in vitro (e.g., by enzymatic synthesis and / or chemical synthesis).

[0052] Sample: As used herein, the term "sample" typically refers to an aliquot of material obtained or derived from a source of interest. In some embodiments, the source of interest is a biological or environmental source. In some embodiments, the source of interest may be or include a cell, tissue, or organism, such as a microorganism, a plant, or an animal (e.g., human). In some embodiments, the source of interest is or includes a biological tissue or fluid. In some embodiments, the source of interest may be or include a preparation generated in a production process. In some embodiments, the sample is a "primary sample" that is obtained directly from the source of interest by any suitable means. In some embodiments, as will be clear from the context, the term "sample" refers to a preparation obtained by processing (e.g., by removing one or more components and / or adding one or more agents) of a primary sample.

[0053] Substituted or Optionally Substituted: As described herein, the compounds of the invention may contain "optionally substituted" moieties. In general, the term "substituted," whether preceded by the term "optionally," means that one or more hydrogens of the specified moiety are replaced with a suitable substituent. "Substituted" applies to one or more hydrogens that are either explicit or implicit from the structure (e.g., [ka] At least [ka] Refers to, [ka] At least [ka] (refers to "optionally substituted"). Unless otherwise specified, an "optionally substituted" group may have a suitable substituent at each substitutable position of the group, and when more than one position in any given structure may be substituted with more than one substituent selected from a particular group, the substituents may be the same or different at all positions. The combinations of substituents envisioned in the present invention are preferably those that result in the formation of stable or chemically feasible compounds. The term "stable" as used herein refers to a compound that is substantially unchanged when subjected to conditions that permit the compound to be produced, detected, and, in certain embodiments, its recovery, purification, and use for one or more of the purposes provided herein. Groups described as "substituted" preferably have 1-4 substituents, more preferably 1 or 2 substituents. Groups described as "optionally substituted" may be unsubstituted or "substituted" as described above.

[0054] Suitable monovalent substituents on a substitutable carbon atom of an "optionally substituted" group are independently halogen, -(CH) 0-4 R°, -(CH2) 0-4 OR°, -O(CH2) 0-4 R o , -O-(CH2) 0-4 C(O)OR°, -(CH2) 0-4 CH(OR°)2, -(CH2) 0-4 SR°, R° may be substituted -(CH2) 0-4 Ph, R° may be substituted -(CH2) 0-4 O(CH2) 0-1 Ph, may be substituted with R° -CH=CHPh, may be substituted with R° -(CH2) 0-4 O(CH2) 0-1 -Pyridyl, -NO2, -CN, -N3, -(CH2) 0-4 N(R°)2, -(CH2) 0-4 N(R°)C(O)R°, -N(R°)C(S)R°, -(CH2) 0-4 N(R°)C(O)NR°2, -N(R°)C(S)NR°2, -(CH2) 0-4 N(R°)C(O)OR°, -N(R°)N(R°)C(O)R°, -N(R°)N(R°)C(O)NR°2, -N(R°)N(R°)C(O)OR°, -(CH2) 0-4 C(O)R°, C(S)R°, -(CH2) 0-4 C(O)OR°, -(CH2) 0-4 C(O)SR°, -(CH2) 0-4 C(O)OSiR°3, -(CH2) 0-4 OC(O)R°, -OC(O)(CH2) 0-4 SR°, -(CH2) 0-4 SC(O)R°, -(CH2) 0-4 C(O)NR°2, -C(S)NR°2, -C(S)SR°, -SC(S)SR°, -(CH2) 0-4 OC(O)NR°2, -C(O)N(OR°)R°, -C(O)C(O)R°, -C(O)CH2C(O)R°, -C(NOR°)R°, -(CH2) 0-4 SSR°, -(CH2) 0-4 S(O)2R°, -(CH2) 0-4 S(O)2OR°, -(CH2)0-4 OS(O)2R°, -S(O)2NR°2, -(CH2) 0-4 S(O)R°, -N(R°)S(O)2NR°2, -N(R°)S(O)2R°, -N(OR°)R°, -C(NH)NR°2, -P(O)2R°, -P(O)R°2, -OP(O)R°2, -OP(O)(OR°)2, SiR°3, -(C 1-4 Linear or branched alkylene)ON(R°)2, or -(C 1-4 linear or branched alkylene)C(O)ON(R°), each R° may be substituted as defined below and is independently hydrogen, C 1-6 Aliphatic, -CH2Ph, -O(CH2) 0-1 Ph, -CH2- (a 5-6 membered heteroaryl ring), or a 3-6 membered saturated, partially unsaturated, or aryl ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or, notwithstanding the above definitions, two independent occurrences of R° together with their intervening atom(s) form a 3-12 membered saturated, partially unsaturated, or aryl mono- or bicyclic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, which may be substituted as defined below.

[0055] Suitable monovalent substituents on R° (or the ring formed by two independent occurrences of R° and their intervening atoms) are independently halogen, -(CH2), 0-2 R λ , -(haloR λ ), -(CH2) 0-2 OH, -(CH2) 0-2 OR λ , -(CH2) 0-2 CH(OR λ )2, -O(HaloR λ ), -CN, -N3, -(CH2) 0-2 C(O)R λ , -(CH2) 0-2 C(O)OH, -(CH2) 0-2 C(O)OR λ , -(CH2) 0-2 S.R. λ , -(CH2) 0-2SH, -(CH2) 0-2 NH2, -(CH2) 0-2 NHR λ , -(CH2) 0-2 NR λ 2, -NO2, -SiR λ 3. -OSiR λ 3. -C(O)SR λ , -(C 1-4 Linear or branched alkylene)C(O)OR λ , or -SSR λ And each R λ is unsubstituted or, if preceded by "halo", is substituted with one or more halogens only, and independently represents C 1-4 Aliphatic, -CH2Ph, -O(CH2) 0-1 Ph is selected from a 3-6 membered saturated, partially unsaturated, or aryl ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur. Suitable divalent substituents on a saturated carbon atom of R° include =O and =S.

[0056] Suitable divalent substituents on a saturated carbon atom of an "optionally substituted" group include ═O ("oxo"), ═S, ═NNR * 2, =NNHC(O)R * , =NNHC(O)OR * , =NNHS(O)2R * , =NR * , =NOR * , -O(C(R * 2)) 2-3 O-, or -S(C(R * 2)) 2-3 S- is mentioned, R * Each independent occurrence of 1-6 aliphatic or unsubstituted 5-6 membered saturated, partially unsaturated, or aryl rings having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur. Preferred divalent substituents attached to adjacent substitutable carbons of an "optionally substituted" group include -O(CR * 2) 2-3 O- and R *Each independent occurrence of 1-6 selected from aliphatic, or unsubstituted 5-6 membered saturated, partially unsaturated, or aryl rings having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur.

[0057] R * Suitable substituents on the aliphatic group include halogen, -R λ , -(Halo R λ ), -OH, -OR λ , -O(HaloR λ ), -CN, -C(O)OH, -C(O)OR λ , -NH2, -NHR λ , -NR λ 2, or -NO2, where each R λ is unsubstituted or, if preceded by "halo", is substituted with one or more halogens only, and independently represents C 1-4 Aliphatic, -CH2Ph, -O(CH2) 0-1 Ph, or a 5-6 membered saturated, partially unsaturated, or aryl ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur.

[0058] Suitable substituents on a substitutable nitrogen of an "optionally substituted" group include -R † , -NR † 2. -C(O)R † , -C(O)OR † , -C(O)C(O)R † , -C(O)CH2C(O)R † , -S(O)2R † , -S(O)NR † 2. -C(S)NR † 2. -C(NH)NR † 2, or -N(R † )S(O)2R † Each R † are independently hydrogen, C which may be substituted as defined below 1-6an aliphatic, unsubstituted -OPh, or an unsubstituted 3-6 membered saturated, partially unsaturated, or aryl ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or, regardless of the above definitions, R † two independent occurrences of together with their intervening atom(s) form an unsubstituted 3-12 membered saturated, partially unsaturated, or mono- or bicyclic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur.

[0059] R † Suitable substituents on the aliphatic groups are independently halogen, -R λ , -(Halo R λ ), -OH, -OR λ , -O(HaloR λ ), -CN, -C(O)OH, -C(O)OR λ , -NH2, -NHR λ , -NR λ 2, or -NO2, and each R λ is unsubstituted or, if preceded by "halo", is substituted with one or more halogens only, and independently represents C 1-4 Aliphatic, -CH2Ph, -O(CH2) 0-1 Ph, or a 3-6 membered saturated, partially unsaturated, or aryl ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur.

[0060] Small molecule: As used herein, the term "small molecule" refers to an organic and / or inorganic compound with a low molecular weight. In general, a "small molecule" is a molecule that is less than about 5 kilodaltons (kD) in size. In some embodiments, a small molecule is less than about 4 kD, 3 kD, 2 kD, or 1 kD. In some embodiments, a small molecule is less than about 800 Daltons (D), about 600 D, about 500 D, about 400 D, about 300 D, about 200 D, or about 100 D. In some embodiments, a small molecule is less than about 2000 g / mol, less than about 1500 g / mol, less than about 1000 g / mol, less than about 800 g / mol, or less than about 500 g / mol. In some embodiments, a small molecule is not a polymer.

[0061] In some embodiments, a small molecule does not comprise a polymer moiety. In some embodiments, a small molecule is not and / or does not comprise a protein or polypeptide (e.g., is not an oligopeptide or peptide). In some embodiments, a small molecule is not and / or does not comprise a polynucleotide (e.g., is not an oligonucleotide). In some embodiments, a small molecule is not and / or does not comprise a polysaccharide (e.g., in some embodiments, a small molecule is not a glycoprotein, proteoglycan, glycolipid, etc.). In some embodiments, a small molecule is not a lipid.

[0062] In some embodiments, a small molecule is a modulator (e.g., an inhibitor or activator). In some embodiments, a small molecule is biologically active. In some embodiments, a small molecule is detectable (e.g., comprises at least one detectable moiety). In some embodiments, a small molecule is a therapeutic agent.

[0063] One of skill in the art will understand, upon reading this disclosure, that certain small molecule compounds described herein may be provided and / or utilized in any of a variety of forms, such as, for example, crystalline forms (e.g., polymorphs, solvates, etc.), salt forms, protected forms, prodrug forms, ester forms, isomeric forms (e.g., optical and / or structural isomers), isotopic forms, etc.

[0064] Those skilled in the art will appreciate that certain small molecule compounds (e.g., the oligosaccharide compounds described herein) have structures that can exist in one or more stereoisomeric forms. In some embodiments, such small molecules may be utilized in accordance with the present disclosure in the form of individual enantiomers, diastereomers, or geometric isomers, or may be in the form of a mixture of stereoisomers, and in some embodiments, such small molecules may be utilized in accordance with the present disclosure in the form of a racemic mixture.

[0065] Those of skill in the art will appreciate that certain small molecule compounds (e.g., the oligosaccharide compounds described herein) have structures that can exist in one or more tautomeric forms. In some embodiments, such small molecules may be utilized in accordance with the present disclosure in the form of individual tautomers or in forms that interconvert between tautomers.

[0066] Those of skill in the art will appreciate that certain small molecule compounds (e.g., oligosaccharide compounds described herein) have structures that allow for isotopic substitution (e.g., in the case of H, 2 H or 3 H, 12 In the case of C 11 C. 13 C, or 14 C. 14 In the case of N 13 N or 15 N, 16 In the case of O 17 O or 18 O. 35 Cl or 37 In the case of Cl 36 Cl, 19 In the case of F 18 F, 127 In case of I131 It will be understood that such small molecules have an isotopically modified form, such as I. In some embodiments, such small molecules may be utilized in accordance with the present disclosure in one or more isotopically modified forms, or mixtures thereof.

[0067] In some embodiments, a reference to a particular small molecule compound (e.g., an oligosaccharide compound described herein) may refer to a particular form of that compound. In some embodiments, a particular small molecule compound may be provided and / or utilized in the form of a salt (e.g., an acid addition or base addition salt form, depending on the compound), and in some such embodiments, the salt form may be a pharma- ceutically acceptable salt form.

[0068] In some embodiments, when a small molecule compound is a naturally occurring or naturally found compound, the compound may be provided and / or utilized in accordance with the present disclosure in a form that is different from that in which it is naturally occurring or found in nature. A person skilled in the art will understand that in some embodiments, the absolute or relative amount of a compound or a preparation of a particular small molecule compound that contains a particular form thereof will differ from the compound present in the reference preparation or source (e.g., with respect to other components of the preparation that contain another form of the compound) that differs from the absolute or relative amount of the compound or form present in a reference preparation of interest (e.g., a primary sample from a source of interest, such as a biological or environmental source). Thus, in some embodiments, for example, a preparation of a single stereoisomer of a small molecule compound may be considered to be a different form from a racemic mixture of the compound, a particular salt of a small molecule compound may be considered to be a different form from another salt form of the compound, a preparation that includes only a form of the compound that includes one stereoisomer of a double bond ((Z) or (E)) may be considered to be a different form from a form of the compound that contains the other stereoisomer of the double bond (E) or (Z), and a preparation in which one or more atoms are isotopes different from those present in a reference preparation may be considered to be a different form.

[0069] Those skilled in the art will recognize that, in small molecule structures, the symbols [ka] It will further be understood to refer to the point of attachment between two atoms.

[0070] Therapeutic Agent: As used herein, the term "therapeutic agent" generally refers to any agent that induces a desired pharmacological effect when administered to an organism. In some embodiments, an agent is considered to be a therapeutic agent if it shows a statistically significant effect across an appropriate population. In some embodiments, the appropriate population may be a population of model organisms. In some embodiments, the appropriate population may be defined by various criteria, such as a certain age group, sex, genetic background, pre-existing clinical conditions, etc. In some embodiments, a therapeutic agent is any substance that can be used to alleviate, ameliorate, relieve, inhibit, prevent, delay the onset, reduce the severity, and / or reduce the incidence of one or more symptoms or characteristics of a disease, disorder, and / or condition. In some embodiments, a "therapeutic agent" is an agent that has been approved or needs to be approved by a government agency before it can be commercially marketed for administration to humans. In some embodiments, a "therapeutic agent" is an agent that requires a medical prescription for administration to humans.

[0071] Treat: As used herein, the terms "treat", "treatment", or "treating" refer to any method used to partially or completely alleviate, ameliorate, relieve, inhibit, prevent, delay onset, reduce severity, and / or reduce incidence of one or more symptoms or characteristics of a disease, disorder, and / or condition. Treatment may be administered to subjects who do not exhibit signs of the disease, disorder, and / or condition. In some embodiments, treatment may be administered to subjects who exhibit only early signs of a disease, disorder, and / or condition, for example, to reduce the risk of developing a condition associated with the disease, disorder, and / or condition.

[0072] Polycationic Oligosaccharide Compositions The present disclosure relates, inter alia, to oligosaccharides which are compounds of formula I: [ka] or a pharma- ceutically acceptable salt thereof, wherein: A is A 1 , A 2 , or A 3 and [ka] Each R 1 and R 2 But independently, in each case, H, R a , and -C(O)-R a Selected from R 1 or R 2 At least one instance of is not H, Each R a But independently, C1-C 20 Aliphatic, C3-C 20 cycloaliphatic, C5-C6 aryl, 3- to 12-membered heterocyclyl containing 1 to 3 heteroatoms selected from N, O, and S; a But there is one or more R b optionally replaced by Each R b are independently halogen, -N3, -R c , -OR c , -SR c , -NHR c , -C(O)-R c , -OC(O)R c , -NHC(O)R c , -C(O)NHR c , and -NHC(O)NHR c is selected from Each R c are independently optionally substituted C1-C 20 Aliphatic, optionally substituted C3-C 20selected from cyclic aliphatic, optionally substituted C5-C6 aryl, optionally substituted 3-12 membered heterocyclyl containing 1-3 heteroatoms selected from N, O, and S, and optionally substituted 4-12 membered heteroaryl containing 1-3 heteroatoms selected from N, O, and S; Y 1 and Y 2 each independently represents an optionally substituted C 1-30 an aliphatic group in which one or more carbons are optionally and independently replaced with -Cy-, -NH-, -NHC(O)-, -C(O)NH-, -NHC(O)O-, -OC(O)NH-, -NHC(O)NH-, -NHC(S)NH-, -C(S)NH-, -C(O)NHSO2-, -SONHC(O)-, -OC(O)O-, -O-, -C(O)-, -OC(O)-, -C(O)O-, -SO-, or -SO2-; each Cy independently represents an optionally substituted C-C 14 an optionally substituted 5-14 membered heterocyclyl ring having 1-3 heteroatoms selected from cycloaliphatic, N, O, and S, and an optionally substituted 5-14 membered heteroaryl ring having 1-3 heteroatoms selected from N, O, and S; Z 1 and Z 2 each independently represents an optionally substituted 5- to 14-membered heterocyclyl ring having 1 to 3 heteroatoms selected from N, O, and S; an optionally substituted 5- to 14-membered heteroaryl ring having 1 to 3 heteroatoms selected from N, O, and S; -N + (M)3, [ka] is a cationic or ionizable group selected from Each M is independently -C0-C6 aliphatic -R z , or -C0-C6 aliphatic -N + (R z )3, Each R z are independently H, optionally substituted C1-C6 aliphatic, optionally substituted C3-C 20selected from cyclic aliphatic, optionally substituted C5-C6 aryl, optionally substituted 3-12 membered heterocyclyl containing 1-3 heteroatoms selected from N, O, and S, and optionally substituted 4-12 membered heteroaryl containing 1-3 heteroatoms selected from N, O, and S; or 2 or more R's z can be taken together with the atom to which they are attached to form an optionally substituted 3- to 12-membered heterocyclyl containing 1-3 heteroatoms selected from N, O, and S, or an optionally substituted 4- to 12-membered heteroaryl containing 1-3 heteroatoms selected from N, O, and S; p is an integer selected from 1, 2, 3, 4, or 5.

[0073] As described herein, A is A 1 , A 2 , or A 3 It is. [ka]

[0074] In some embodiments, A is A 1 Or A 2 In some embodiments, A is A 1 In some embodiments, A is A 2 In some embodiments, A is A 3 In some embodiments, A is A 1 and the oligosaccharide is a compound of formula Ia, [ka] or a pharma- ceutically acceptable salt thereof, wherein R 1 , R 2 , Y 1 , Y 2 , Z 1 , and Z 2 are as described in classes and subclasses herein, both alone and in combination.

[0075] In some embodiments, the oligosaccharide is a compound of formula Ia: [ka] or a pharma- ceutically acceptable salt thereof, Each R 1 and R 2 But independently, in each case, H, R a , and -C(O)-R a Selected from R 1 or R 2 At least one instance of is not H, Each R a But independently, C1-C 20 Aliphatic, C3-C 20 cycloaliphatic, C5-C6 aryl, 3- to 12-membered heterocyclyl containing 1 to 3 heteroatoms selected from N, O, and S; a But there is one or more R b optionally replaced by Each R b are independently halogen, -N3, -R c , -OR c , -SR c , -NHR c , -C(O)-R c , -OC(O)R c , -NHC(O)R c , -C(O)NHR c , and -NHC(O)NHR c is selected from Each R c are independently optionally substituted C1-C 20 Aliphatic, optionally substituted C3-C 20 selected from cyclic aliphatic, optionally substituted C5-C6 aryl, optionally substituted 3-12 membered heterocyclyl containing 1-3 heteroatoms selected from N, O, and S, and optionally substituted 4-12 membered heteroaryl containing 1-3 heteroatoms selected from N, O, and S; Y 1 and Y 2 each independently represents an optionally substituted C 1-30an aliphatic group in which one or more carbons are optionally and independently replaced with -Cy-, -NH-, -NHC(O)-, -C(O)NH-, -NHC(O)O-, -OC(O)NH-, -NHC(O)NH-, -NHC(S)NH-, -C(S)NH-, -C(O)NHSO2-, -SONHC(O)-, -OC(O)O-, -O-, -C(O)-, -OC(O)-, -C(O)O-, -SO-, or -SO2-; each Cy independently represents an optionally substituted C-C 14 an optionally substituted 5-14 membered heterocyclyl ring having 1-3 heteroatoms selected from cycloaliphatic, N, O, and S, and an optionally substituted 5-14 membered heteroaryl ring having 1-3 heteroatoms selected from N, O, and S; Z 1 and Z 2 each independently represents an optionally substituted 5- to 14-membered heterocyclyl ring having 1 to 3 heteroatoms selected from N, O, and S; an optionally substituted 5- to 14-membered heteroaryl ring having 1 to 3 heteroatoms selected from N, O, and S; -N + (M)3, [ka] is a cationic or ionizable group selected from Each M is independently -C0-C6 aliphatic -R z , or -C0-C6 aliphatic -N + (R z )3, Each R z are independently H, optionally substituted C1-C6 aliphatic, optionally substituted C3-C 20 selected from cyclic aliphatic, optionally substituted C5-C6 aryl, optionally substituted 3-12 membered heterocyclyl containing 1-3 heteroatoms selected from N, O, and S, and optionally substituted 4-12 membered heteroaryl containing 1-3 heteroatoms selected from N, O, and S; or 2 or more R's zcan be taken together with the atom to which they are attached to form an optionally substituted 3- to 12-membered heterocyclyl containing 1-3 heteroatoms selected from N, O, and S, or an optionally substituted 4- to 12-membered heteroaryl containing 1-3 heteroatoms selected from N, O, and S.

[0076] In some embodiments, A is A 2 and the oligosaccharide is a compound of formula Ib, [ka] or a pharma- ceutically acceptable salt thereof, wherein R 1 , R 2 , Y 1 , Y 2 , Z 1 , and Z 2 are as described in classes and subclasses herein, both alone and in combination.

[0077] In some embodiments, the oligosaccharide is a compound of formula Ib: [ka] or a pharma- ceutically acceptable salt thereof, Each R 1 and R 2 But independently, in each case, H, R a , and -C(O)-R a Selected from R 1 or R 2 At least one instance of is not H, Each R a But independently, C1-C 20 Aliphatic, C3-C 20 cycloaliphatic, C5-C6 aryl, 3- to 12-membered heterocyclyl containing 1 to 3 heteroatoms selected from N, O, and S; a But there is one or more R b optionally replaced by Each R b are independently halogen, -N3, -R c , -ORc , -SR c , -NHR c , -C(O)-R c , -OC(O)R c , -NHC(O)R c , -C(O)NHR c , and -NHC(O)NHR c is selected from Each R c are independently optionally substituted C1-C 20 Aliphatic, optionally substituted C3-C 20 selected from cyclic aliphatic, optionally substituted C5-C6 aryl, optionally substituted 3-12 membered heterocyclyl containing 1-3 heteroatoms selected from N, O, and S, and optionally substituted 4-12 membered heteroaryl containing 1-3 heteroatoms selected from N, O, and S; Y 1 and Y 2 each independently represents an optionally substituted C 1-30 an aliphatic group in which one or more carbons are optionally and independently replaced with -Cy-, -NH-, -NHC(O)-, -C(O)NH-, -NHC(O)O-, -OC(O)NH-, -NHC(O)NH-, -NHC(S)NH-, -C(S)NH-, -C(O)NHSO2-, -SONHC(O)-, -OC(O)O-, -O-, -C(O)-, -OC(O)-, -C(O)O-, -SO-, or -SO2-; each Cy independently represents an optionally substituted C-C 14 an optionally substituted 5-14 membered heterocyclyl ring having 1-3 heteroatoms selected from cycloaliphatic, N, O, and S, and an optionally substituted 5-14 membered heteroaryl ring having 1-3 heteroatoms selected from N, O, and S; Z 1 and Z 2 each independently represents an optionally substituted 5- to 14-membered heterocyclyl ring having 1 to 3 heteroatoms selected from N, O, and S; an optionally substituted 5- to 14-membered heteroaryl ring having 1 to 3 heteroatoms selected from N, O, and S; -N + (M)3, [ka] is a cationic or ionizable group selected from Each M is independently -C0-C6 aliphatic -R z , or -C0-C6 aliphatic -N + (R z )3, Each R z are independently H, optionally substituted C1-C6 aliphatic, optionally substituted C3-C 20 selected from cyclic aliphatic, optionally substituted C5-C6 aryl, optionally substituted 3-12 membered heterocyclyl containing 1-3 heteroatoms selected from N, O, and S, and optionally substituted 4-12 membered heteroaryl containing 1-3 heteroatoms selected from N, O, and S; or 2 or more R's z can be taken together with the atom to which they are attached to form an optionally substituted 3- to 12-membered heterocyclyl containing 1-3 heteroatoms selected from N, O, and S, or an optionally substituted 4- to 12-membered heteroaryl containing 1-3 heteroatoms selected from N, O, and S.

[0078] In some embodiments, A is A 3 and the oligosaccharide is a compound of formula Ic, [ka] or a pharma- ceutically acceptable salt thereof, 1 , R 2 , Y 1 , Y 2 , Z 1 , and Z 2 are as described in classes and subclasses herein, both alone and in combination.

[0079] In some embodiments, the oligosaccharide is a compound of formula Ic: [ka] or a pharma- ceutically acceptable salt thereof, Each R 1 and R 2 But independently, in each case, H, R a , and -C(O)-R a Selected from R 1 or R 2 At least one instance of is not H, Each R a But independently, C1-C 20 Aliphatic, C3-C 20 cycloaliphatic, C5-C6 aryl, 3- to 12-membered heterocyclyl containing 1 to 3 heteroatoms selected from N, O, and S; a But there is one or more R b optionally replaced by Each R b are independently halogen, -N3, -R c , -OR c , -SR c , -NHR c , -C(O)-R c , -OC(O)R c , -NHC(O)R c , -C(O)NHR c , and -NHC(O)NHR c is selected from Each R c are independently optionally substituted C1-C 20 Aliphatic, optionally substituted C3-C 20 selected from cyclic aliphatic, optionally substituted C5-C6 aryl, optionally substituted 3-12 membered heterocyclyl containing 1-3 heteroatoms selected from N, O, and S, and optionally substituted 4-12 membered heteroaryl containing 1-3 heteroatoms selected from N, O, and S; Y 1 and Y 2 each independently represents an optionally substituted C 1-30an aliphatic group in which one or more carbons are optionally and independently replaced with -Cy-, -NH-, -NHC(O)-, -C(O)NH-, -NHC(O)O-, -OC(O)NH-, -NHC(O)NH-, -NHC(S)NH-, -C(S)NH-, -C(O)NHSO2-, -SONHC(O)-, -OC(O)O-, -O-, -C(O)-, -OC(O)-, -C(O)O-, -SO-, or -SO2-; each Cy independently represents an optionally substituted C-C 14 an optionally substituted 5-14 membered heterocyclyl ring having 1-3 heteroatoms selected from cycloaliphatic, N, O, and S, and an optionally substituted 5-14 membered heteroaryl ring having 1-3 heteroatoms selected from N, O, and S; Z 1 and Z 2 each independently represents an optionally substituted 5- to 14-membered heterocyclyl ring having 1 to 3 heteroatoms selected from N, O, and S; an optionally substituted 5- to 14-membered heteroaryl ring having 1 to 3 heteroatoms selected from N, O, and S; -N + (M)3, [ka] is a cationic or ionizable group selected from Each M is independently -C0-C6 aliphatic -R z , or -C0-C6 aliphatic -N + (R z )3, Each R z are independently H, optionally substituted C1-C6 aliphatic, optionally substituted C3-C 20 selected from cyclic aliphatic, optionally substituted C5-C6 aryl, optionally substituted 3-12 membered heterocyclyl containing 1-3 heteroatoms selected from N, O, and S, and optionally substituted 4-12 membered heteroaryl containing 1-3 heteroatoms selected from N, O, and S; or 2 or more R's zcan be taken together with the atom to which they are attached to form an optionally substituted 3- to 12-membered heterocyclyl containing 1-3 heteroatoms selected from N, O, and S, or an optionally substituted 4- to 12-membered heteroaryl containing 1-3 heteroatoms selected from N, O, and S; p is 1, 2, 3, 4, or 5.

[0080] In some embodiments, p is 1 and the oligosaccharide is a compound of formula Ic-i: [ka] or a pharma- ceutically acceptable salt thereof, wherein R 1 , R 2 , Y 1 , Y 2 , Z 1 , and Z 2 are as described in classes and subclasses herein, both alone and in combination.

[0081] In some embodiments, p is 2 and the oligosaccharide is a compound of formula Ic-ii: [ka] or a pharma- ceutically acceptable salt thereof, wherein R 1 , R 2 , Y 1 , Y 2 , Z 1 , and Z 2 are as described in classes and subclasses herein, both alone and in combination.

[0082] In some embodiments, p is 3 and the oligosaccharide is a compound of formula Ic-iii: [ka] or a pharma- ceutically acceptable salt thereof, wherein R 1 , R 2 , Y 1 , Y 2 , Z 1, and Z 2 are as described in classes and subclasses herein, both alone and in combination.

[0083] In some embodiments, p is 4 and the oligosaccharide is a compound of formula Ic-iv: [ka] or a pharma- ceutically acceptable salt thereof, wherein R 1 , R 2 , Y 1 , Y 2 , Z 1 , and Z 2 are as described in classes and subclasses herein, both alone and in combination.

[0084] In some embodiments, p is 5 and the oligosaccharide is a compound of formula Ic-v: [ka] or a pharma- ceutically acceptable salt thereof, wherein R 1 , R 2 , Y 1 , Y 2 , Z 1 , and Z 2 are as described in classes and subclasses herein, both alone and in combination.

[0085] The oligosaccharide compounds provided by the present invention contain disulfide moieties, which surprisingly and unexpectedly improves the expression of RNA in the target compared to the use of similar oligosaccharides that lack such disulfide moieties.See, for example, Figures 1C and 1D in Example 1.Without being bound by theory, it is believed that the oligosaccharide compounds of the present invention reduce the inherent cytotoxicity of other cationic compositions used for nucleic acid delivery.

[0086] Generally, as described herein, each R 1 and R 2 independently, in each instance, H, Ra , and -C(O)-R a Selected from R 1 or R 2 At least one instance of is not H. In some embodiments, each R 1 and R 2 is independently, in each case, R a , and -C(O)-R a In some embodiments, R 1 and R 2 Each of R a In some embodiments, R 1 and R 2 Each of R a And each R a are independent, C1-C 20 Aliphatic, C3-C 20 cycloaliphatic, C5-C6 aryl, 3- to 12-membered heterocyclyl containing 1 to 3 heteroatoms selected from N, O, and S; a is one or more R b is optionally replaced by

[0087] In some embodiments, R 1 and R 2 Each of R a and R a is one or more R b C1-C optionally substituted with 20 In some embodiments, R 1 and R 2 Each of R a And each R a is one or more R b C1-C optionally substituted with 14 In some embodiments, R 1 and R 2 Each of R a And each R a is one or more R b C1-C optionally substituted with 10 In some embodiments, R 1 and R 2 Each of R a and Ra is one or more R b C5-C optionally substituted with 10 In some embodiments, R 1 and R 2 Each of R a and R a is one or more R b C5-C optionally substituted with 10 In some embodiments, R 1 and R 2 Each of R a and R a is C5-C 10 In some embodiments, R 1 and R 2 Each of R a and R a is methyl, ethyl, n-propyl, n-butyl, n-pentyl, n-hexyl, n-heptyl, n-octyl, or n-nonyl. 1 and R 2 Each of R a And each R a is, independently, [ka] is selected from.

[0088] In some embodiments, R 1 and R 2 Each of R a And each R a is one or more R b C3-C optionally substituted with 20 In some embodiments, R 1 and R 2 Each of R a And each R a is one or more R b In some embodiments, R 1 and R 2 Each of R a and R ais cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl.

[0089] In some embodiments, R 1 and R 2 Each of R a and R a is one or more R b In some embodiments, R 1 and R 2 Each of R a and R a is phenyl.

[0090] In some embodiments, R 1 and R 2 Each of R a and R a is one or more R b In some embodiments, R is a 3-12 membered heterocyclyl containing 1-3 heteroatoms selected from N, O, and S, optionally substituted with 1 and R 2 Each of R a and R a is one or more R b and R is a 3- to 6-membered heterocyclyl containing 1 to 3 heteroatoms selected from N, O, and S, optionally substituted with

[0091] In some embodiments, R 1 and R 2 Each of the groups is -C(O)-R a And each R a are independent, C1-C 20 Aliphatic, C3-C 20 cycloaliphatic, C5-C6 aryl, 3- to 12-membered heterocyclyl containing 1 to 3 heteroatoms selected from N, O, and S; a is one or more R b is optionally replaced by

[0092] In some embodiments, R 1 and R 2Each of the groups is -C(O)-R a In some embodiments, each R 1 and R 2 is -C(O)-R a And each R a may independently be one or more R b C1-C optionally substituted with 20 In some embodiments, R 1 and R 2 Each of the groups is -C(O)-R a And each R a may independently be one or more R b C1-C optionally substituted with 14 In some embodiments, R 1 and R 2 Each of the groups is -C(O)-R a And each R a may independently be one or more R b C1-C optionally substituted with 10 In some embodiments, R 1 and R 2 Each of the groups is -C(O)-R a And each R a may independently be one or more R b C5-C optionally substituted with 10 In some embodiments, R 1 and R 2 Each of the groups is -C(O)-R a And each R a may independently be one or more R b C5-C optionally substituted with 10 In some embodiments, R 1 and R 2 Each of the groups is -C(O)-R a And each R a independently, C5-C 10 In some embodiments, R 1 and R 2 Each of the groups is -C(O)-R a And each R ais independently selected from methyl, ethyl, n-propyl, n-butyl, n-pentyl, n-hexyl, n-heptyl, n-octyl, and n-nonyl. 1 and R 2 Each of the groups is -C(O)-R a And each R a is, independently, [ka] is selected from.

[0093] In some embodiments, R 1 and R 2 Each of the groups is -C(O)-R a And each R a may independently be one or more R b C3-C optionally substituted with 20 In some embodiments, R 1 and R 2 Each of the groups is -C(O)-R a And each R a may independently be one or more R b In some embodiments, R 1 and R 2 Each of the groups is -C(O)-R a And each R a is independently selected from cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl. 1 and R 2 Each of the groups is -C(O)-R a And each R a may independently be one or more R b Polycyclic C optionally substituted with 10 -C 20 In some embodiments, R 1 or R 2 One or more of the following is: [ka]

[0094] In some embodiments, each R 1 and R 2 is -C(O)-R a And each R a may independently be one or more R b In some embodiments, R 1 and R 2 Each of the groups is -C(O)-R a and R a is phenyl.

[0095] In some embodiments, R 1 and R 2 Each of the groups is -C(O)-R a And each R a may independently be one or more R b In some embodiments, R is a 3-12 membered heterocyclyl containing 1-3 heteroatoms selected from N, O, and S, optionally substituted with 1 and R 2 Each of the groups is -C(O)-R a And each R a may independently be one or more R b and R is a 3- to 6-membered heterocyclyl containing 1 to 3 heteroatoms selected from N, O, and S, optionally substituted with

[0096] In some embodiments, R 1 and R 2 each of which is independently [ka] is selected from.

[0097] As described herein, each R b are independently halogen, -N3, -R c , -OR c , -SR c , -NHR c , -C(O)-R c , -OC(O)R c , -NHC(O)R c, -C(O)NHR c , and -NHC(O)NHR c In some embodiments, R b is halogen. In some embodiments, R b is -N3. In some embodiments, R b is R c In some embodiments, R b -OR c In some embodiments, R b -SR c In some embodiments, R b -NHR c In some embodiments, R b is -C(O)-R c In some embodiments, R b is -OC(O)R c In some embodiments, R b is -NHC(O)R c In some embodiments, R b is -C(O)NHR c In some embodiments, R b is -NHC(O)NHR c It is.

[0098] As described herein, each R c are independently optionally substituted C-C 20 Aliphatic, C3-C 20 In some embodiments, R is selected from cycloaliphatic, C5-C6 aryl, 3-12 membered heterocyclyl containing 1-3 heteroatoms selected from N, O, and S, and 4-12 membered heteroaryl containing 1-3 heteroatoms selected from N, O, and S. c is an optionally substituted C1-C 20 In some embodiments, R c is an optionally substituted C3-C 20 In some embodiments, R c is an optionally substituted C-C aryl. In some embodiments, Rc is an optionally substituted 3-12 membered heterocyclyl containing 1-3 heteroatoms selected from N, O, and S. In some embodiments, R c is an optionally substituted 4-12 membered heteroaryl containing 1-3 heteroatoms selected from N, O, and S.

[0099] As described herein, Y 1 and Y 2 each independently represents an optionally substituted C 1-30 is an aliphatic group, Y 1 and / or Y 2 One or more carbons of the group are optionally and independently substituted with -Cy-, -NH-, -NHC(O)-, -C(O)NH-, -NHC(O)O-, -OC(O)NH-, -NHC(O)NH-, -NHC(S)NH-, -C(S)NH- -C(O)NHSO2-, -SONHC(O)-, -OC(O)O-, -O-, -C(O)-, -OC(O)-, -C(O)O-, -SO-, or -SO2-.

[0100] In some embodiments, Y 1 and Y 2 are each independently C1-C 10 Aliphatic, C0-C4-aliphatic-NHC(O)NH-C0-C4aliphatic, C0-C4-aliphatic-NHC(S)NH-C0-C4aliphatic, C0-C4-aliphatic-C(O)NH-C0-C4aliphatic, C0-C4-aliphatic-C( S) selected from NH-C0-C4 aliphatic, C0-C4-aliphatic-NHC(O)-C0-C4 aliphatic, C0-C4-aliphatic-NHSO2-C0-C4 aliphatic, and C0-C4-aliphatic-C(O)-C0-C4 aliphatic.

[0101] In some embodiments, Y 1 and Y 2 are C1-C 10 In some embodiments, Y is aliphatic. 1 and Y 2 Each is methylene, ethylene, propylene, or butylene. 1 and Y2 are each -CH2-CH2-.

[0102] In some embodiments, Y 1 and Y 2 are each C-C-aliphatic-NHC(O)NH-C-C-aliphatic. 1 and Y 2 are each C1-C4-aliphatic-NHC(O)NH-C1-C4 aliphatic. 1 and Y 2 are each -CH2-CH2-NHC(O)NH-CH2-CH2-.

[0103] In some embodiments, Y 1 and Y 2 are each C-C-aliphatic-NHC(S)NH-C-C-aliphatic. 1 and Y 2 are each C1-C4-aliphatic-NHC(S)NH-C1-C4 aliphatic. 1 and Y 2 are each -CH2-CH2-NHC(S)NH-CH2-CH2-.

[0104] In some embodiments, Y 1 and Y 2 are each C-C-aliphatic-C(O)NH-C-C-aliphatic. 1 and Y 2 are each C1-C4-aliphatic-C(O)NH-C1-C4 aliphatic. 1 and Y 2 are each -CH2-CH2-C(O)NH-CH2-CH2-.

[0105] In some embodiments, Y 1 and Y 2 are each C-C-aliphatic-NHC(O)-C-C-aliphatic. 1 and Y 2are each C1-C4-aliphatic-NHC(O)-C1-C4 aliphatic. 1 and Y 2 are each -CH2-CH2-NHC(O)-CH2-CH2-.

[0106] In some embodiments, Y 1 and Y 2 are each C-C-aliphatic-NHSO-C-C-aliphatic. 1 and Y 2 are each C1-C4-aliphatic-NHSO2-C1-C4 aliphatic. 1 and Y 2 are respectively -CH2-CH2-NHSO2-CH2-CH2-.

[0107] In some embodiments, Y 1 is C1-C 10 Aliphatic, C0-C4-aliphatic-NHC(O)NH-C0-C4aliphatic, C0-C4-aliphatic-NHC(S)NH-C0-C4aliphatic, C0-C4-aliphatic-C(O)NH-C0-C4aliphatic, C0-C4-aliphatic- selected from C(S)NH-C0-C4 aliphatic, C0-C4-aliphatic-C(O)NH-C0-C4 aliphatic, C0-C4-aliphatic-NHSO2-C0-C4 aliphatic, and C0-C4-aliphatic-C(O)-C0-C4.

[0108] In some embodiments, Y 1 is C1-C 10 In some embodiments, Y is aliphatic. 1 is methylene, ethylene, propylene, or butylene. In some embodiments, Y 1 is -CH2-CH2-.

[0109] In some embodiments, Y 1 is C-C-aliphatic-NHC(O)NH-C-C-aliphatic. In some embodiments, Y 1is C1-C4-aliphatic-NHC(O)NH-C1-C4 aliphatic. In some embodiments, Y 1 is -CH2-CH2-NHC(O)NH-CH2-CH2-.

[0110] In some embodiments, Y 1 is C-C-aliphatic-NHC(S)NH-C-C-aliphatic. In some embodiments, Y 1 is C1-C4-aliphatic-NHC(S)NH-C1-C4 aliphatic. In some embodiments, Y 1 is -CH2-CH2-NHC(S)NH-CH2-CH2-.

[0111] In some embodiments, Y 1 is C-C-aliphatic-C(O)NH-C-C-aliphatic. In some embodiments, Y 1 is C1-C4-aliphatic-C(O)NH-C1-C4 aliphatic. In some embodiments, Y 1 is -CH2-CH2-C(O)NH-CH2-CH2-.

[0112] In some embodiments, Y 1 is C-C-aliphatic-NHC(O)-C-C-aliphatic. In some embodiments, Y 1 is C1-C4-aliphatic-NHC(O)-C1-C4 aliphatic. In some embodiments, Y 1 is -CH2-CH2-NHC(O)-CH2-CH2-.

[0113] In some embodiments, Y 1 is C-C-aliphatic-NHSO-C-C-aliphatic. In some embodiments, Y 1 is C1-C4-aliphatic-NHSO2-C1-C4 aliphatic. In some embodiments, Y 1 is -CH2-CH2-NHSO2-CH2-CH2-.

[0114] In some embodiments, Y 2 is C1-C10 Aliphatic, C0-C4-aliphatic-NHC(O)NH-C0-C4aliphatic, C0-C4-aliphatic-NHC(S)NH-C0-C4aliphatic, C0-C4-aliphatic-C(O)NH-C0-C4aliphatic, C0-C4-aliphatic- selected from C(S)NH-C0-C4 aliphatic, C0-C4-aliphatic-C(O)NH-C0-C4 aliphatic, C0-C4-aliphatic-NHSO2-C0-C4 aliphatic, and C0-C4-aliphatic-C(O)-C0-C4.

[0115] In some embodiments, Y 2 is C1-C 10 In some embodiments, Y is aliphatic. 2 is methylene, ethylene, propylene, or butylene. In some embodiments, Y 2 is -CH2-CH2-.

[0116] In some embodiments, Y 2 is C-C-aliphatic-NHC(O)NH-C-C-aliphatic. In some embodiments, Y 2 is C1-C4-aliphatic-NHC(O)NH-C1-C4 aliphatic. In some embodiments, Y 2 is -CH2-CH2-NHC(O)NH-CH2-CH2-.

[0117] In some embodiments, Y 2 is C-C-aliphatic-NHC(S)NH-C-C-aliphatic. In some embodiments, Y 2 is C1-C4-aliphatic-NHC(S)NH-C1-C4 aliphatic. In some embodiments, Y 2 is -CH2-CH2-NHC(S)NH-CH2-CH2-.

[0118] In some embodiments, Y 2 is C-C-aliphatic-C(O)NH-C-C-aliphatic. In some embodiments, Y 2 is C1-C4-aliphatic-C(O)NH-C1-C4 aliphatic. In some embodiments, Y 2is -CH2-CH2-C(O)NH-CH2-CH2-.

[0119] In some embodiments, Y 2 is C-C-aliphatic-NHC(O)-C-C-aliphatic. In some embodiments, Y 2 is C1-C4-aliphatic-NHC(O)-C1-C4 aliphatic. In some embodiments, Y 2 is -CH2-CH2-NHC(O)-CH2-CH2-.

[0120] In some embodiments, Y 2 is C-C-aliphatic-NHSO-C-C-aliphatic. In some embodiments, Y 2 is C1-C4-aliphatic-NHSO2-C1-C4 aliphatic. In some embodiments, Y 2 is -CH2-CH2-NHSO2-CH2-CH2-.

[0121] Generally, as described herein, each Cy independently represents an optionally substituted C3-C 14 a cyclic aliphatic ring, a 5- to 14-membered heterocyclyl ring having 1 to 3 heteroatoms selected from N, O and S; a 5- to 14-membered heteroaryl ring having 1 to 3 heteroatoms selected from N, O and S.

[0122] Generally, as described herein, Z 1 and Z 2 each independently represents an optionally substituted 5- to 14-membered heterocyclyl ring having 1 to 3 heteroatoms selected from N, O, and S; a 5- to 14-membered heteroaryl ring having 1 to 3 heteroatoms selected from N, O, and S; -N + (M)3, [ka] is a cationic or ionizable group selected from:

[0123] In some embodiments, Z 1 and Z2 each independently represents an optionally substituted 5- to 14-membered heterocyclyl ring having 1 to 3 heteroatoms selected from N, O, and S; an optionally substituted 5- to 14-membered heteroaryl ring having 1 to 3 heteroatoms selected from N, O, and S; -N + (M)3, [ka] is a cationic or ionizable group selected from:

[0124] In some embodiments, Z 1 and Z 2 are each an optionally substituted 5-14 membered heterocyclyl ring having 1-3 heteroatoms selected from N, O, and S. In some embodiments, Z 1 and Z 2 are each an optionally substituted 5-6 membered heterocyclyl ring having 1-3 heteroatoms selected from N, O, and S. In some embodiments, Z 1 and Z 2 are each an optionally substituted 6-membered heterocyclyl ring having 1 to 3 heteroatoms selected from N, O, and S. In some embodiments, Z 1 and Z 2 are each selected from optionally substituted piperidinyl, piperazinyl, and morpholinyl.

[0125] In some embodiments, Z 1 and Z 2 are each an optionally substituted 5-14 membered heteroaryl ring having 1-3 heteroatoms selected from N, O, and S.

[0126] In some embodiments, Z 1 and Z 2 are respectively, -N + (M)3. In some embodiments, Z 1 and Z 2 are respectively, -N + (C0-C6 aliphatic-R zIn some embodiments, Z 1 and Z 2 are respectively, -N + (R z In some embodiments, Z 1 and Z 2 are respectively, -N + H3. In some embodiments, Z 1 and Z 2 are respectively, -N + H(R z In some embodiments, Z 1 and Z 2 are respectively, -N + H(C1-C6 aliphatic). In some embodiments, Z 1 and Z 2 are respectively, -N + (H)2CH3. In some embodiments, Z 1 and Z 2 are respectively, -N + H(CH3)2. In some embodiments, Z 1 and Z 2 are respectively, -N + (CH3)3.

[0127] In some embodiments, Z 1 and Z 2 are respectively, -N + (R z )2-C1-C6 aliphatic-N + (R z In some embodiments, Z 1 and Z 2 are respectively, -N + (R z )(C1-C6 aliphatic-N + (R z ) 3) 2. In some embodiments, Z 1 and Z 2 are, respectively, [ka] It is.

[0128] In some embodiments, Z1 and Z 2 are, respectively, [ka] It is.

[0129] In some embodiments, Z 1 and Z 2 are, respectively, [ka] It is.

[0130] In some embodiments, Z 1 and Z 2 are, respectively, [ka] It is.

[0131] In some embodiments, Z 1 and Z 2 are, respectively, [ka] It is.

[0132] In some embodiments, Z 1 and Z 2 are, respectively, [ka] It is.

[0133] In some embodiments, Z 1 is an optionally substituted 5-14 membered heterocyclyl ring having 1-3 heteroatoms selected from N, O, and S. In some embodiments, Z 1 are each an optionally substituted 5-6 membered heterocyclyl ring having 1-3 heteroatoms selected from N, O, and S. In some embodiments, Z 1is an optionally substituted 6-membered heterocyclyl ring having 1 to 3 heteroatoms selected from N, O, and S. In some embodiments, Z 1 is selected from optionally substituted piperidinyl, piperazinyl, and morpholinyl.

[0134] In some embodiments, Z 1 -N + (M)3. In some embodiments, Z 1 -N + (C0-C6 aliphatic-R z In some embodiments, Z 1 -N + (R z In some embodiments, Z 1 -N + H3. In some embodiments, Z 1 -N + H(R z In some embodiments, Z 1 -N + H(C1-C6 aliphatic). In some embodiments, Z 1 -N + (H)2CH3. In some embodiments, Z 1 -N + H(CH3)2. In some embodiments, Z 1 -N + (CH3)3.

[0135] In some embodiments, Z 1 -N + (R z )2-C1-C6 aliphatic-N + (R z In some embodiments, Z 1 -N + (R z )(C1-C6 aliphatic-N + (R z ) 3) 2. In some embodiments, Z 1 teeth, [ka] It is.

[0136] In some embodiments, Z 1 teeth, [ka] It is.

[0137] In some embodiments, Z 1 teeth, [ka] It is.

[0138] In some embodiments, Z 1 teeth, [ka] It is.

[0139] In some embodiments, Z 1 teeth, [ka] It is.

[0140] In some embodiments, Z 1 teeth, [ka] It is.

[0141] In some embodiments, Z 2 is an optionally substituted 5-14 membered heterocyclyl ring having 1-3 heteroatoms selected from N, O, and S. In some embodiments, Z 2 are each an optionally substituted 5-6 membered heterocyclyl ring having 1-3 heteroatoms selected from N, O, and S. In some embodiments, Z 2is an optionally substituted 6-membered heterocyclyl ring having 1 to 3 heteroatoms selected from N, O, and S. In some embodiments, Z 2 is selected from optionally substituted piperidinyl, piperazinyl, and morpholinyl.

[0142] In some embodiments, Z 2 -N + (M)3. In some embodiments, Z 2 -N + (C0-C6 aliphatic-R z In some embodiments, Z 2 -N + (R z In some embodiments, Z 2 -N + H3. In some embodiments, Z 2 -N + H(R z In some embodiments, Z 2 -N + H(C1-C6 aliphatic). In some embodiments, Z 2 -N + (H)2CH3. In some embodiments, Z 2 -N + H(CH3)2. In some embodiments, Z 2 -N + (CH3)3.

[0143] In some embodiments, Z 2 -N + (R z )2-C1-C6 aliphatic-N + (R z In some embodiments, Z 2 -N + (R z )(C1-C6 aliphatic-N + (R z ) 3) 2. In some embodiments, Z 2 teeth, [ka] It is.

[0144] In some embodiments, Z 2 teeth, [ka] It is.

[0145] In some embodiments, Z 2 teeth, [ka] It is.

[0146] In some embodiments, Z 2 teeth, [ka] It is.

[0147] In some embodiments, Z 2 teeth, [ka] It is.

[0148] In some embodiments, Z 2 teeth, [ka] It is.

[0149] Generally, as described herein, each M is independently -C-C aliphatic -R z , or -C0-C6 aliphatic -N + (R z In some embodiments, each M is a C-C aliphatic -R z In some embodiments, each M is -C0-C6 aliphatic -N + (R z )3.

[0150] Generally, as described herein, each R z are independently H, optionally substituted C1-C6 aliphatic, optionally substituted C3-C 20 cycloaliphatic, optionally substituted C5-C6 aryl, optionally substituted 3- to 12-membered heterocyclyl containing 1 to 3 heteroatoms selected from N, O, and S, and optionally substituted 4- to 12-membered heteroaryl containing 1 to 3 heteroatoms selected from N, O, and S, or two or more R z can be taken together with the atom to which they are attached to form an optionally substituted 3- to 12-membered heterocyclyl containing 1-3 heteroatoms selected from N, O, and S, or an optionally substituted 4- to 12-membered heteroaryl containing 1-3 heteroatoms selected from N, O, and S.

[0151] In some embodiments, each R z is H. In some embodiments, each R z is an optionally substituted C-C aliphatic. In some embodiments, each R z is an optionally substituted C3-C 20 In some embodiments, each R z is an optionally substituted C-C aryl. In some embodiments, each R z is an optionally substituted 3-12 membered heterocyclyl containing 1-3 heteroatoms selected from N, O, and S. In some embodiments, each R z is an optionally substituted 4-12 membered heteroaryl containing 1-3 heteroatoms selected from N, O, and S.

[0152] In some embodiments, two or more R z can be taken together with the atom to which they are attached to form an optionally substituted 3-12 membered heterocyclyl containing 1-3 heteroatoms selected from N, O, and S. In some embodiments, two or more R zcan be taken together with the atom to which they are attached to form an optionally substituted 4-12 membered heteroaryl containing 1-3 heteroatoms selected from N, O, and S.

[0153] In some embodiments, Z 1 R on Part z and Z 2 R on Part z can be taken together to form a 4-6 membered heterocycle having 1-3 heteroatoms selected from N, O, and S.

[0154] As used herein, a "cationic" moiety is a group that has a net positive charge. As used herein, an "ionizable" moiety is a group that may have a neutral charge at a certain pH, but may become charged (e.g., cationic) at a different pH. For example, in some embodiments, the ionizable moiety becomes cationic (i.e., positively charged) at physiological pH (e.g., a pH of about 7.4). Additionally, in some embodiments, the cationic or ionizable moiety Z described herein is 1 and Z 2 The moiety further comprises one or more suitable counterions (e.g., anions for each cationic or ionizable moiety). For example, in some embodiments, Z 1 and Z 2 The moieties include counterions that are halides, hydroxides, carboxylates, sulfates, phosphates, nitrates, alkyls having 1 to 6 carbon atoms, sulfonates, and arylsulfonates. 1 and Z 2 The moieties include a counterion that is acetate (CH3COO-), chloride (Cl-), iodide (I-), bromide (Br-), or fluoride (F-). Reference to a particular counterion, such as those shown in Table 1, is intended to refer to the inclusion of a single charged moiety, as well as all chemically feasible counterions.

[0155] In some embodiments, Z 1 and Z 2are each independently [ka] [ka] is selected from.

[0156] In some embodiments, the compound of formula I is a compound of formula Id: [ka] or a pharma- ceutically acceptable salt thereof, wherein n and m are each independently selected from 0, 1, 2, 3, 4, 5, or 6; a , Y 1 , Y 2 , Z 1 , and Z 2 are as described in classes and subclasses herein, both alone and in combination.

[0157] In some embodiments, the oligosaccharide is a compound of formula Id: [ka] or a pharma- ceutically acceptable salt thereof, Each R a But independently, C1-C 20 Aliphatic, C3-C 20 cycloaliphatic, C5-C6 aryl, 3- to 12-membered heterocyclyl containing 1 to 3 heteroatoms selected from N, O, and S; a But there is one or more R b optionally replaced by Each R b are independently halogen, -N3, -R c , -OR c , -SR c , -NHR c , -C(O)-R c , -OC(O)R c , -NHC(O)R c , -C(O)NHR c , and -NHC(O)NHRc is selected from Each R c are independently optionally substituted C1-C 20 Aliphatic, optionally substituted C3-C 20 selected from cyclic aliphatic, optionally substituted C5-C6 aryl, optionally substituted 3-12 membered heterocyclyl containing 1-3 heteroatoms selected from N, O, and S, and optionally substituted 4-12 membered heteroaryl containing 1-3 heteroatoms selected from N, O, and S; Y 1 and Y 2 each independently represents an optionally substituted C 1-30 an aliphatic group in which one or more carbons are optionally and independently replaced with -Cy-, -NH-, -NHC(O)-, -C(O)NH-, -NHC(O)O-, -OC(O)NH-, -NHC(O)NH-, -NHC(S)NH-, -C(S)NH-, -C(O)NHSO2-, -SONHC(O)-, -OC(O)O-, -O-, -C(O)-, -OC(O)-, -C(O)O-, -SO-, or -SO2-; each Cy independently represents an optionally substituted C-C 14 an optionally substituted 5-14 membered heterocyclyl ring having 1-3 heteroatoms selected from cycloaliphatic, N, O, and S, and an optionally substituted 5-14 membered heteroaryl ring having 1-3 heteroatoms selected from N, O, and S; Z 1 and Z 2 each independently represents an optionally substituted 5- to 14-membered heterocyclyl ring having 1 to 3 heteroatoms selected from N, O, and S; an optionally substituted 5- to 14-membered heteroaryl ring having 1 to 3 heteroatoms selected from N, O, and S; -N + (M)3, [ka] is a cationic or ionizable group selected from Each M is independently -C0-C6 aliphatic -R z , or -C0-C6 aliphatic -N + (Rz )3, Each R z are independently H, optionally substituted C1-C6 aliphatic, optionally substituted C3-C 20 selected from cyclic aliphatic, optionally substituted C5-C6 aryl, optionally substituted 3-12 membered heterocyclyl containing 1-3 heteroatoms selected from N, O, and S, and optionally substituted 4-12 membered heteroaryl containing 1-3 heteroatoms selected from N, O, and S; or 2 or more R's z can be taken together with the atom to which they are attached to form an optionally substituted 3- to 12-membered heterocyclyl containing 1-3 heteroatoms selected from N, O, and S, or an optionally substituted 4- to 12-membered heteroaryl containing 1-3 heteroatoms selected from N, O, and S; n and m are each independently selected from 0, 1, 2, 3, 4, 5, or 6.

[0158] In some embodiments, the compound of formula Id is a compound of formula Id-i: [ka] or a pharma- ceutically acceptable salt thereof, wherein R a , Z 1 , and Z 2 are as described in classes and subclasses herein, both alone and in combination.

[0159] In some embodiments, the present disclosure provides a compound selected from Table 1: [Table 1-1] [Table 1-2] [Table 1-3] [Table 1-4] [Table 1-5] [Table 1-6] [Table 1-7] [Table 1-8] [Table 1-9] [Table 1-10] or a pharma- ceutically acceptable salt thereof.

[0160] In some embodiments, the provided compounds are provided and / or utilized in the form of a salt (e.g., a pharma- ceutically acceptable salt). Reference to a compound provided herein is understood to include a reference to its salt, unless otherwise indicated. Furthermore, reference to a particular salt herein, for example, in Table 1, is intended to include a reference to the free base form of the compound, so long as such compound is chemically feasible.

[0161] Exemplary compounds in Table 1 may contain a counter ion (e.g., Cl - , I - It is understood that the specific counterions provided above are represented as specific salts (e.g., chloride salts, iodide salts, etc.) including salts of the cationic nitrogen groups of Table 1. One of ordinary skill in the art will appreciate that any suitable counterion can be used in combination with the cationic nitrogen groups of Table 1. Thus, the specific counterions provided above are provided by way of example and are not intended to be limiting.

[0162] Complexes and Compositions The compositions described herein exhibit unexpectedly improved properties compared to previously described complexes. Furthermore, the present disclosure encompasses the insight that cationic and / or ionizable oligosaccharides are surprisingly useful for the delivery and targeted expression of certain therapeutic agents, e.g., nucleic acids, RNA.

[0163] Previous work on cationic oligosaccharides has focused on their use with DNA. Specifically, Carbajo-Gordillo et al. reported the use of certain oligosaccharides for DNA nanocomplexation and delivery. See Carbajo-Gordillo, et al., Chem. Comm., 55:8227-8230 (2019). However, the oligosaccharide-DNA complexes reported by Carbajo-Gordillo et al., specifically when complexed with RNA, exhibit surprisingly different properties than those reported in the present application. For example, the compositions reported herein, in some embodiments, exhibit different behavior in vivo, such as targeting different systems in the body (i.e., causing increased expression of RNA compared to other parts of the body), and can be prepared with significantly reduced oligosaccharide to nucleic acid ratios. For at least these reasons, the complexes reported here exhibit unexpected benefits over previously reported complexes.

[0164] Additionally, the compounds reported herein exhibit improved ratios of cationic moieties, or ionizable cationic groups (on the oligosaccharide) to anionic moieties (on the nucleic acid). For example, as described herein, the complexes include a ratio of cationic groups to anionic groups, referred to as the "N / P ratio." As described herein, the N / P ratio refers to the molar ratio of cationic groups (or ionizable groups that can become cationic, referred to as the "N" of N / P) in a composition that includes a cationic oligosaccharide compound to anionic groups in a composition that includes mRNA (referred to as the "P" of N / P). The compositions reported herein exhibit favorable ratios compared to previously reported complexes with DNA, thereby providing concentrated complexes for RNA delivery. For example, the Carbajo-Gordillo complex requires an N / P of approximately 20:1 for effective targeting and delivery of pDNA. In contrast, the complexes of the present invention include an N / P ratio of less than 20:1 for comparable targeting and delivery of RNA. It is understood that N / P ratios may also be expressed as single digits, e.g., 5, and the numbers presented herein are referred to as ratios of X:1. For example, an N / P of 5 is intended to refer to an N / P of 5:1. Similarly, an N / P of 10 is intended to refer to an N / P of 10:1, etc.

[0165] For example, in some embodiments, the N / P ratio of the complexes reported herein is less than 20:1. In some embodiments, the N / P ratio of the complexes reported herein is 15:1 or less. In some embodiments, the N / P ratio of the complexes reported herein is 12:1 or less. In some embodiments, the N / P ratio of the complexes reported herein is 10:1 or less. In some embodiments, the N / P ratio of the complexes reported herein is 5:1 or less. In some embodiments, the N / P ratio of the complexes reported herein is 2:1 or less. In some embodiments, the N / P ratio of the complexes reported herein is 1:1 or less. In some embodiments, the N / P ratio of the complexes reported herein is about 1:1 to about 15:1. In some embodiments, the N / P ratio of the complexes reported herein is about 1:1 to about 12:1. In some embodiments, the N / P ratio of the complexes reported herein is about 1:1 to about 10:1. In some embodiments, the N / P ratio of the complexes reported herein is about 1:1, about 2:1, about 3:1, about 4:1, about 5:1, about 6:1, about 7:1, about 8:1, about 9:1, about 10:1, about 11:1, about 12:1, about 13:1, about 14:1, about 15:1, about 16:1, about 17:1, about 18:1, or about 19:1.

[0166] In some embodiments, the complexes described herein have a diameter of about 30 nm to about 300 nm. In some embodiments, the complexes described herein have a diameter of about 50 nm to about 200 nm. In some embodiments, the complexes described herein have a diameter of about 50, 60, 70, 80, 90, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, or 200 nm. In some embodiments, the complexes described herein have a diameter of about 30 nm to about 150 nm. In some embodiments, the complexes described herein have a diameter of about 30 nm to about 100 nm. In some embodiments, the complexes described herein have a diameter of less than 100 nm. In some embodiments, the complexes described herein have a diameter of about 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, or 100 nm.

[0167] In some embodiments, the compositions or conjugates described herein further comprise a pharma- ceutically acceptable surfactant. In some embodiments, the pharma- ceutically acceptable surfactant is selected from polysorbates (e.g., polysorbate 20 (Tween 20), polysorbate 40 (Tween 40), polysorbate 60 (Tween 60), and polysorbate 80 (Tween 80)), poloxamers, and amphiphilic groups comprising a moiety selected from polyalkylene glycols (e.g., polyethylene glycols), poly(2-oxazoline), poly(2-methyl-2-oxazoline), polysarcosine, polyvinylpyrrolidone, and poly[N-(2-hydroxypropyl)methacrylamide], wherein the moiety comprises one or more C 12 -C 20 It is bonded to an aliphatic group.

[0168] In some embodiments, the molar ratio of oligosaccharide to surfactant is about 1:0.0075 to about 1:3. In some embodiments, the molar ratio of oligosaccharide to surfactant is about 1:0.0075 to about 1:1.5. In some embodiments, the molar ratio of oligosaccharide to surfactant is about 1:1. In some embodiments, the molar ratio of oligosaccharide to surfactant is about 1:0.0075, about 1:0.01, about 1:0.1, about 1:0.5, about 1:1, about 1:1.5, about 1:2, about 1:2.5, or about 1:3.

[0169] In some embodiments, the surfactant is a polysorbate. In some embodiments, the molar ratio of oligosaccharide to polysorbate is 1:0.0075 to 1:3. In some embodiments, the surfactant is a polysorbate. In some embodiments, the molar ratio of oligosaccharide to polysorbate is 1:0.0075 to 1:1.5. In some embodiments, the surfactant is a polysorbate. In some embodiments, the molar ratio of oligosaccharide to polysorbate is 1:0.0075 to 1:1. In some embodiments, the ratio of oligosaccharide to polysorbate is about 1:0.0075, about 1:0.01, about 1:0.1, about 1:0.5, about 1:1, about 1:1.5, about 1:2, about 1:2.5, or about 1:3.

[0170] In some embodiments, the complexes comprising an oligosaccharide and a pharma- ceutically acceptable surfactant have a diameter of about 30 nm to about 150 nm. In some embodiments, the complexes described herein have a diameter of about 30 nm to about 100 nm. In some embodiments, the complexes comprising an oligosaccharide and a pharma- ceutically acceptable surfactant have a diameter of less than 100 nm. In some embodiments, the complexes comprising an oligosaccharide and a pharma- ceutically acceptable surfactant have a diameter of about 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, or 100 nm.

[0171] RNA In some embodiments, the complexes described herein comprise one or more oligosaccharide compositions and a nucleic acid. In some embodiments, the nucleic acid is RNA.

[0172] In some embodiments, the RNA applicable to the technology described herein is single-stranded RNA. In some embodiments, the RNA disclosed herein is linear RNA. In some embodiments, the single-stranded RNA is non-coding RNA in that its nucleotide sequence does not contain an open reading frame (or its complementary strand). In some embodiments, the single-stranded RNA has a nucleotide sequence that codes (or is the complementary strand of the sequence that codes) for a polypeptide or multiple polypeptides (e.g., epitopes) of the present disclosure.

[0173] In some embodiments, the RNA is or includes siRNA, and miRNA, or other non-coding RNA.

[0174] In many embodiments, the related RNA comprises at least one open reading frame (ORF) (e.g., is an mRNA), in some embodiments, the related RNA comprises a single ORF, and in some embodiments, the related RNA comprises more than one ORF.

[0175] In some embodiments, the RNA comprises, for example, an ORF encoding a polypeptide of interest, or encoding multiple polypeptides of interest. In some embodiments, the RNA produced according to the techniques provided herein comprises multiple ORFs (e.g., encoding multiple polypeptides). In some embodiments, the RNA produced according to the techniques provided herein comprises a single ORF encoding multiple polypeptides. In some such embodiments, the polypeptide is or comprises an antigen or epitope (e.g., an associated antigen) thereof.

[0176] In some embodiments, an ORF for use according to the present disclosure encodes a polypeptide that includes a signal sequence that is functional in a mammalian cell, e.g., an endogenous signal sequence or a heterologous signal sequence. In some embodiments, the signal sequence directs secretion of the encoded polypeptide, and in some embodiments, the signal sequence directs transport of the encoded polypeptide to a defined cellular compartment, preferably the cell surface, the endoplasmic reticulum (ER), or an endosomal-lysosomal compartment.

[0177] In some embodiments, the ORF encodes a polypeptide that includes a multimerization element (e.g., a native or heterologous multimerization element). In some embodiments, an ORF that encodes a surface polypeptide (e.g., that includes a signal sequence that directs surface localization) includes a multimerization element.

[0178] In some embodiments, the ORF encodes a polypeptide that includes a transmembrane element or domain.

[0179] In some embodiments, the ORF is codon optimized for expression in a particular host, eg, a mammalian host, eg, a human cell.

[0180] In some embodiments, the RNA comprises unmodified uridine residues, and RNA comprising only unmodified uridine residues may be referred to as "uRNA". In some embodiments, the RNA comprises one or more modified uridine residues, and in some embodiments, such RNA (e.g., RNA comprising fully modified uridine residues) may be referred to as "modRNA". In some embodiments, the RNA may be a self-amplifying RNA (saRNA). In some embodiments, the RNA may be a trans-amplifying RNA (taRNA) (see, e.g., WO2017 / 162461).

[0181] In some embodiments, the relevant RNA comprises a portion encoding a polypeptide or a portion encoding multiple polypeptides. In some particular embodiments, such a portion or portions may encode a polypeptide or polypeptides that is or includes a biologically active polypeptide or portion thereof (e.g., a therapeutic protein such as an enzyme or cytokine, or a replacement protein or antibody or portion thereof). In some particular embodiments, such a portion or portions may encode a polypeptide or polypeptides that is or includes an antigen (or epitope thereof), cytokine, enzyme, etc. In some embodiments, the encoded polypeptide or polypeptides may be or include one or more neoantigens or neoepitopes associated with a tumor. In some embodiments, the encoded polypeptide or polypeptides may be or include one or more antigens (or epitopes thereof) of an infectious agent (e.g., bacteria, fungi, viruses, etc.). In certain embodiments, the encoded polypeptide may be a variant of a wild-type polypeptide.

[0182] In some embodiments, the single-stranded RNA (e.g., mRNA) may include a region encoding a secretion signal (e.g., a region encoding a secretion signal that allows one or more encoded target entities to be secreted upon translation by a cell). In some embodiments, such a region encoding a secretion signal may be or may include a non-human secretion signal. In some embodiments, such a region encoding a secretion signal may be or may include a human secretion signal.

[0183] In some embodiments, a single-stranded RNA (e.g., an mRNA) may include at least one non-coding element (e.g., to improve RNA stability and / or translation efficiency). Examples of non-coding elements include, but are not limited to, a 3' untranslated region (UTR), a 5' UTR, a cap structure (e.g., in some embodiments, an enzymatically added cap, in some embodiments, a co-transcriptional cap), a polyadenine (polyA) tail (e.g., in some embodiments, may be or include 100 or more A residues, and / or in some embodiments may include one or more "interrupt" [i.e., non-A] sequence elements), and any combination thereof. Exemplary embodiments of such non-coding elements can be found, for example, in WO2011015347, WO2017053297, US10519189, US10494399, WO2007024708, WO2007036366, WO2017060314, WO2016005324, WO2005038030, WO2017036889, WO2017162266, and WO2017162461, each of which is incorporated by reference herein in its entirety.

[0184] form At least four forms useful for RNA pharmaceutical compositions (e.g., immunogenic compositions or vaccines) have been developed: unmodified uridine containing mRNA (uRNA), nucleoside-depleted mRNA (modRNA), self-amplifying mRNA (saRNA), and trans-amplifying RNA (taRNA).

[0185] Features of the unmodified uridine platform may include, for example, one or more of inherent adjuvant effect, good tolerability and safety, and potent antibody and T cell responses.

[0186] The characteristics of the modified uridine (e.g., pseudouridine) platform may include reduced adjuvant effects, blunted immune innate immune sensor activation capability, and thus increased antigen expression, good tolerability and safety, as well as strong antibody and CD4 T cell responses. As described herein, the present disclosure provides insight that such strong antibody and CD4 T cell responses may be particularly useful for vaccination.

[0187] Characteristics of a self-amplifying platform may include, for example, long duration of polypeptide (eg, protein) expression, good tolerability and safety, and high potential for efficacy at very low vaccine doses.

[0188] In some embodiments, a self-amplifying platform (e.g., RNA) comprises two nucleic acid molecules, one nucleic acid molecule encoding a replicase (e.g., a viral replicase) and another nucleic acid molecule capable of being replicated by the replicase in trans (a trans-replication system) (e.g., a repcon). In some embodiments, a self-amplifying platform (e.g., RNA) comprises multiple nucleic acid molecules, the nucleic acids encoding multiple replicases and / or replicas.

[0189] In some embodiments, the trans-replication system comprises the presence of both nucleic acid molecules within a single host cell.

[0190] In some such embodiments, the nucleic acid encoding the replicase (e.g., a viral replicase) is unable to autonomously replicate in a target cell and / or target organism, In some such embodiments, the nucleic acid encoding the replicase (e.g., a viral replicase) lacks at least one conserved sequence element important for (-) strand synthesis from a (+) strand template and / or (+) strand synthesis from a (-) strand template.

[0191] In some embodiments, the self-amplifying RNA comprises a 5'-cap, and in some trans-replication systems, at least the RNA encoding the replicase is capped. Without wishing to be bound by any one theory, it has been found that the 5'-cap can be important for high-level expression of the gene of interest in trans.

[0192] In some embodiments, the self-amplifying platform does not require viral particle propagation (e.g., is not associated with undesired viral particle formation). In some embodiments, the self-amplifying platform is incapable of forming viral particles.

[0193] In some embodiments, the RNA may include an internal ribosome entry site (IRES) element. In some embodiments, the RNA does not include an IRES site, specifically, in some embodiments, the saRNA does not include an IRES site. In some such embodiments, translation of the gene of interest and / or replicase is not driven by an IRES element. In some embodiments, the IRES element is replaced by a 5'-cap. In some such embodiments, the replacement by a 5'-cap does not affect the sequence of the polypeptide encoded by the RNA.

[0194] In some embodiments, the complexes described herein comprise modRNA, saRNA, taRNA, or uRNA. In some embodiments, the complexes comprise modRNA. In some embodiments, the complexes comprise saRNA. In some embodiments, the complexes comprise taRNA. In some embodiments, the complexes comprise uRNA.

[0195] How to use The conjugates described herein are useful for the treatment and prevention of diseases, disorders, and conditions in subjects described herein. In some embodiments, the disclosure provides a method of treating a disease, disorder, or condition comprising administering to a patient a conjugate described herein. In some embodiments, the disclosure provides a use of a conjugate described herein for the treatment of a disease, disorder, or condition. In some embodiments, the disease, disorder, or condition is an infectious disease, cancer, an autoimmune disease, or a rare disease.

[0196] In some embodiments, the infectious disease is caused by or associated with a viral pathogen. In some embodiments, the viral pathogen is of a family selected from Poxviridae, Rhabdoviridae, Filoviridae, Paramyxoviridae, Hepadnaviridae, Coronaviridae, Caliciviridae, Picornaviridae, Reoviridae, Retroviridae, and Orthomyxoviridae. In some embodiments, the infectious disease is caused by or associated with a virus selected from SARS-CoV-2, influenza, Crimean-Congo hemorrhagic fever (CCHF), Ebola virus, Lassa virus, Marburg virus, HIV, Nipah virus, and MERS-CoV.

[0197] In some embodiments, the infectious disease is caused by or associated with a bacterial pathogen. In some embodiments, the bacterial pathogen is Actinomyces israelii, bacillus antracis, Bacteroides fragilis, Bordetella pertussis, Borrelia burgdorferi, Borrelia garinii, Borrelia afzelii, Borrelia recurrentis, Brucella abortus, Brucella canis, Brucella melitensis, Brucella suis, Campolobacter jejuni, Chlamydia pneumoniae, Chlamydia trachomatis, Chlamydophila psittaci, Clostridium botulinum, Clostridium difficile, Clostridium perfringens, Clostridium tetani, Corynebacterium idphteriae, Ehrlichia canis, Ehrlichia chaffeensis, Enterococcus faecalis, Enterococcus faecium, Escherichia coli, Francisella tularensis, Haemophilus influenzae, Helicobacter pylori, Klebsiella pneumoniae, Legionella pneumophila, Leptospira, Listeria monocytogenes, Mycobacterium leprae, Mycobacterium tuberculosis, Mycoplasma pneumoniae, Neisseria gonorrhoeae, Neisseria meningitidis, Pseudomonas aeruginosa, Nocardia asteroids, Rickettsia ricektssii, Salmonella typhi, Salmonella typhimurium, Shigella sonnei, Shigelladysenteriae, Staphylococcus aureus, Staphylococcus epidermidis, Staphylococcus saprophyticus, Streptococcus agalactiae, Streptococcus pneumoniae, Streptococcus pyogenes, Streptococcus viridans, Treponema pallidum, Vibrio cholerae, and Yersinia pestis.

[0198] In some embodiments, the infectious disease is caused by or associated with a parasite, hi some embodiments, the parasite is of a family selected from Plasmodium, Leishmania, Cryptosporidium, Entamoeba, Trypanosomas, Schistosomes, Ascaris, Echinococcus, and Taeniidae.

[0199] In some embodiments, the disease, disorder, or condition is cancer, hi some embodiments, the cancer is selected from bladder cancer, breast cancer, colorectal cancer, renal cancer, lung cancer, lymphoma, melanoma, oral / oropharyngeal cancer, pancreatic cancer, prostate cancer, thyroid cancer, and uterine cancer.

[0200] In some embodiments, the disease, disorder, or condition is a genetic disorder. In some embodiments, the genetic disorder is associated with a gain-of-function or loss-of-function mutation.

[0201] In some embodiments, the disease, disorder, or condition is an autoimmune disease, hi some embodiments, the autoimmune disease is selected from Addison's disease, celiac disease, rheumatoid arthritis, lupus, inflammatory bowel disease, dermatomyositis, multiple sclerosis, diabetes, Guillain-Barre syndrome, chronic inflammatory demyelinating polyneuropathy, psoriasis, pernicious anemia, Graves' disease, Hashimoto's thyroiditis, myasthenia gravis, and Sjogren's syndrome vasculitis.

[0202] In some embodiments, the disease, disorder or condition is a rare disease.As described herein, a rare disease refers to a life-threatening or chronically debilitating disease that has a very low incidence (e.g., less than 1 / 2000 people) and requires a special combination of efforts to address them.

[0203] In some embodiments, the present disclosure provides conjugates that can selectively target specific systems in the body. For example, in some embodiments, the conjugates described herein can selectively target the lung, liver, spleen, heart, brain, lymph nodes, bladder, kidney, and pancreas. As described herein, a conjugate "selectively targets" an organ if a single target expresses mRNA at 65% or more than expression in other organs after administration (e.g., 65% or more of the mRNA in the entire body is expressed from a single organ, with the remaining 35% distributed among one or more different organs). In some embodiments, the conjugates described herein selectively target the lung. In some embodiments, the conjugates described herein selectively target the liver. In some embodiments, the conjugates described herein selectively target the spleen. In some embodiments, the conjugates described herein selectively target the heart.

[0204] Method of service The present disclosure provides, inter alia, a complex (e.g., a pharmaceutical composition or pharmaceutical formulation as referred to herein) administered to a subject. For example, in some embodiments, the complex is administered as a monotherapy. In some embodiments, the complex is administered as part of a combination therapy. In some embodiments, the concentration of total RNA (e.g., the total concentration of all of the one or more RNA molecules) in the pharmaceutical compositions described herein is about 0.01 mg / mL to about 0.5 mg / mL, or about 0.05 mg / mL to about 0.1 mg / mL.

[0205] Pharmaceutical compositions, as used herein, may further comprise pharma- ceutically acceptable excipients, including any and all solvents, dispersion media, diluents, or other liquid vehicles, dispersing or suspending aids, surface active agents, isotonicity agents, thickening or emulsifying agents, preservatives, solid binders, lubricants, and the like, suitable for the particular dosage form desired. Remington's The Science and Practice of Pharmacy, 21st Edition, AR Gennaro (Lippincott, Williams & Wilkins, Baltimore, MD, 2006; incorporated herein by reference in its entirety) discloses various excipients used in formulating pharmaceutical compositions and known techniques for their preparation. Use of any conventional excipient vehicle is contemplated within the scope of this disclosure unless it is incompatible with the substance or its derivatives, such as by producing any undesirable biological effects or otherwise interacting in a deleterious manner with any other component(s) of the pharmaceutical composition.

[0206] In some embodiments, the excipients are approved for human and veterinary use. In some embodiments, the excipients are approved by the U.S. Food and Drug Administration. In some embodiments, the excipients are pharmaceutical grade. In some embodiments, the excipients meet the standards of the United States Pharmacopoeia (USP), the European Pharmacopoeia (EP), the British Pharmacopoeia, and / or the International Pharmacopoeia.

[0207] Pharmaceutically acceptable excipients used in the manufacture of pharmaceutical compositions include, but are not limited to, inert diluents, dispersing and / or granulating agents, surface active agents and / or emulsifying agents, disintegrating agents, binders, preservatives, buffers, lubricants, and / or oils. Such excipients may be optionally included in pharmaceutical preparations. Excipients such as cocoa butter and suppository waxes, coloring agents, coating agents, sweeteners, flavoring agents, and / or perfumes may be present in the composition, according to the judgment of the formulator.

[0208] General considerations in the formulation and / or manufacture of pharmaceutical products can be found, for example, in Remington: The Science and Practice of Pharmacy 21st ed., Lippincott Williams & Wilkins, 2005, which is incorporated herein by reference in its entirety.

[0209] In some embodiments, the pharmaceutical compositions provided herein can be formulated using one or more pharma- ceutically acceptable carriers or diluents, as well as any other known adjuvants and excipients, e.g., as can be found in Remington: The Science and Practice of Pharmacy 21st ed., Lippincott Williams & Wilkins, 2005 (hereby incorporated by reference in its entirety).

[0210] The pharmaceutical conjugates and compositions described herein can be administered by any suitable method known in the art. As will be appreciated by those skilled in the art, the route and / or mode of administration may depend on several factors, including, but not limited to, the stability and / or pharmacokinetics and / or pharmacodynamics of the pharmaceutical compositions described herein.

[0211] In some embodiments, the pharmaceutical compositions described herein are formulated for parenteral administration, which typically includes modes of administration other than enteral and topical administration by injection, including, but not limited to, intravenous, intramuscular, intraarterial, intrathecal, intracapsular, intraorbital, intracardiac, intradermal, intraperitoneal, transtracheal, subcutaneous, subcuticular, intraarticular, subcapsular, subarachnoid, intraspinal, epidural, and intrasternal injection and infusion.

[0212] In some embodiments, the pharmaceutical compositions described herein are formulated for intravenous administration. In some embodiments, pharma- ceutically acceptable carriers that may be useful for intravenous administration include sterile aqueous solutions or dispersions, and sterile powders for the preparation of sterile injectable solutions or dispersions.

[0213] In some specific embodiments, the pharmaceutical compositions described herein are formulated for subcutaneous (sc) administration. In some specific embodiments, the pharmaceutical compositions described herein are formulated for intramuscular (im) administration.

[0214] Therapeutic compositions must typically be sterile and stable under the conditions of manufacture and storage. The compositions can be formulated as solutions, dispersions, powders (e.g., lyophilized powders), microemulsions, lipid nanoparticles, or other ordered structures suitable for high drug concentration. The carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (e.g., glycerol, propylene glycol, liquid polyethylene glycol, and the like), and suitable mixtures thereof. Proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersion, and by the use of surfactants. In many cases, it is preferable to include an isotonic agent in the composition, for example, sugar, mannitol, sorbitol, or polyalcohol such as sodium chloride. In some embodiments, prolonged absorption of the injectable composition can be brought about by including an agent that delays absorption, for example, monostearate salts and gelatin.

[0215] Sterile injectable solutions can be prepared by incorporating the active compound in the required amount in the appropriate solvent with one or a combination of ingredients enumerated above, as required, followed by microfilter sterilization.

[0216] In some embodiments, the dispersions are prepared by incorporating the active compound into a sterile vehicle containing a basic dispersion medium and the required other ingredients from those enumerated above. In the case of sterile powders for the preparation of sterile injectable solutions, the preferred methods of preparation are vacuum drying and freeze-drying (lyophilization) which yield a powder of the active ingredient plus any additional desired ingredients from a previously sterile-filtered solution thereof.

[0217] Examples of suitable aqueous and non-aqueous carriers that can be used in the pharmaceutical compositions described herein include water, ethanol, polyols (such as glycerol, propylene glycol, polyethylene glycol, and the like) and suitable mixtures thereof, vegetable oils such as olive oil, and injectable organic esters such as ethyl oleate. Proper fluidity can be maintained, for example, by the use of coating materials such as lecithin, by the maintenance of the required particle size in the case of dispersions, and by the use of surfactants.

[0218] These compositions may also contain adjuvants such as preservatives, wetting agents, emulsifiers, and dispersing agents. Prevention of the presence of microorganisms can be ensured both by sterilization procedures and by the inclusion of various antibacterial and antifungal agents, such as parabens, chlorobutanol, phenol, sorbic acid, etc. It may also be desirable to include isotonic agents such as sugars, sodium chloride, etc. in the pharmaceutical compositions described herein. In addition, prolonged absorption of injectable pharmaceutical forms can be brought about by the inclusion of agents that delay absorption, such as aluminum monostearate and gelatin.

[0219] The formulations of the pharmaceutical compositions described herein may be prepared by any method known or hereafter developed in the art of pharmacology. In general, such preparation methods include the step of bringing into association the active ingredient(s) with a diluent or other excipient and / or one or more other accessory ingredients, and then, if necessary and / or desired, shaping and / or packaging the product into the desired single or multiple dosage unit.

[0220] Pharmaceutical compositions according to the present disclosure may be prepared, packaged, and / or sold in bulk, as a single unit dose, and / or as a plurality of single unit doses. As used herein, a "unit dose" is a discrete amount of a pharmaceutical composition comprising a predetermined amount of at least one RNA product produced using the systems and / or methods described herein.

[0221] In some embodiments, the active agent that may be included in the pharmaceutical composition described herein is or includes a therapeutic agent administered in a combination therapy described herein. The pharmaceutical composition described herein may be administered in combination therapy, i.e., in conjunction with other agents. In some embodiments, such a therapeutic agent may include an agent that results in the depletion or functional inactivation of regulatory T cells. For example, in some embodiments, the combination therapy may include the provided pharmaceutical composition and at least one immune checkpoint inhibitor.

[0222] In some embodiments, the pharmaceutical compositions described herein may be administered in conjunction with radiation therapy and / or autologous peripheral stem cell or bone marrow transplantation.

[0223] In some embodiments, the pharmaceutical compositions described herein can be frozen to allow for long-term storage.

[0224] Although the description of pharmaceutical compositions provided herein is directed primarily to pharmaceutical compositions suitable for administration to humans, it will be understood by those skilled in the art that such compositions are generally suitable for administration to animals of all kinds. Modifications of pharmaceutical compositions suitable for administration to humans to make them suitable for administration to a variety of animals are well understood, and an ordinarily skilled veterinary pharmacologist can design and / or implement such modifications with no more than routine experimentation, if any.

[0225] Methods of preparing the compositions described herein As described herein, the present disclosure relates to, inter alia, an oligosaccharide of formula Ia: [ka] or a pharma- ceutically acceptable salt thereof, comprising reacting a compound of formula II [ka] with a first acid to obtain a compound of formula Ia; Y 1 and Y 2 are each -CH-CH-NHC(S)NH-CH-CH-, Z 1 and Z 2 are each -NH3Cl, R 1 and R 2 are respectively -C(O)-R a and R a is optionally substituted C1-C 20 It is aliphatic, PG 1 is a nitrogen protecting group.

[0226] In some embodiments, the method of preparing a compound of formula II comprises reacting a compound of formula III: [ka] Contacting with a compound of formula IV in the presence of a base, [ka] to obtain a compound of formula II.

[0227] In some embodiments, the method of preparing a compound of formula II comprises reacting a compound of formula IIIa with [ka] Contacting with a compound of formula IVa in the presence of a base, [ka] to obtain a compound of formula II.

[0228] In some embodiments, the method of preparing a compound of formula IIIa includes contacting a compound of formula III with CSCl 2 to obtain a compound of formula IIIa.

[0229] In some embodiments, the method of preparing a compound of formula III comprises reacting a compound of formula V: [ka] with a second acid to obtain a compound of formula III, wherein PG 2 is a suitable nitrogen protecting group.

[0230] In some embodiments, the method of preparing a compound of formula V comprises reacting a compound of formula VI with [ka] Contacting with a compound of formula VIa [ka] to obtain a compound of formula V.

[0231] In some embodiments, the method of preparing a compound of formula VI comprises reacting a compound of formula VII with [ka] Contacting with a compound of formula VIIa [ka] to obtain a compound of formula VI.

[0232] In some embodiments, the method of preparing a compound of formula VIIa comprises reacting a compound of formula VIII with [ka] with a compound of formula VIIIa in the presence of dioxane, [ka] to obtain a compound of formula VIIa.

[0233] In some embodiments, the method of preparing a compound of formula VII comprises reacting a compound of formula IX: [ka] sodium methoxide to obtain a compound of formula VII.

[0234] In some embodiments, the method of preparing a compound of formula IX comprises reacting a compound of formula X with [ka] with thioacetic acid in the presence of a third base to provide a compound of formula IX.

[0235] In some embodiments, PG 1 and P.G. 2 are each independently selected from Boc (tert-butoxycarbonyl), Fmoc (fluorenylmethyloxycarbonyl), Cbz (benzyl chloroformate), Troc (2,2,2-trichloroethoxycarbonyl), trityl (triphenylmethyl), phthalimide, tetrachlorophthalimide, and trifluoroacemide.

[0236] Exemplary embodiments The following numbered embodiments are non-limiting examples of certain aspects of the present disclosure.

[0237] Embodiment 1. A compound of formula I: [ka] or a pharma- ceutically acceptable salt thereof, wherein: A is A 1 , A 2 , or A 3 and [ka] Each R 1 and R 2 But independently, in each case, H, R a , and -C(O)-R a Selected from R 1 or R 2 At least one instance of is not H, Each Ra But independently, C1-C 20 Aliphatic, C3-C 20 cycloaliphatic, C5-C6 aryl, 3- to 12-membered heterocyclyl containing 1 to 3 heteroatoms selected from N, O, and S; a But there is one or more R b optionally replaced by Each R b are independently halogen, -N3, -R c , -OR c , -SR c , -NHR c , -C(O)-R c , -OC(O)R c , -NHC(O)R c , -C(O)NHR c , and -NHC(O)NHR c is selected from Each R c are independently optionally substituted C1-C 20 Aliphatic, optionally substituted C3-C 20 selected from cyclic aliphatic, optionally substituted C5-C6 aryl, optionally substituted 3-12 membered heterocyclyl containing 1-3 heteroatoms selected from N, O, and S, and optionally substituted 4-12 membered heteroaryl containing 1-3 heteroatoms selected from N, O, and S; Y 1 and Y 2 each independently represents an optionally substituted C 1-30 an aliphatic group in which one or more carbons are optionally and independently replaced with -Cy-, -NH-, -NHC(O)-, -C(O)NH-, -NHC(O)O-, -OC(O)NH-, -NHC(O)NH-, -NHC(S)NH-, -C(S)NH-, -C(O)NHSO2-, -SONHC(O)-, -OC(O)O-, -O-, -C(O)-, -OC(O)-, -C(O)O-, -SO-, or -SO2-; each Cy independently represents an optionally substituted C-C 14an optionally substituted 5-14 membered heterocyclyl ring having 1-3 heteroatoms selected from cycloaliphatic, N, O, and S, and an optionally substituted 5-14 membered heteroaryl ring having 1-3 heteroatoms selected from N, O, and S; Z 1 and Z 2 each independently represents an optionally substituted 5- to 14-membered heterocyclyl ring having 1 to 3 heteroatoms selected from N, O, and S; an optionally substituted 5- to 14-membered heteroaryl ring having 1 to 3 heteroatoms selected from N, O, and S; -N + (M)3, [ka] is a cationic or ionizable group selected from Each M is independently -C0-C6 aliphatic -R z , or -C0-C6 aliphatic -N + (R z )3, Each R z are independently H, optionally substituted C1-C6 aliphatic, optionally substituted C3-C 20 selected from cyclic aliphatic, optionally substituted C5-C6 aryl, optionally substituted 3-12 membered heterocyclyl containing 1-3 heteroatoms selected from N, O, and S, and optionally substituted 4-12 membered heteroaryl containing 1-3 heteroatoms selected from N, O, and S; or 2 or more R's z can be taken together with the atom to which they are attached to form an optionally substituted 3- to 12-membered heterocyclyl containing 1-3 heteroatoms selected from N, O, and S, or an optionally substituted 4- to 12-membered heteroaryl containing 1-3 heteroatoms selected from N, O, and S; The compound, or a pharma- ceutically acceptable salt thereof, wherein p is an integer selected from 1, 2, 3, 4, and 5.

[0238] Embodiment 2. The compound is of formula Ia: [ka] or a pharma- ceutically acceptable salt thereof.

[0239] Embodiment 3. The compound is of formula Ib: [ka] or a pharma- ceutically acceptable salt thereof.

[0240] Embodiment 4. The compound is of formula Ic: [ka] or a pharma- ceutically acceptable salt thereof.

[0241] Embodiment 5.R 1 and R 2 Each independently, R a , and -C(O)-R a Selected from R a But, C1-C 20 The compound of any one of embodiments 1-4, which is aliphatic.

[0242] Embodiment 6.R 1 and R 2 are respectively -C(O)-R a and R a But, C1-C 14 The compound of any one of embodiments 1-5, which is aliphatic.

[0243] Embodiment 7. Each R a But, C5-C 10 The compound of any one of embodiments 1-6, which is a straight chain alkyl.

[0244] Embodiment 8.R 1 and R 2 are respectively -C(O)-R a and R a but, [ka] 2. The compound of embodiment 1, wherein

[0245] Embodiment 9.Y 1 and Y 2 However, C1-C 10 Aliphatic, C0-C4-aliphatic-NHC(O)NH-C0-C4 aliphatic, C0-C4-aliphatic-NHC(S)NH-C0-C4 aliphatic, C0-C4-aliphatic-C(O)NH-C0-C4 aliphatic, C0-C4-aliphatic-C(S)NH-C0-C4 aliphatic A compound according to any one of embodiments 1 to 8, selected from aliphatic, C0-C4-aliphatic-NHC(O)-C0-C4 aliphatic, C0-C4-aliphatic-NHSO2-C0-C4 aliphatic, and C0-C4-aliphatic-C(O)-C0-C4 aliphatic.

[0246] Embodiment 10.Y 1 and Y 2 is each a C1-C4 aliphatic -NHC(S)NH-C1-C4 aliphatic.

[0247] Embodiment 11.Y 1 and Y 2 is each —CH2—CH2—NHC(S)NH—CH2—CH2—.

[0248] Embodiment 12.Z 1 and Z 2 Each independently, N + (M)3, [ka]

[0249] 12. The compound according to any one of embodiments 1 to 11, selected from: Embodiment 13.Z 1 and Z 2 However, each independently, [ka] [ka] 12. The compound according to any one of embodiments 1 to 11, selected from:

[0250] Embodiment 14. The oligosaccharide is a compound of formula Id: [ka] or a pharma- ceutically acceptable salt thereof, wherein m and n are each independently selected from 0, 1, 2, 3, 4, 5, or 6.

[0251] Embodiment 15. The oligosaccharide is a compound of formula Id-i: [ka] or a pharma- ceutically acceptable salt thereof.

[0252] Embodiment 16. A compound according to any one of embodiments 1 to 15, further comprising one or more suitable counterions.

[0253] Embodiment 17 The compound of embodiment 1, wherein the oligosaccharide is selected from Table 1.

[0254] Embodiment 18. A complex comprising the compound according to any one of embodiments 1 to 17 and a nucleic acid.

[0255] Embodiment 19. The complex of embodiment 18, wherein the nucleic acid is RNA.

[0256] Embodiment 20 The complex of embodiment 19, wherein the RNA is modRNA, saRNA, taRNA, or uRNA.

[0257] Embodiment 21. A complex according to any one of embodiments 18 to 20, wherein the N / P ratio is less than 20:1.

[0258] Embodiment 22. The complex of embodiment 21, wherein the N / P ratio is 12:1 or less.

[0259] Embodiment 23. The complex of any one of embodiments 18 to 22, wherein the complex has a diameter of about 30 nm to about 150 nm.

[0260] Embodiment 24. A method for delivering a composition to a target in a subject, comprising administering to the subject a complex described in any one of embodiments 18 to 23.

[0261] Embodiment 25. The method of embodiment 24, wherein the target is selected from the liver, lung, or spleen.

[0262] Embodiment 26. A method for treating a disease, disorder, or condition in a subject, comprising administering to the subject a conjugate described in any one of embodiments 18 to 23.

[0263] Embodiment 27. The method of embodiment 26, wherein the disease, disorder, or condition is an infectious disease, cancer, a genetic disorder, an autoimmune disease, or a rare disease.

[0264] Embodiment 28 The method of any one of embodiments 24 to 27, wherein the complex is administered intramuscularly.

[0265] Embodiment 29. The method of any one of embodiments 24 to 27, wherein the complex is administered subcutaneously.

[0266] Embodiment 30. Use of a compound according to any one of embodiments 1 to 17 in medicine.

[0267] Embodiment 31. Use of a conjugate according to embodiment 18 in medicine.

[0268] Embodiment 32. Use of a complex according to embodiment 18 for increasing or causing an increase in expression of RNA in a target.

[0269] Embodiment 33. Use of a conjugate according to embodiment 18 for the treatment of a disease, disorder or condition.

[0270] Embodiment 34. The use of embodiment 33, wherein the disease, disorder, or condition is an infectious disease, cancer, a genetic disorder, an autoimmune disease, or a rare disease.

[0271] Embodiment 35. An oligosaccharide of formula Ia: [ka] or a pharma- ceutically acceptable salt thereof, comprising reacting a compound of formula II [ka] with a first acid to obtain said compound of formula Ia; Y 1 and Y 2 are each -CH-CH-NHC(S)NH-CH-CH-, Z 1 and Z 2 are each -NH3Cl, R 1 and R 2 are respectively -C(O)-R a and R a is optionally substituted C1-C 20 It is aliphatic, PG 1 is a nitrogen protecting group.

[0272] Embodiment 36. Compounds of formula III are [ka] Contacting with a compound of formula IV in the presence of a base, [ka] 36. The method of embodiment 35, further comprising obtaining said compound of formula II.

[0273] Embodiment 37. Compounds of formula IIIa are reacted with [ka] Contacting with a compound of formula IVa in the presence of a base, [ka] 36. The method of embodiment 35, further comprising obtaining said compound of formula II.

[0274] Embodiment 38. The method of embodiment 37, further comprising contacting the compound of formula III with CSCl2 to obtain a compound of formula IIIa.

[0275] Embodiment 39. A compound of formula V is [ka] with a second acid to obtain the compound of formula III, 2 37. The method of embodiment 36, wherein: is a suitable nitrogen protecting group.

[0276] Embodiment 40. Compound of Formula VI is [ka] Contacting with a compound of formula VIa [ka] 40. The method of embodiment 39, further comprising obtaining said compound of formula V.

[0277] Embodiment 41. Compound of Formula VII is [ka] Contacting with a compound of formula VIIa [ka] 41. The method of embodiment 40, further comprising obtaining said compound of formula VI.

[0278] Embodiment 42. Compounds of formula VIII are reacted with [ka] with a compound of formula VIIIa in the presence of dioxane, [ka] The method of embodiment 41, further comprising obtaining said compound of formula VIIa.

[0279] Embodiment 43. Compounds of formula IX are reacted with [ka] 43. The method of embodiment 41 or 42, further comprising contacting with sodium methoxide to obtain the compound of formula VII.

[0280] Embodiment 44. A compound of formula X is [ka] 44. The method of embodiment 43, further comprising contacting with thioacetic acid in the presence of a third base to obtain said compound of formula IX.

[0281] The foregoing is a description of certain non-limiting embodiments of the subject matter described herein. It should therefore be understood that the embodiments described herein are merely illustrative of the subject matter reported herein. Reference to the details of the illustrated embodiments is not intended to limit the scope of the claims, which themselves recite those features that are deemed essential.

[0282] The systems and methods of the claimed subject matter are intended to encompass variations and adaptations developed using information from the embodiments described herein. Adaptations, modifications, or both of the systems and methods described herein may be performed by one of ordinary skill in the relevant art.

[0283] Throughout the description, when a system is described as having, including, or comprising particular components, or a method is described as having, including, or comprising particular steps, it is further contemplated that there are systems within the inventive subject matter that consist essentially of or consist of the recited components, and that there are methods within the inventive subject matter that consist essentially of or consist of the recited processing steps.

[0284] It should be understood that the order of steps or order for performing certain actions is immaterial so long as any embodiment of the subject matter described herein remains operable. Moreover, two or more steps or actions may be conducted simultaneously.

[0285] Acknowledgements The applicants would like to thank the Consejo Superior de Investigaciones Cientificas and FIUS / UNIVERSITY OF SEVILLE / for their support and contribution to the development of this study. EXAMPLES

[0286] The examples provided herein document and support certain aspects of the present disclosure, but are not intended to limit the scope of any claims. The following non-limiting examples are provided to further illustrate certain teachings provided by the present disclosure. In light of this application, those skilled in the art will understand that various modifications can be made to the specific embodiments shown in these examples without departing from the spirit and scope of the teachings of the present invention.

[0287] In the examples below, the following abbreviations may be used: aq. (aqueous); ACN (acetonitrile); CSA (camphorsulfonic acid); d (days or days); Da / kDa (daltons / kilodaltons); DCM (dichloromethane); ddH2O (double distilled H2O); DEA (diethylamine); DHP (dihydropyran); DMF (N,N-dimethylformamide); DIPEA (N,N-diisopropylethylamine); DMAP (4-dimethylaminopyridine); DOTMA (1,2-di-O-octadecenyl-3-trimethylammonium propane); DODMA (1,2-dioleyloxy-3-dimethylaminopropane), DOPE (1,2-dioleoyl-sn-glycero-3-phosphoethanolamine); DMSO (dimethylsulfoxide); EA (ethyl acetate); ee (enantiomeric excess); equiv. (equivalents); ethanol (EtOH); h (hours or hours); Hex (hexane); HP LC (high performance liquid chromatography); IPA (isopropyl alcohol); im (intramuscular); iv (intravenous); KHMDS (potassium bis(trimethylsilyl)amide); LAH (lithium aluminum hydride); LCMS (liquid chromatography-mass spectrometry); LDA (lithium diisopropylamide); LiHMDS (lithium bis(trimethylsilyl)amide); MeOH (methanol); min (minutes or minutes); NMR (nuclear magnetic resonance); Pd / C (palladium on carbon); PEI (polyethyleneimine); PPhO (triphenylphosphine oxide); Pt / C (platinum on carbon); rb (round bottom); Rf (retention); rt or RT (room temperature); sc (subcutaneous); SM (starting material); TEA (triethylamine); THF (tetrahydrofuran); THP (tetrahydropyran); TLC (thin layer chromatography); TsOH (p-toluenesulfonic acid or tosylate); and UV (ultraviolet).

[0288] Example 1 - Conjugation Protocol Complexation of the exemplary embodiments described herein is produced by mixing asymmetric volumes of an RNA-containing solution and a cationic oligosaccharide-containing solution. As used herein, reference to "paOS" refers to the cationic oligosaccharides described herein. For the RNA solution, the required concentration of RNA was prepared by diluting appropriate volumes of ddH2O, RNA stock, and buffer (6x). Oligosaccharide solutions were prepared in separate tubes by diluting oligosaccharides in DMSO to the desired concentration. The RNA and cationic oligosaccharide phases were mixed in a volume ratio of 9:1 (RNA:oligosaccharide). The formulated complexes were incubated at room temperature for 5-10 minutes for stabilization. The buffer used for formulation in all experiments was MBS (MES-buffered sucrose (10 mM MES, pH 6.1, 10% sucrose)).

[0289] Complexes of either ssJRL13 or JRL13 with saRNA were formulated at different N / P ratios. JRL13 is a compound described as compound 8 in Carbajo-Gordillo, et al., Chem. Comm., 55:8227-8230 (2019) and has the following structure: [ka] ssJRL13 is a compound of the following structure: [ka]

[0290] Complexes with either ssJRL13 or JRL13 at an N / P ratio of 12 were tested in C2C12 and HepG2 cell lines at a dose range of 12.5-400 ng of formulated RNA. Formulations were complexed in MBS buffer (final concentration 10% w / v sucrose, 10 mM MES, pH 6.1) at a final RNA concentration of 0.05 mg / ml, with a mixing ratio of RNA-containing and oligosaccharide-containing solutions of 9:1 (v:v) in all cases. Formulations were characterized prior to injection to confirm hydrodynamic diameter and zeta potential. Figure 1A shows the percentage of free RNA quantified by gel electrophoresis of saRNA formulated at different N / P ratios from 0 to 3 for either JRL13 or ssJRL13. Figure 1B shows the hydrodynamic diameter of formulated saRNA at different N / P ratios with either JRL13 or ssJRL13. Figures 1C-1D show expression of saRNA encoding luciferase 24 hours after transfection of C2C12 cells (Figure 1C) or HepG2 cells (Figure 1D) with saRNA formulated in N / P12 with either JRL13 or ssJRL13 at 12.5 ng-400 ng RNA / well. Data here represent three independent experiments (n=3) that were technically repeated twice. Figures 1E-1F show expression viability of cells 24 hours after transfection of C2C12 cells (Figure 1E) or HepG2 cells (Figure 1F) with saRNA formulated in N / P12 with either JRL13 or ssJRL13 at 12.5 ng-400 ng RNA / well. Data here represent three independent experiments (n=3) that were technically repeated twice.

[0291] Example 2 - Intramuscular vaccination Fifteen female BALB / c mice were divided into three groups. One group received only buffer as a negative control, and two groups received 2 μg of formulated saRNA encoding the hemagglutinin (HA) protein of influenza strain California / 7 / 2009. All saRNA formulations were administered im into one of the legs. All saRNA groups were formulated with different oligosaccharides (JRL13 or ssJRL13) at N / P6. The formulations were complexed in MBS buffer (final concentration 10% w / v sucrose, 10 mM MES, pH 6.1) at a final RNA concentration of 0.05 mg / ml, and the mixing ratio of RNA-containing solution and oligosaccharide-containing solution was 9:1 (v:v) in all cases. Animals were subjected to non-invasive serological monitoring at different time points (days 0, 14, 21, 28, 49) over a period of 49 days, and spleens were removed at the end of the experiment to quantify CD4 / CD8 T cell responses against influenza HA peptides. Anti-influenza HA antibodies in serum were quantified by enzyme-linked immunosorbent assay. Virus neutralization titers were quantified by VNT assay. CD4 / CD8 T cell responses were quantified by IFN-ELISPOT of splenocytes. Figure 2A shows the hydrodynamic diameter of saRNA formulated with either JRL13 or ssJRL13. Figure 2B shows the serological levels of specific IgG against HA over the course of the experiment at a serum dilution of 1:300.

[0292] Example 3 - Synthesis Scheme Scheme 1 illustrates the synthesis of compounds of formula I, where A is 1 and R 1 and R 2 are both -C(O)-R a and Y 1 and Y 2 are both -(CH2)2- and Z 1 and Z 2 is NH3 + (Compounds ssJRL13 and PRX022 in Scheme 1). Scheme 1 also shows general routes (Routes A1, A2, B1, and B2) that can be implemented for the synthesis of compounds of formula I, where A is A 1 and R1 and R 2 are both -C(O)-R a and Y 1 and Y 2 are both -(CH2)2-NHC(S)NH-(CH2)2-, and Z 1 and Z 2 is identical (compound 8T in Scheme 1): [ka]

[0293] Scheme 2 shows the synthesis of compounds of formula I, where A is 2 and R 1 and R 2 are both -C(O)-R a and Y 1 and Y 2 are both -(CH2)2- and Z 1 and Z 2 is NH3 + (Compound PRX104 in Scheme 2). Scheme 1 also shows general routes (Routes A1, A2, B1, and B2) that can be implemented for the synthesis of compounds of formula I, where A is A 2 and R 1 and R 2 are both -C(O)-R a and Y 1 and Y 2 are both -(CH2)2-NHC(S)NH-(CH2)2-, and Z 1 and Z 2 is identical (compound 8S in Scheme 2): [ka]

[0294] In some embodiments, R 1 and R 2 are both -C(O)-R a The synthesis of compounds of formula I, [ka]

[0295] In some embodiments, the synthesis of compounds of formula I according to Scheme 1 includes the step of adding a cationic moiety Z 1 and Z 2 The reaction steps leading to the installation of involved the following isothiocyanate or amine reagents: [ka]

[0296] In some embodiments, the following precursors used in the synthesis of certain compounds described herein were prepared according to known methods:

[0297] 6,6'-diiodo-6,6'-dideoxy-α,α'-trehalose (1T) was prepared according to a procedure described in the literature. See JM Garcia Fernandez, et al., Carbohydr. Res. 1995, 268, 57-71.

[0298] 6,6'-Dithio-6,6'-di-S-acetyl-α,α'-trehalose (2T). Compound 2T was synthesized using a procedure similar to that described by Bong. See D. Bong, et al., Chem. Commun. 2011, 47, 2853-2855. In this example, potassium thioacetate was replaced with equimolar amounts of triethylamine and thioacetic acid, which were added sequentially (in that order) to the reaction mixture.

[0299] 6,6'-Dithio-α,α'-trehalose (3T). Compound 3T was quantitatively obtained by treating compound 2 with sodium methoxide according to the procedure described by Bong. D. Bong, et al., Chem. Commun. 2011, 47, 2853-2855.

[0300] 6,6'-Diiodo-6,6'-dideoxy-sucrose (1S). Compound 1S was prepared from commercially available reagents according to literature procedures. See JM Garcia Fernandez, et al., Carbohydr. Res. 1994, 265, 249-269.

[0301] 6,6'-Di(mercaptoacetyl)-2,3,4,1',3',4'-hexa-O-acetylsucrose (2S). Compound 2S was obtained by sequential treatment of compound 1S with acetic anhydride and thioacetic acid, adapting the procedure described in the literature. See WJ Lee, et al., J. Am. Chem. Soc. 1993, 115, 1860-1869.

[0302] As used herein, an arrow is followed by a code in parentheses, e.g., "(→code)" indicates the lipophilic tail (R 1 and R 2 substituent) or cationic moiety (Z in the compound of formula I 1 and Z 2 For example, "hexanoyl chloride (→L1)" is intended to refer to the moiety L1 attached to the compound via the use of hexanoyl chloride, as described in the table above.

[0303] Hexanoyl (CAS#2051-49-2, →L1) and decanoyl (CAS#112-13-0, →L3) chlorides were purchased from commercial sources.

[0304] 2-(N-tert-butoxycarbonylamino)ethanethiol (CAS#67385-09-5), 2-morpholinoethanamine (CAS#2038-03-1, →C9), 2-morpholinoethyl isothiocyanate (CAS#2038-03-1, →C9), and 2-(2-aminoethyl)-1,3-di-(tert-butoxycarbonyl)guanidine (CAS#203258-44-0, →C11) were purchased from commercial sources.

[0305] 2-(N-tert-butoxycarbonylamino)ethyl isothiocyanate (→C1) was prepared according to the procedure described in D. M. Kneeland, et al., J. Am. Chem. Soc. 1993, 115, 10042-10055.

[0306] N-(4-Hydroxybutyl)-N-(tert-butoxycarbonyl)ethylenediamine (→OH) was synthesized from commercially available N-(4-hydroxybupyr)ethylenediamine by sequential primary amine trifluoroacetylation with ethyl trifluoroacetate, carbamoylation of the remaining amino group with BocO, and base-promoted trifluoroacetide hydrolysis.

[0307] The synthetic intermediates 4, 5T, 5S, 6T-L1, 6T-L3, 6S-L3, diamines ssJRL9, PRX017, PRX104, and diisothiocyanates 7T-L1, 7T-L3, and 7S-L3 in the reaction sequences shown in Schemes 1 and 2 were prepared as described below:

[0308] 2-(tert-Butoxycarbonylamino)ethyl methoxycarbonyl disulfide (4). The chiral disulfide 4 was synthesized by adapting the procedure described by Pilkington for cysteine. See LIPilkington, et al., Chem. Commun. 2019, 55, 8868-8871. Briefly, a solution of commercially available 2-(tert-butoxycarbonylamino)ethanethiol (or Boc-protected cysteamine, Boc-Cyst, 1.09 g, 6.16 mmol) in fresh deoxygenated dioxane (20 mL) was treated with methoxycarbonylsulfanyl chloride (0.78 g, 0.55 mL, 6.16 mmol) under a N2 atmosphere at 0 °C. The reaction mixture was allowed to warm to room temperature and stirred for 16 h. The mixture was then diluted with DCM (50 mL) and washed with water (50 mL). The organic layer was decanted, dried (MgSO4), filtered and concentrated to dryness to give a colorless oil 4 (yield 1.07 g, 65%), the purity of which was confirmed by TLC, 1 H and13 The product was confirmed by C NMR and MS. Compound 4 was used in the next step without further purification. TLC(1:5 EtOAc-petroleum ether) 0.50 1 H NMR(400MHz,CDCl3) δ 5.39 (bs,1H,NH),3.92 (s,3H,OMe),3.40 (q,2H, 3 J H,H 5.8Hz,CH2NH),2.89 (t,2H,CH2S),1.47 (s,9H,CMe3). 13 C NMR (100.6 MHz, CDCl3) δ 178.5 (CO thiocarbonate), 155.8 (CO carbamate), 79.5 (CMe3), 67.1 (OMe), 39.5 (CH2S), 38.3 (CH2N), 28.4 (CMe3) ESI-MS (m / z) 290.18 ([M+Na] + ).

[0309] 6,6'-Bis-(2-(tert-butoxycarbonylamino)ethyldithio)-α,α'-trehalose (5). To a solution of disulfide 4 (0.48 g, 1.82 mmol) in freshly degassed MeOH (10 mL) at 0 °C was added a solution of dithiol 3T (0.28 g, 0.76 mmol) in MeOH (5 mL) dropwise over a period of 1 h. The reaction was stirred at 0 °C for an additional 1 h and then the solvent was evaporated under reduced pressure. The resulting syrupy residue was purified by column chromatography (20:1 EtOAc-EtOH → 45:5:3 EtOAc-EtOH-water) to give 5T. Yield 0.39 g (71%). TLC(45:5:3 EtOAc-EtOH-water) 0.46 1 H NMR(400MHz,MeOD) δ 5.17 (d,2H,J 1,2 3.8Hz,H-1),3.97 (ddd,2H,J 4,5 3.8Hz,J 5,6a 2.1Hz,J 5,6b 8.6Hz,H-5),3.79 (t,2H,J2,3 = J 3,4 = 9.3Hz,H-3),3.52 (dd,2H,H-2),3.38 (m,4H,CH2N),3.29 (dd,2H,J 6a,6b 13.6Hz,H-6a),3.23 (dd,2H,H-4),2.94 (dd,2H,H-6b),2.83 (m,4H,CH2S),1.46 (s,18H,CMe3). 13 C NMR(100.6MHz,MeOD) δ156.9 (CO),93.0 (C-1),78.9 (CMe3),73.4 (C-4),73.1 (C-3),71.8 (C-2),71.2 (C-5),43.2 (C-6),39.4 (CH2N),37.6 (CH2S),37.4 (CMe3). ESI-MS (m / z) 1471.71 ([2M+Na] + ), 747.49 ([M+Na] + ).

[0310] 6,6'-Bis(tert-butoxycarbonylaminoethyldithio)-sucrose (5S). To a solution of dithioacetate 2S (1.00 g, 1.41 mmol) in MeOH (20 mL) degassed at room temperature, NaOMe (76 mg, 1.41 mmol) was added and the solution was stirred at room temperature for 45 min. The reaction mixture was then cooled to 0° C. and a solution of disulfide 4 (0.90 g, 3.38 mmol) in freshly degassed MeOH (10 mL) was added. The reaction was further stirred at 0° C. for 1 h and concentrated to dryness. The resulting syrupy residue was purified by column chromatography with gradient elution (20:1 EtOAc-EtOH→45:5:3 EtOAc-EtOH-water) to give compound 5S. A 68% yield was obtained (0.70 g). TLC (45:5:3 EtOAc-EtOH-water) 0.45. 1 H NMR(400MHz,MeOD) δ 5.39 (d,1H,J 1,2 3.8Hz, H-1 glc ), 4.08 (m,2H,H-3,4 fru ), 4.02 (m,1H,H-5glc ),4.01 (m,1H,H-5 fru ),3.72 (t,1H,J 2,3 = J 3,4 9.3Hz,H-3 glc ),3.62 (s,2H,H-1 fru ),3.46 (dd,1H,H-2 glc ),3.37 (m,4H,CH2NHBoc),3.27 (m,2H,H-6 glc ,H-6a fru ),3.25 (dd,1H,J 4,5 9.3Hz,H-4 glc ),3.12 (dd,1H,J 5,6b 3.8Hz,J 6a,6b 13.6Hz,H-6b fru ),2.99 (dd,1H,J 5,6b 7.5Hz,J 6a,6b 13.4Hz,H-6b glc ),2.81 (m,4H,CH2S),1.46 (bs,18H,CMe3). 13 C NMR(100.6MHz,MeOD) δ156.9 (CO),103.9 (C-2 fru ),91.9 (C-1 glc ),80.4 (C-5 fru ),78.9 (CMe3),77.9,78.1 (C-3,4 fru ),73.0,72.9 (C-3,4 glc ),71.9 (C-2 glc ),71.2 (C-5 glc ),62.8 (C-1 fru ),42.6,42.5 (C-6),39.5,39.4 (CH2NHBoc),37.6,37.4 (CH2S),27.5 (CMe3). ESI-MS (m / z) 725.25 ([M+H] + ).

[0311] General procedure for complete hydroxyl acylation of 5T and 5S. In a typical experiment, a solution of derivative 5T or 5S (0.18 g, 0.25 mmol) and DMAP (0.55 g, 4.51 mmol) in DMF (10 mL) under N2 atmosphere was added dropwise over 30 min to a solution of the corresponding acyl chloride (2.26 mmol) in DMF (mL) under N2 at 0 °C. The reaction mixture was allowed to warm to room temperature over 2 h and further stirred overnight. The reaction was then diluted with a diethyl ether-toluene mixture (1:1, 100 mL) and subsequently washed with water (2 x 50 mL) and aqueous 1N HCl (50 mL). The organic layer was dried over MgSO4, filtered, concentrated under reduced pressure and the syrupy residue was purified by column chromatography using the eluent indicated in each case to give R 1 as defined by code L1 or L3 in the lipid reagent list above. a The corresponding 6T or 6S reaction intermediates bearing substituents were obtained.

[0312] 6,6'-Bis[2-(tert-butoxycarbonylamino)ethyldithio]-2,2',3,3',4,4'-hexa-O-hexanoyl-α,α'-trehalose (6T-L1). Eluent: petroleum ether → 1:5 EtOAc-petroleum ether. Yield: 79%. TLC(1:3 EtOAc-petroleum ether) 0.47 1 H NMR(400MHz,CDCl3) δ 5.51 (t,3H,J 2,3 = J 3,4 9.5Hz,H-3),5.33 (d,2H,J 1,2 3.7Hz,H-1),5.13 (dd,2H,H-2),5.00 (bs,2H,NH),4.98 (t,2H,J 4,5 9.5Hz,H-4),3.96 (ddd,2H,J 5,6a 3.7Hz,J 5,6b 7.0Hz,H-5),3.40 (m,4H,CH2N),2.85 (m,4H,H-6),2.76 (t,4H, 3 J H,H6.4Hz,CH2S),2.37,2.28,2.22 (3 t,12H,CH2CO),1.59 (m,12H,CH2CH2CO),1.46 (s,18H,CMe3),1.30 (m,24H,CH2CH2CH3),0.91 (m,18H,CH2CH3). 13 C NMR (100.6 MHz, CDCl3) δ 172.4, 172.3 (CO ester), 155.7 (CO carbamate), 90.9 (C-1), 79.5 (CMe3), 71.2 (C-4), 69.7 (C-3), 69.5 (C-5), 69.4 (C-2), 42.0 (C-6), 39.0 (CH2N), 38.1 (CH2S), 34.0 (CH2CO), 31.2, 22.3 (CH2CH2CH3), 28.3 (CMe3), 24.4 (CH2CH2CO), 13.8 (CH2CH3). ESI-MS (m / z) 1336.09 ([M+Na] + ).

[0313] 6,6'-Bis[2-(tert-butoxycarbonylamino)ethyldithio]-2,2',3,3',4,4'-hexa-O-decanoyl-α,α'-trehalose (6T-L3). Eluent petroleum ether → 1:5 EtOAc-petroleum ether. Yield: 70%. TLC(1:3 EtOAc-petroleum ether) 0.40. 1 H NMR(400MHz,CDCl3) δ 5.50 (t,3H,J 2,3 = J 3,4 9.7Hz,H-3),5.33 (d,2H,J 1,2 4.0Hz,H-1),5.12 (dd,2H,H-2),4.99 (bs,2H,NH),4.98 (t,2H,J 4,5 9.7Hz,H-4),3.96 (ddd,2H,J 5,6a 4.1Hz,J 5,6b 6.9Hz,H-5),3.42 (bq,4H, 3 J H,H 6.2Hz,CH2N),2.88,2.84 (2dd,4H,J 6a,6b13.8Hz,H-6),2.76 (t,4H,CH2S),2.36,2.28,2.24 (3 m,12H,CH2CO),1.62,1.58 (2 m,12H,CH2CH2CO),1.46 (s,18H,CMe3),1.28 (m,72H,(CH2)6CH3),0.90 (m,18H,CH2CH3). 13 C NMR (100.6 MHz, CDCl3) δ 172.4 (CO ester), 155.8 (CO carbamate), 91.0 (C-1), 79.5 (CMe3), 71.3 (C-4), 69.7 (C-3), 69.5 (C-5), 69.4 (C-2), 42.0 (C-6), 39.1 (CH2N), 38.2 (CH2S), 34.2-34.1 (CH2CO), 31.9-31.8, 22.7 ((CH2)2CH3), 29.5-29.1 ((CH2)4CH2CH2CH3), 28.4 (CMe3), 24.9-24.7 (CH2CH2CO), 14.2, 14.1 (CH2CH3). ESI-MS (m / z) 1550.02 ([M-Boc+H] + ), 1695.01 ([M+HCO2] - ).

[0314] 6,6'-Bis[2-(tert-butoxycarbonylamino)ethyldithio]-2,3,4,1',3',4'-hexa-O-decanoyl-sucrose (6S-L3): eluent petroleum ether → 1:5 EtOAc-petroleum ether. Yield 74%. TLC(1:4 EtOAc-petroleum ether) 0.63. 1 H NMR(400MHz,CDCl3) δ 5.60 (t,1H,J 1,2 3.7Hz, H-1 glc ), 5.51 (d,1H,J 1,2 6.7Hz, H-3 fru ),5.45 (t,1H,J 4,5 6.7Hz, H-4 fru ),5.43 (t,1H,J 2,3 = J 3,4 9.9Hz, H-3 glc),5.10 (bs,2H,NHBoc),5.04 (t,1H,J 4,5 9.9Hz,H-4 glc ),4.93 (dd,1H,H-2 glc ),4.32 (ddd,1H,J 5,6a 4.0Hz,J 5,6b 6.6Hz,H-5 glc ),4.29 (ddd,1H,J 5,6a 7.6Hz,J 5,6b 5.7Hz,H-5 fru ),4.14,4.07 (2d,2H,J 1a,1b 10.0Hz,H-1 fru ),3.44 (m,4H,CH2N),3.18 (dd,1H,J 6a,6b 13.8Hz,H-6a fru ),3.09 (dd,1H,H-6b fru ),3.00 (dd,1H,J 6a,6b 13.8Hz,H-6a glc ),2.89 (dd,1H,H-6b fru ),2.80 (t,4H,CH2S), 2.46-2.19 (m,12H,CH2CO), 1.65-1.50 (m,12H,CH2CH2CO), 1.46 (s,18H,CMe3), 1.28 (m,72H,(CH2)6CH3), 0.88 (m,18H,CH2CH3). 13 C NMR(100.6MHz,CDCl3) δ 172.9-172.3 (CO dimer),155.8 (CO dimer),103.5 (C-2 fru ),90.0 (C-1 glc ),79.5 (C-5 fru ),79.4(CMe3),77.2(C-3). fru ),75.6 (C-4 fru ),70.8 (C-3 glc ),69.9 (C-2 glc ),69.2 (C-5 glc ),69.1 (C-4 glc ),62.9 (C-1 fru ),41.8 (C-6 glc ),41.6 (C-6 fru),39.3 (CH2NHBoc),38.4,38.2 (CH2S),34.1-33.8 (CH2CO),31.9-31.8,22.7 ((CH2)2CH3),29.6-29.0 ((CH2)4CH2CH2CH3),28.4 (CMe3),25.0-24.7 (CH2CH2CO),14.1 (CH2CH3). ESI-MS (m / z) 1695.29 ([M+HCO2] - ).

[0315] General procedure for tert-butoxycarbonyl group hydrolysis in reaction intermediates 6T and 6S. To a solution of 6T or 6S in DCM (5 mL per 0.1 mmol of substrate) at room temperature, trifluoroacetic acid (5 mL per 0.1 mmol of substrate) was added. The reaction mixture was stirred at room temperature for 1 h, then the solvent was evaporated under reduced pressure and traces of acid were removed by repeated coevaporation with water. The resulting residue was lyophilized from 10 mM HCl to give the corresponding diamines ssJRL9, PRX017, or PRX104 as hydrochloride salts in quantitative yields.

[0316] Example 3a - Compound ssJRL9. TLC(45:5:3 EtOAc-EtOH-water) 0.50 1 H NMR(600MHz,MeOD) δ 5.50 (t,3H,J 2,3 = J 3,4 9.5Hz,H-3),5.38 (d,2H,J 1,2 3.7Hz,H-1),5.15 (dd,2H,H-2),5.08 (t,2H,J 4,5 9.5Hz,H-4),4.06 (m,2H,H-5),3.30 (t,4H, 3 J H,H 6.6Hz,CH2N),3.00 (d,4H,J 5,65.7Hz, H-6), 2.98, 2.92 (2m, 4H, CH2S), 2.44, 2.34, 2.28 (3m, 12H, CH2CO), 1.67, 1.59 (2m, 12H, CH2CH2CO), 1.35 (m, 24H, CH2CH2CH3), 0.94 (m, 18H, CH3). 13 C NMR(100.6MHz, MeOD) δ 172.7, 172.4 (CO), 90.5 (C-1), 70.9 (C-4), 69.9 (C-3), 69.6 (C-2), 69.3 (C-5), 40.9 (C-6), 37.6 (CH2N), 35.6 (CH2S), 33.8 - 33.6 (CH2CO), 31.1 - 31.0, 22.0 (CH2CH2CH3), 24.2 - 24.1 (CH2CH2CO), 13.0 - 12.9 (CH2CH3). ESI-MS (m / z) 1113.98 ([M - HCl - Cl] + ), 557.44 ([M - 2Cl] 2+ ).

[0317] Example 3b - Compound PRX017. 1 H NMR(400MHz, CDCl3) δ 5.56 (t, 2H, J 2,3 = J 3,4 9.6Hz, H-3), 5.40 (d, 2H, J 1,2 4.0Hz, H-1), 5.15 (dd, 2H, H-2), 5.07 (t, 2H, J 4,5 9.6Hz, H-4), 4.04 (ddd, 2H, J 5,6a 4.2, J 5,6b 7.0Hz, H-5), 3.31 (t, 4H, 3 J H,H 6.6Hz, CH2NH2), 3.02, 2.98 (2dd, 4H, J 6a,6b 13.2Hz, H-6), 2.94 (m, 4H, CH2S), 2.43, 2.34, 2.23 (3m, 6H, CH2CO), 2.23 (3m, 12H, CH2CO), 1.67, 1.60 (2m, 12H, CH2CH2CO), 1.33 (m, 72H, (CH2)6CH3), 0.93 (m, 18H, CH3). 13 C NMR(100.6MHz,CDCl3) δ 172.5,172.3(CO),90.4(C-1),71.0(C-4),69.9(C-3),69.7(C-2),69.3(C-5),40.9(C-6),37.6(CH2N),34.0(CH2S),33.7-33.6 (CH2CO), 31.8-31.7,22.4((CH2)2CH3), 29.4-28.9((CH2)4CH2CH2CH3), 24.7-24.5(CH2CH2CO),13.2-13.1(CH3). ESI-MS (m / z) 1449.95 ([M-HCl-Cl] + ),725.55 ([M-2Cl] 2+ ).

[0318] Enclosure 3c-Indicator PRX104. 1 H NMR(400MHz,MeOD) δ 5.70 (t,1H,J 1,2 3.6Hz,H-1 glc ),5.58 (d,1H,J 1,2 7.0Hz,H-3 fru ),5.51 (t,1H,J 2,3 9.4Hz,J 3,4 10.3Hz,H-3 glc ),5.49 (dd,1H,J 4,5 5.1Hz,H-4 fru ),5.12 (t,1H,J 4,5 10.3Hz,H-4 glc ),4.94 (dd,1H,H-2 glc ),4.42 (ddd,1H,J 5,6a 3.3Hz,J 5,6b 6.0Hz,H-5 glc ),4.37 (ddd,1H,J 5,6a 6.0Hz,J 5,6b 8.0Hz,H-5 fru ),4.21 (s,2H,H-1 fru ),3.33 (m,4H,CH2N),3.26 (dd,1H,J 6a,6b 14.0Hz,H-6a fru),3.21 (dd,1H,H-6b fru ),3.14 (dd,1H,J 6a,6b 14.2Hz,H-6a glc ),3.04 (dd,1H,H-6b fru ),3.00 (t,4H,CH2S),2.45-2.25 (m,12H,CH2CO),1.71-1.56 (m,12H,CH2CH2CO),1.32 (m,72H,(CH2)6CH3),0.92 (m,18H,CH2CH3). 13 C NMR(100.6MHz,CDCl3) δ 172.9-172.4 (CO エステル),103.6 (C-2 fru ),90.0 (C-1 glc ),79.5 (C-5 fru ),77.2 (C-3 fru ),75.5 (C-4 fru ),70.8 (C-3 glc ),69.8 (C-2 glc ),69.1 (C-5 glc ),68.9 (C-4 glc ),62.8 (C-1 fru ),41.4 (C-6 glc ),41.3 (C-6 fru ),38.8,38.4 (CH2N),34.0-33.7 (CH2S,CH2CO),31.9-31.8,22.7 ((CH2)2CH3),29.6-29.1 ((CH2)4CH2CH2CH3),24.9-24.7 (CH2CH2CO),14.1 (CH2CH3). ESI-MS (m / z) 1450.18 ([M-HCl-Cl] + ),726.10 ([M-2Cl] 2+ )

[0319] General procedure for the synthesis of diisothiocyanate reaction intermediates 7T and 7S. To a solution of the corresponding diamine ssJRL9, PRX017, or PRX104 (1 mmol) in a heterogeneous mixture of water and DCM (1:1, mL), CaCO3 (0.48 g, 4.8 mmol) and Cl2CS (0.22 ml, 2.4 mmol) were added successively. The mixture was stirred vigorously at room temperature for 1 h, then transferred to a decantation funnel and diluted with water and DCM (1:1, 100 mL). The organic layer was decanted and washed with water (50 mL) and saturated aqueous NaHCO3 (50 mL). The organic phase was dried (MgSO), filtered, and concentrated to give the corresponding diisothiocyanates 7T-L1, 7T-L3, or 7S-L3, respectively, in essentially quantitative yield as pale syrups, which were used without further purification in the preparation of compounds 8T and 8S (Schemes 1 and 2, Routes B1 and B2).

[0320] 6,6'-Bis(2-isothiocyanatoethyldithio)-2,2',3,3',4,4'-hexa-O-hexanoyl-α,α'-trehalose (7T-L1). Yield 93%. TLC(1:4 EtOAc-petroleum ether) 0.33. 1 H NMR(600MHz,CDCl3) δ 5.52 (t,2H,J 2,3 = J 3,4 9.7Hz,H-3),5.32 (d,2H,J 1,2 3.9Hz,H-1),5.09 (dd,2H,H-2),4.98 (t,2H,J 4,5 9.7Hz,H-4),3.95 (ddd,2H,J 5,6a 4.3Hz,J 5,6b 6.8Hz,H-5),3.81 (t,4H, 3 J H,H 6.6Hz,CH2N),2.91 (m,8H,H-6,CH2S),2.35,2.28,2.23 (3 m,12H,CH2CO),1.58 (m,12H,CH2CH2CO),1.29 (m,24H,CH2CH2CH3),0.90 (m,18H,CH3). 13C NMR(150.9MHz,CDCl3) δ 172.4 (CO),132.9 (NCS),91.1 (C-1),71.0 (C-4),69.6,69.5 (C-2,3),69.4 (C-5),43.9 (CH2NCS),42.7 (CH2S),38.0 (C-6),34.1-34.0 (CH2CO),31.3-31.1,22.3-22.2 (CH2CH2CH3),24.5-24.4 (CH2CH2CO),13.8-13.8 (CH2CH3). ESI-MS 1197.55 ([M+H] + ), 1241.72 ([M+HCO2] - ).

[0321] 6,6'-Bis(2-isothiocyanatoethyldithio)-2,2',3,3',4,4'-hexa-O-decanoyl-α,α'-trehalose (7T-L3). Yield: 49%. TLC(1:4 EtOAc-petroleum ether) 0.51. 1 H NMR(400MHz,CDCl3) δ 5.49 (t,2H,J 2,3 = J 3,4 9.6Hz,H-3),5.32 (d,2H,J 1,2 4.0Hz,H-1),5.08 (dd,2H,H-2),4.98 (t,2H,J 4,5 9.6Hz,H-4),3.94 (ddd,2H,J 5,6a 4.5Hz,J 5,6b 6.7Hz,H-5),3.80 (t,4H, 3 J H,H 6.5Hz,CH2N),2.90 (m,8H,H-6,CH2S),2.35,2.28,2.22 (3 m,12H,CH2CO),1.58 (m,12H,CH2CH2CO),1.26 (m,72H,CH2(CH2)6CH3),0.88 (m,18H,CH3). 13C NMR(100.6MHz,CDCl3) δ 172.4 (CO),133.0 (NCS),91.1 (C-1),71.1 (C-4),69.5 (C-2,3),69.4 (C-5),43.9 (CH2NCS),42.7 (CH2S),38.0 (C-6),34.1 (CH2CO),31.9-31.8,29.5-29.1 ((CH2)6CH3),24.8 (CH2CH2CO),22.6 (CH2CH2CH2CO),14.1 (CH2CH3). ESI-MS 1577.82 ([M+HCO2] - ).

[0322] 6,6'-Bis(2-isothiocyanatoethyldithio)-2,3,4,1',3',4'-hexa-O-decanoyl-sucrose dihydrochloride (7S-L3). Yield 83%. TLC(1:5 EtOAc-petroleum ether) 0.75. 1 H NMR(400MHz,CDCl3) δ 5.58 (t,1H,J 1,2 3.5Hz, H-1 glc ), 5.51 (d,1H,J 1,2 7.0Hz, H-3 fru ), 5.43 (m, 3H, H-3 glc ,H-4 fru ),5.03 (t,1H,J 3,4 = J 4,5 9.8Hz, H-4 glc ), 4.90 (dd,1H,J 2,3 9.8Hz, H-2 glc ),4.32 (ddd,1H,J 5,6a 3.3Hz,J 5,6b 6.0Hz, H-5 glc ),4.28 (ddd,1H,J 5,6a 6.0Hz,J 5,6b 8.0Hz, H-5 fru ), 4.14 (d,1H,J 1a,1 12.0Hz, H-1a fru ), 4.07 (d,1H,H-1b fru ),3.85 (t,4H, 3 JH,H 6.5Hz,CH2NCS),3.20 (dd,1H,J 6a,6b 13.7Hz, H-6a fru ),3.11 (dd,1H,H-6b fru ),3.06 (dd,1H,J 6a,6b 14.1Hz, H-6a glc ), 2.95 (t,5H,H-6b fru ,CH2S),2.41-2.20 (m,12H,CH2CO),1.66-1.50 (m,12H,CH2CH2CO),1.27 (m,72H,(CH2)6CH3),0.88 (m,18H,CH2CH3). 13 C NMR (100.6MHz, CDCl3) δ 172.9-172.4 (CO ester), 132.9, 132.8 (NCS), 103.6 (C-2 fru ),90.0 (C-1 glc ),79.5 (C-5 fru ), 76.9 (C-3 fru ),75.5 (C-4 fru ), 70.7 (C-3 glc ),69.9 (C-2 glc ),69.2 (C-5 glc ),68.9 ​​(C-4 glc ),62.8 (C-1 fru ),44.1,44.0 (CH2NCS),42.3 (C-6 glc ), 42.0 (C-6 fru ),37.9,37.8 (CH2S),34.1-33.8 (CH2CO),31.9-31.8,22.7 ((CH2)2CH3),29.5-29.1 ((CH2)4CH2CH2CH3),24.9-24.7 (CH2CH2CO),14.1 (CH2CH3). ESI-MS (m / z) 1578.98 ([M+HCO2] - )

[0323] General procedures for the synthesis of compounds of formula I according to Routes A1, A2, B1, and B2 of Schemes 1 and 2.

[0324] Route A1 (Schemes 1 and 2): A solution of the corresponding diamine dihydrochloride (ssJRL9, PRX017, or PRX104, 0.1 mmol) in DCM (10 mL) and triethylamine (EtN, 0.3 mmol, 41 μL) was treated with the corresponding isothiocyanate reagent SCN-(CH)-Z in DCM (5 mL). a -PG 1 A solution of (0.3 mmol) of Et3N was added over time. The reaction mixture was stirred at room temperature for 16 hours while monitoring the pH to ensure it remained basic (if the pH was found to be below neutral, it should be readjusted to slightly basic (approximately pH 8) by adding an aliquot of Et3N). Once the reaction was complete (TLC showed complete disappearance of the diamine starting material and a higher R f After 1 h of 1000 s, the reaction mixture was concentrated to dryness and the crude material was purified by column chromatography using the indicated eluent. The resulting intermediate with a Boc-protected amino group was then treated with a 1:1 DCM-TFA mixture (10 mL) at room temperature for 1 h, followed by evaporation of the solvent under reduced pressure. Traces of TFA were removed by coevaporation with toluene (3×10 mL). Lyophilization from 10 mM HCl afforded the target products 8T and 8S in the yields indicated in each case.

[0325] In some embodiments, the following compounds of formula I characterized by structure 8T were synthesized according to Scheme 1, route A1: ssJRL13, PRX022.

[0326] Route A2 (Schemes 1 and 2): Similarly to Route A1, Route A2 can be prepared by cleaving compounds ssJRL9, PRX017, or PRX104 with the isothiocyanate reagent SCN-(CH)-Z using a similar protocol. 1Upon completion of the reaction, the reaction mixture was transferred to a decantation funnel and partitioned between DCM and 0.1 N aqueous HCl (1:1, 20 mL). The organic layer was decanted, dried over MgSO4 or Na2SO4, filtered, and evaporated under reduced pressure. In these cases, column chromatographic purification was performed. The resulting products were lyophilized from 10 mM HCl to give the target products 8T or 8S in the yields indicated in each case.

[0327] In some embodiments, the following compound of formula I, characterized by structure 8, was synthesized according to Scheme 1, route A2: ssJLF99.

[0328] Route B1 (Schemes 1 and 2): To a solution of the corresponding diisothiocyanate reaction intermediate 7T or 7S (0.1 mmol) in DCM (10 mL) is added the corresponding amine reagent H2N-(CH2)2-Z in DCM (5 mL). a -PG 1 (0.3 mmol) was added. The reaction mixture was stirred at room temperature for 16 hours while monitoring the pH to ensure it remained basic. When the reaction was complete (TLC showed complete disappearance of the diisothiocyanate starting material and a lower R f After 1 h of 1000 s, the reaction mixture was concentrated to dryness and the crude material was purified by column chromatography using the indicated eluent. The resulting intermediate was further treated with a 1:1 DCM-TFA mixture (10 mL) at room temperature for 1 h, followed by evaporation of the solvent under reduced pressure and coevaporation of traces of acidic material with toluene (3×10 mL) and lyophilization from 10 mM HCl to give the target product 8T or 8S in the indicated yield in each case.

[0329] In some embodiments, the following compounds of formula I characterized by structure 8 were synthesized according to Scheme 1, route B1: ssJLF102, ssJLF97, ssJLF94, PRX034, PRX035, PRX036, JLF512, JLF513.

[0330] Route B2 (Schemes 1 and 2): Similarly to Route B1, Route B2 involves the reaction of compounds of structure 7T or 7S with the amine reagent H2N-(CH2)2-Z using a similar protocol. 1 Upon completion of the reaction, the reaction mixture was transferred to a decantation funnel and partitioned between DCM and 0.1 N aqueous HCl (1:1, 20 mL). The organic layer was decanted, dried over MgSO4 or Na2SO4, filtered, and evaporated under reduced pressure. In these cases, column chromatographic purification is not necessary. The resulting products were lyophilized from 10 mM HCl to give the target products 8T or 8S in the indicated yields.

[0331] In some embodiments, the following compounds of formula I characterized by structures 8T and 8S were synthesized according to Scheme 1, route B2: ssJLF99, JLF515, PRX106, PRX108, PRX109.

[0332] Example 3d - Compound ssJRL13 It was synthesized from ssJRL9 and the corresponding isothiocyanate (code C1) according to Scheme 1, Route A1, as detailed below. To a solution of diamine ssJRL9 (0.20 g, 0.18 mmol) in DCM (5 mL), Et3N (75 μL, 0.54 mmol, 1.5 equiv), and 2-(tert-butoxycarbonylamino)ethyl isothiocyanate (87 mg, 0.43 mmol, 1.2 equiv) was added over time. The reaction mixture was stirred at room temperature for 16 h and concentrated to dryness. The residue was purified by column chromatography using 1:2 EtOAc-toluene as eluent to give the di-Boc protected intermediate 6,6′-bis[3-(2-(tert-butoxycarbonylamino)ethyl)thioureidoethyldithio)]-2,2′,3,3′,4,4′-hexa-O-hexanoyl-α,α′-trehalose in 93% yield (0.26 g). TLC(1:2 EtOAc-toluene) 0.21 1 H NMR(600MHz,CDCl3) δ 7.09-6.90 (bs,4H,NHCS),5.51 (t,3H,J2,3 = J 3,4 9.8Hz,H-3),5.42 (d,2H,J 1,2 3.7Hz,H-1),5.27 (bs,2H,NHCO),5.10 (dd,2H,H-2),5.00 (t,2H,J 4,5 9.7Hz,H-4),3.79 (m,2H,H-5),3.87,3.62 (2 bs,8H,CH2NHCS),3.34 (bt,4H, 3 J H,H 5.2Hz,CH2NHBoc),2.94 (bt,4H,CH2S),2.91 (m,4H,H-6),2.37,2.26,2.24 (3 t,12H,CH2CO),1.63 (m,12H,CH2CH2CO),1.56 (s,18H,CMe3),1.45 (s,18H,CMe3),1.31 (m,24H,CH2CH2CH3),0.90 (m,18H,CH2CH3). 13 C NMR (150.9MHz, CDCl3) δ 181.2 (CS), 172.7, 172.4 (CO ester), 157.2 (CO carbamate), 90.4 (C-1), 80.0 (CMe3), 71.1 (C-4), 69.7 (C-2,5), 69.5 (C-3), 42.7 (CH2NHCS), 42.4 (C-6), 39.9 (CH2NHBoc), 37.3 (CH2S), 34.1, 34.0 (CH2CO), 31.3, 31.2, 22.2 (CH2CH2CH3), 28.4 (CMe3), 24.5-24.4 (CH2CH2CO), 13.9, 13.8 (CH2CH3). ESI-MS (m / z) 1541.02 ([M+Na] + ).

[0333] Subsequent treatment of the di-Boc intermediate (0.21 g, 0.14 mmol) with a 1:1 DCM-TFA mixture (8 mL) at room temperature for 1 h, followed by evaporation of the solvent in vacuo and lyophilization from dilute HCl afforded the deprotected diamine ssJR13 in essentially quantitative yield. 1 H NMR(600MHz,MeOD) δ 5.54 (t,3H,J 2,3= J 3,4 9.7Hz,H-3),5.37 (d,2H,J 1,2 3.9Hz,H-1),5.19 (dd,2H,H-2),5.05 (t,2H,J 4,5 9.7Hz,H-4),4.07 (m,2H,H-5),3.87,3.78 (2 m,8H,CH2NHCS),3.17 (t,4H, 3 J H,H 6.1Hz,CH2NH2),2.99 (dd,2H,J 5,6a 3.2Hz,J 6a,6b 14.4Hz,H-6a),2.93 (m,6H,H-6b,CH2S),2.44,2.35,2.27 (3 m,12H,CH2CO),1.63,1.60 (2 m,12H,CH2CH2CO),1.35 (m,24H,CH2CH2CH3),0.94 (m,18H,CH3). 13 C NMR(150.9MHz,MeOD) δ 181.0 (CS),172.7,172.4,172.3 (CO ester),90.5 (C-1),71.1 (C-4),70.1 (C-3),69.5 (C-2),69.0 (C-5),42.8,40.9 (CH2NHCS),40.9 (C-6),39.5 (CH2NH2),36.4 (CH2S),33.9,33.6,33.5 (CH2CO),31.2,31.0,22.0 (CH2CH2CH3),24.3,24.1 (CH2CH2CO),13.0,12.9,12.8 (CH2CH3). ESI-MS (m / z) 1318.00 ([M-HCl-Cl] + ), 659.47 ([M-2Cl] 2+ )

[0334] Example 3e - Compound ssJLF102 It was synthesized from isothiocyanate 7T-L1 and the corresponding amine reagent (code C18) according to Scheme 1, route B1. Overall yield (2 steps) 79%. Chemical formula: C 62 H 118 Cl4N8O 15S6. Molecular weight: 1549.83. ESI-MS (m / z) 1403.6 ([M-3HCl-Cl] + ), 702.97 ([M-2HCl-2Cl] + ).

[0335] Example 3f - Compound ssJLF97 It was synthesized from isothiocyanate 7T-L1 and the corresponding amine reagent (code OH3) according to Scheme 1, Route B1. Overall yield (2 steps) 78%. Chemical formula: C 66 H 122 Cl2N6O 17 S6. Molecular weight: 1534.99. ESI-MS (m / z) 731.87 ([M-2Cl] 2+ ).

[0336] Example 3g - Compound ssJLF94 It was synthesized from isothiocyanate 7T-L1 and the corresponding amine reagent (code C11) according to Scheme 1, Route B1. Overall yield (2 steps) 87%. Chemical formula: C 60 H 110 Cl2N 10 O 15 S6. Molecular weight: 1474.86. ESI-MS (m / z) 701.84 ([M-2Cl] 2+ ).

[0337] Example 3h - Compound ssJLF99 It was synthesized from isothiocyanate 7T-L3 and the corresponding amine reagent (code C9) according to Scheme 1, route B2, or from compound PRX017 and the corresponding isothiocyanate reagent (code C9) according to Scheme 1, route A2. Yield 93% (route B2) or 89% (route A2). Molecular weight: 1867.60. ESI-MS (m / z) 1794.02 ([M-HCl-Cl] + ), 898.07 ([M-2Cl] 2+ ).

[0338] Example 3i - Compound PRX022 It was synthesized from compound PRX017 and the corresponding isothiocyanate reagent (code C1) according to scheme 1, route A1. Yield 94%. Chemical formula: C 82 H 154 Cl2N6O 15 S6. Molecular weight: 1727.42. ESI-MS (m / z) 1655.04 ([M-HCl-Cl] + ), 828.10 ([M-2Cl] 2+ ).

[0339] Example 3j - Compound JLF512 It was synthesized from isothiocyanate 7T-L1 and the corresponding amine reagent (code C1-U2) according to Scheme 1, Route B1. Overall yield (2 steps) 99%. Chemical formula: C 60 H 110 Cl2N6O 15 S6. Molecular weight: 1418.83. ESI-MS (m / z) 1345.62 ([M-HCl-Cl] + ), 673.83 ([M-2Cl] 2+ ).

[0340] Example 3k - Compound PRX034 It was synthesized from isothiocyanate 7T-L1 and the corresponding amine reagent (code C1-U5) according to Scheme 1, Route B1. Overall yield (2 steps) 91%. Chemical formula: C 62 H 114 Cl2N6O 15 S6. Molecular weight: 1446.88. ESI-MS (m / z) 687.42 ([M-2Cl] 2+ ).

[0341] Example 3l - Compound PRX035 It was synthesized from isothiocyanate 7T-L1 and the corresponding amine reagent (code C1-U8) according to Scheme 1, Route B1. Overall yield (2 steps) 89%. Chemical formula: C 64 H 118 Cl2N6O 15 S6. Molecular weight: 1474.94. ESI-MS (m / z) 701.44 ([M-2Cl] 2+ ).

[0342] Example 3m - Compound PRX036 It was synthesized from isothiocyanate 7T-L1 and the corresponding amine reagent (code C1-U5) according to Scheme 1, Route B1. Overall yield (2 steps) 92%. Chemical formula: C 62 H 110 Cl2N6O 15 S6. Molecular weight: 1442.85. ESI-MS (m / z) 1369.79 ([M-HCl-Cl] + ).

[0343] Example 3n- Compound JLF513 It was synthesized from isothiocyanate 7T-L1 and the corresponding amine reagent (code C11-U2) according to Scheme 1, Route B1. Overall yield (2 steps) 85%. Chemical formula: C 62 H 114 Cl2N 10 O 15 S6. Molecular weight: 1502.91. ESI-MS (m / z) 1429.64 ([M-HCl-Cl] + ), 715.43 ([M-2Cl] 2+ ).

[0344] Example 3o - Compound JLF515 It was synthesized from isothiocyanate 7T-L3 and the corresponding amine reagent (code C9-U2) according to Scheme 1, route B2. Yield 81%. Chemical formula: C 92 H 170 Cl2N6O 17 S6. Molecular weight: 1895.66. ESI-MS (m / z) 1823.01 ([M-HCl-Cl] + ), 912.10 ([M-2Cl] 2+ ).

[0345] Example 3p - Compound PRX106 It was synthesized from isothiocyanate 7S-L3 and the corresponding amine reagent (code C9) according to Scheme 1, route B2. Yield 75%. Chemical formula: C 90 H 166 Cl2N6O 17S6. Molecular weight: 1867.60. ESI-MS (m / z) 1795.20 ([M-HCl-Cl] + ), 898.21 ([M-2Cl] 2+ ).

[0346] Example 3q - Compound PRX108 It was synthesized from isothiocyanate 7S-L3 and the corresponding amine reagent (code C10.1) according to Scheme 1, route B2. Yield 82%. Chemical formula: C 88 H 156 Cl2NO 15 S6. Molecular weight: 1829.52. ESI-MS (m / z) 1757.15 ([M-HCl-Cl] + ), 879.21 ([M-2Cl] 2+ ).

[0347] Example 3r - Compound PRX109 It was synthesized from isothiocyanate 7S-L3 and the corresponding amine reagent (code C59) according to Scheme 1, route B2. Yield 70%. Chemical formula: C 92 H 170 Cl2N6O 17 S6. Molecular weight: 1898.66. ESI-MS (m / z) 1823.26 ([M-HCl-Cl] + ), 912.27 ([M-2Cl] 2+ ).

[0348] Example 4 - Intramuscular Vaccination Fifteen female BALB / c mice were divided into three groups. One group received only buffer as a negative control, and the other two groups received 2 μg of formulated saRNA encoding the hemagglutinin (HA) protein of influenza strain California / 7 / 2009. All saRNA formulations were administered im into one of the legs. All saRNA groups were formulated with different oligosaccharides (JRL13 or ssJRL13) at N / P6. The formulations were complexed in MBS buffer (final concentration 10% w / v sucrose, 10 mM MES, pH 6.1) at a final RNA concentration of 0.05 mg / ml, and the mixing ratio of RNA solution and oligosaccharide solution was 9:1 (v:v) in all cases. Animals were subjected to non-invasive serological monitoring at different time points (days 0, 14, 21, 28, 49) over a period of 49 days, and spleens were removed at the end of the experiment to quantify the CD4 / CD8 T cell response to influenza HA peptides. Anti-influenza HA antibodies in serum were quantified by enzyme immunoassay. CD4 / CD8 T cell responses were quantified by IFN-ELISPOT of splenocytes. Figure 3A is a bar graph showing the hydrodynamic diameter of saRNA formulated with either JRL13 or ssJRL13. Figure 3B is a plot showing the serological levels of specific IgG to HA over the course of the experiment at a serum dilution of 1:300. Figure 3C is a plot showing the end-point titration of the serological levels of specific IgG to HA. Figure 3D is a bar graph showing the CD8 / CD4 response to the HA peptide pool. This example shows that the introduction of a disulfide bond into the cationic element of JRL13 results in a significant improvement in overall immunogenicity.

[0349] Example 5 - Intramuscular vaccination Twenty female BALB / c mice were divided into four groups. One group received only buffer as a negative control, and the other three groups received 2 μg of formulated saRNA encoding the hemagglutinin (HA) protein of influenza strain California / 7 / 2009. All saRNA formulations were administered im into one of the legs. All saRNA groups were formulated with different oligosaccharides (ssJRL13, ssJLF97, or ssJLF94) at N / P6. The formulations were complexed in MBS buffer (final concentration 10% w / v sucrose, 10 mM MES, pH 6.1) at a final RNA concentration of 0.01 mg / ml, and the mixing ratio of RNA solution and oligosaccharide solution was 9:1 (v:v) in all cases. Animals were subjected to non-invasive serological monitoring at different time points (days 0, 14, 21, 28, and 49) over a period of 49 days, and spleens were removed at the end of the experiment to quantify CD4 / CD8 T cell responses to influenza HA peptides. Anti-influenza HA antibodies in serum were quantified by enzyme immunoassay. CD4 / CD8 T cell responses were quantified by IFN-ELISPOT of splenocytes. Figure 4A is a bar graph of the hydrodynamic diameter of saRNA formulated with either ssJRL13, ssJRL13, or ssJLF94. Figure 4B is a plot showing serological levels of specific IgG to HA over the course of the experiment at a serum dilution of 1:300. Figure 4C is a plot showing the end-point titration of serological levels of specific IgG to HA. Figure 4D is a bar graph showing CD8 / CD4 responses to HA peptide pools.

Claims

1. Compounds of Formula I 【Chemistry 1】 or a pharma- ceutically acceptable salt thereof, A is A 1 , A 2 , or A 3 and 【Chemistry 2】 Each R 1 and R 2 independently, in each instance, H, R a and -C(O)-R a is selected from R 1 Or R 2 At least one instance of is not H, Each R a But independently, C 1 -C 20 aliphatic, C 3 -C 20 cycloaliphatic, C 5 -C 6 aryl, 3- to 12-membered heterocyclyl containing 1 to 3 heteroatoms selected from N, O, and S; a But one or more R b optionally replaced by Each R b are independently halogen, -N 3 , -R c , -OR c , -SR c , -NHR c , -C(O)-R c , -OC(O)R c , -NHC(O)R c , -C(O)NHR c and -NHC(O)NHR c is selected from Each R c is independently an optionally substituted C 1 -C 20 Aliphatic, optionally substituted C 3 -C 20 Cycloaliphatic, optionally substituted C 5 -C 6 aryl, optionally substituted 3- to 12-membered heterocyclyl containing 1 to 3 heteroatoms selected from N, O, and S, and optionally substituted 4- to 12-membered heteroaryl containing 1 to 3 heteroatoms selected from N, O, and S; Y 1 and Y 2 each independently represents an optionally substituted C 1-30 an aliphatic group in which one or more carbons are optionally and independently selected from -Cy-, -NH-, -NHC(O)-, -C(O)NH-, -NHC(O)O-, -OC(O)NH-, -NHC(O)NH-, -NHC(S)NH-, -C(S)NH-, and -C(O)NHSO 2 -, -SO 2 NHC(O)-, -OC(O)O-, -O-, -C(O)-, -OC(O)-, -C(O)O-, -SO-, or -SO 2 - is replaced by Each Cy is independently an optionally substituted C 3 -C 14 cycloaliphatic, optionally substituted 5-14 membered heterocyclyl rings having 1-3 heteroatoms selected from N, O, and S, and optionally substituted 5-14 membered heteroaryl rings having 1-3 heteroatoms selected from N, O, and S; Z 1 and Z 2 are each independently an optionally substituted 5- to 14-membered heterocyclyl ring having 1 to 3 heteroatoms selected from N, O, and S; an optionally substituted 5- to 14-membered heteroaryl ring having 1 to 3 heteroatoms selected from N, O, and S; + (M) 3 , 【Chemistry 3】 is a cationic or ionizable group selected from Each M is independently -C 0 -C 6 Aliphatic-R z , or -C 0 -C 6 Aliphatic-N + (R z ) 3 and Each R z are independently H, optionally substituted C 1 -C 6 Aliphatic, optionally substituted C 3 -C 20 Cycloaliphatic, optionally substituted C 5 -C 6 aryl, optionally substituted 3- to 12-membered heterocyclyl containing 1-3 heteroatoms selected from N, O, and S, and optionally substituted 4- to 12-membered heteroaryl containing 1-3 heteroatoms selected from N, O, and S; or Two or more R's z can be taken together with the atom to which they are attached to form an optionally substituted 3- to 12-membered heterocyclyl containing 1-3 heteroatoms selected from N, O, and S, or an optionally substituted 4- to 12-membered heteroaryl containing 1-3 heteroatoms selected from N, O, and S; The compound, or a pharma- ceutically acceptable salt thereof, wherein p is an integer selected from 1, 2, 3, 4, and 5.

2. The compound is a compound of formula Ia 【Chemistry 4】 or a pharma- ceutically acceptable salt thereof.

3. The compound is a compound of formula Ib 【Chemistry 5】 or a pharma- ceutically acceptable salt thereof.

4. The compound is of formula Ic, 【Chemistry 6】 or a pharma- ceutically acceptable salt thereof.

5. R 1 and R 2 Each independently represents R a and -C(O)-R a is selected from R a But, C 1 -C 20 The compound according to any one of claims 1 to 4, which is aliphatic.

6. R 1 and R 2 are each -C(O)-R a and R a But, C 1 -C 14 The compound according to any one of claims 1 to 5, which is aliphatic.

7. Each R a But, C 5 -C 10 The compound according to any one of claims 1 to 6, which is a straight chain alkyl.

8. R 1 and R 2 are each -C(O)-R a and R a but, 【Chemistry 7】 2. The compound of claim 1 ,

9. Y 1 and y 2 が、each々、C 1 -C 10 Aliphatic, C 0 -C 4 -Aliphatic-NHC(O)NH-C 0 -C 4 Aliphatic, C 0 -C 4 -Aliphatic-NHC(S)NH-C 0 -C 4 Aliphatic, C 0 -C 4 -Aliphatic-C(O)NH-C 0 -C 4 Aliphatic, C 0 -C 4 -Aliphatic-C(S)NH-C 0 -C 4 Aliphatic, C 0 -C 4 -Aliphatic-NHC(O)-C 0 -C 4 Aliphatic, C 0 -C 4 -Aliphatic-NHSO 2 -C 0 -C 4 Aliphatics, and C 0 -C 4 -Aliphatic -C(O)-C 0 -C 4 Compounds described in claims 1 to 8 of claims 1 to 8.

10. Y 1 and Y 2 However, each 1 -C 4 Aliphatic-NHC(S)NH-C 1 -C 4 The compound according to any one of claims 1 to 9, which is aliphatic.

11. Y 1 and Y 2 are each -CH 2 -CH 2 -NHC(S)NH-CH 2 -CH 2 The compound according to claim 1, wherein

12. Z 1 and Z 2 Each independently represents N + (M) 3 , 【Chemistry 8】 The compound according to any one of claims 1 to 11, selected from:

13. Z 1 and Z 2 However, each independently, 【Chemistry 9】 【Chemistry 10】 The compound according to any one of claims 1 to 11, selected from:

14. The oligosaccharide is a compound of formula Id 【Chemistry 11】 or a pharma- ceutically acceptable salt thereof, wherein m and n are each independently selected from 0, 1, 2, 3, 4, 5, or 6.

15. The oligosaccharide is a compound of formula Id-i 【Chemistry 12】 or a pharma- ceutically acceptable salt thereof.

16. The compound of any one of claims 1 to 15, further comprising one or more suitable counter ions.

17. 2. The compound of claim 1, wherein the oligosaccharide is selected from Table 1.

18. A complex comprising the compound according to any one of claims 1 to 17 and a nucleic acid.

19. The complex of claim 18 , wherein the nucleic acid is RNA.

20. The complex of claim 19, wherein the RNA is modRNA, saRNA, taRNA, or uRNA.

21. The complex according to claims 18 to 20, wherein the N / P ratio is less than 20:

1.

22. 22. The complex of claim 21, wherein the N / P ratio is 12:1 or less.

23. The complex of any one of claims 18 to 22, wherein the complex has a diameter of about 30 nm to about 150 nm.

24. A method for delivering a composition to a target in a subject, the method comprising administering to the subject a complex according to any one of claims 18 to 23.

25. 25. The method of claim 24, wherein the target is selected from the liver, lung, or spleen.

26. A method of treating a disease, disorder, or condition in a subject, comprising administering to the subject a conjugate according to any one of claims 18 to 23.

27. 27. The method of claim 26, wherein the disease, disorder, or condition is an infectious disease, cancer, a genetic disorder, an autoimmune disease, or a rare disease.

28. The method of any one of claims 24 to 27, wherein the complex is administered intramuscularly.

29. The method of any one of claims 24 to 27, wherein the complex is administered subcutaneously.

30. Use of a compound according to any one of claims 1 to 17 in medicine.

31. 20. Use of the conjugate of claim 18 in medicine.

32. 20. Use of the complex of claim 18 to increase or cause an increase in expression of RNA in a target.

33. 20. Use of the conjugate of claim 18 for the treatment of a disease, disorder, or condition.

34. 34. The use of claim 33, wherein the disease, disorder, or condition is an infectious disease, cancer, a genetic disorder, an autoimmune disease, or a rare disease.

35. Oligosaccharides of formula Ia 【Chemistry 13】 or a pharma- ceutically acceptable salt thereof, comprising reacting a compound of formula II 【Chemistry 14】 with a first acid to obtain said compound of formula Ia; Y 1 and Y 2 are each -CH 2 -CH 2 -NHC(S)NH-CH 2 -CH 2 - and Z 1 and Z 2 are each -NH 3 Cl, R 1 and R 2 are each -C(O)-R a and R a is optionally substituted C 1 -C 20 It is aliphatic, P.G. 1 is a nitrogen protecting group.

36. The compound of formula III is 【Chemistry 15】 Contacting with a compound of formula IV in the presence of a base, 【Chemistry 16】 36. The method of claim 35, further comprising obtaining the compound of formula II.

37. The compound of formula IIIa is 【Chemistry 17】 Contacting with a compound of formula IVa in the presence of a base, 【Chemistry 18】 36. The method of claim 35, further comprising obtaining the compound of formula II.

38. The compound of formula III is 2 to obtain the compound of formula IIIa.

39. The compound of formula V is 【Chemistry 19】 with a second acid to obtain the compound of formula III, 2 37. The method of claim 36, wherein is a suitable nitrogen protecting group.

40. The compound of formula VI is 【Chemistry 20】 Contacting with a compound of formula VIa 【Chemistry 21】 40. The method of claim 39, further comprising obtaining the compound of formula V.

41. The compound of formula VII is 【Chemical 22】 Contacting with a compound of formula VIIa 【Chemistry 23】 41. The method of claim 40, further comprising obtaining the compound of formula VI.

42. The compound of formula VIII is 【Chemistry 24】 with a compound of formula VIIIa in the presence of dioxane, 【Chemistry 25】 42. The method of claim 41, further comprising obtaining the compound of formula VIIa.

43. The compound of formula IX is 【Chemistry 26】 43. The method of claim 41 or 42, further comprising contacting with sodium methoxide to obtain a compound of formula VII.

44. The compound of formula X is 【Chemistry 27】 44. The method of claim 43, further comprising contacting with thioacetic acid in the presence of a third base to obtain the compound of formula IX.